

Cite this: *Nanoscale Adv.*, 2020, 2, 5046

Biomedical nanomaterials for immunological applications: ongoing research and clinical trials

Vincent Lenders, † Xanthippi Koutsoumpou, † Ara Sargsian
and Bella B. Manshian *

Research efforts on nanomaterial-based therapies for the treatment of autoimmune diseases and cancer have spiked and have made rapid progress over the past years. Nanomedicine has been shown to contribute significantly to overcome current therapeutic limitations, exhibiting advantages compared to conventional therapeutics, such as sustained drug release, delayed drug degradation and site-specific drug delivery. Multiple nanodrugs have reached the clinic, but translation is often hampered by either low targeting efficiency or undesired side effects. Nanomaterials, and especially inorganic nanoparticles, have gained criticism due to their potential toxic effects, including immunological alterations. However, many strategies have been attempted to improve the therapeutic efficacy of nanoparticles and exploit their unique properties for the treatment of inflammation and associated diseases. In this review, we elaborate on the immunomodulatory effects of nanomaterials, with a strong focus on the underlying mechanisms that lead to these specific immune responses. Nanomaterials to be discussed include inorganic nanoparticles such as gold, silica and silver, as well as organic nanomaterials such as polymer-, dendrimer-, liposomal- and protein-based nanoparticles. Furthermore, various approaches for tuning nanomaterials in order to enhance their efficacy and attenuate their immune stimulation or suppression, with respect to the therapeutic application, are described. Additionally, we illustrate how the acquired insights have been used to design immunotherapeutic strategies for a variety of diseases. The potential of nanomedicine-based therapeutic strategies in immunotherapy is further illustrated by an up to date overview of current clinical trials. Finally, recent efforts into enhancing immunogenic cell death through the use of nanoparticles are discussed.

Received 12th June 2020
Accepted 22nd August 2020

DOI: 10.1039/d0na00478b

rsc.li/nanoscale-advances

1. Introduction

Our immune system has a crucial role in protecting us from various diseases. In the presence of danger signals, such as infection, tissue damage and cancer, an immune response is initiated that surveilles and eliminates foreign intruders and

NanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, B-3000 Leuven, Belgium. E-mail: bella.manshian@kuleuven.be

† These authors contributed equally to this work.



Vincent Lenders is currently a Ph.D. researcher at the Nanohealth and Optical Imaging group at KU Leuven. His research interests include nanomedicine and advanced drug delivery systems for immunological and perinatal applications. He obtained his M.Sc. in Bioscience Engineering from KU Leuven in 2019.



Xanthippi Koutsoumpou is a Ph.D. researcher at the Nanohealth and Optical Imaging group, KU Leuven. Her research interests include nanomedicine, magnetic hyperthermia and drug delivery systems for cancer treatment. She obtained her M.Sc. in Nanosciences and Nanotechnologies from Aristotle University of Thessaloniki in 2018.



cancerous cells.¹ However, dysregulation of self-tolerance can occur either by autoantigen triggering or by cross-reaction between self and foreign antigens. This subsequently leads to an immune reactivity against self-antigens and eventually results in an autoimmune disease.² Additionally, cancerous cells have the ability to avoid recognition by the immune system by tumour-induced tolerance, leading to cancer growth and evasion.³ Therefore, there is a high need for the development of immune suppressive therapies for the treatment of autoimmune diseases such as; rheumatoid arthritis (RA), diabetes, inflammatory bowel disease (IBD) and multiple sclerosis (MS). Multiple immunomodulatory agents are used for the treatment of inflammation in autoimmune diseases, but limitations, such as side effects caused by low solubility and adherence of drugs, impede their therapeutic efficiency.⁴ Contrarily, cancer immunotherapy involves immunostimulatory therapies in order to overcome the immunosuppressive activity of cancer cells. Several immunotherapeutic strategies have shown promising results in cancer treatment, such as tumour-antigen vaccination, immune checkpoint blockade and adoptive cell therapy.⁵ However, undesired side effects and the immunosuppressive tumour microenvironment hinder the effectiveness of these strategies.⁶

Some of these therapeutic limitations can be mitigated by the emerging field of nanomedicine, as nanomaterials can facilitate the targeted delivery of immunosuppressive agents, protecting them from degradation, improving drug absorption and preventing unwanted accumulation at off-target organs and tissues.⁷ The gained bioavailability of the drugs, for example by reducing the degradation in the gastrointestinal tract for oral delivery,⁸ significantly improves therapeutic efficacy. The extensiveness of the increase in drug availability can be controlled through modifications applied to the surface of nanoparticles, as they can be steered towards specific tissues or

exhibit a stimuli-responsive behaviour for targeted and controlled drug release.⁹ Additionally, nanoparticles demonstrate potential advantages for immune stimulation. They have shown promising results as nanovaccines, for co-delivery of antigens and adjuvants, specifically to antigen presenting cells (APCs). Due to their unique properties, nanoparticles can protect antigens from premature degradation, improve their stability, enhance the cell uptake by APCs and stimulate immune response, as they exhibit good adjuvant properties themselves.¹⁰ Furthermore, nanoparticles can improve the therapeutic efficacy of cancer immunotherapy, by the targeted co-delivery of various immunomodulatory cytokines and immune checkpoint inhibitors to the tumour microenvironment (TME) in order to reprogram it and resume immune surveillance.¹¹ Moreover, nanoparticles can co-deliver anti-cancer drugs and immunomodulatory compounds resulting in a synergistic anti-tumour therapeutic effect.⁵

However, in the process of designing nanomaterial-based therapies, it is key to understand the different mechanisms by which these nanomaterials interact and interfere with the immune system. Therefore, we summarize in this review the current understanding of interaction mechanisms of different nanomaterials with the immune system, focusing both on how nanomaterials can inflict stress and the different signaling pathways involved in the onset of the immune response. The mechanisms of the most important inorganic nanomaterials (gold, silica and silver) and organic nanomaterials (polymers, dendrimers, liposomes and proteins) will be discussed in detail. Additionally, strategies leveraging the improved understanding of the immunomodulatory behavior of nanoparticles, are elaborated on for a variety of immunological applications. The major potential of nanoparticles in immunotherapy is further illustrated by an up to date overview of current clinical trials.



Ara Sargsian finished his Masters thesis successfully at the Nanohealth and Optical Imaging group at KU Leuven and from 1/09/2020 he will be a part of the group as a Ph.D. researcher. His research interests include Developing ex vivo cultures of animal and human explants for toxicity screening and efficacy testing of new drugs and nanomedical formulations. He obtained his M.Sc. in

Biomedical science (specialisation: Biomedical Basic and Translational Research) from KU Leuven in 2020.



Bella Manshian is a group leader at the Nanohealth and Optical Imaging group at KU Leuven. Bella's research focuses on nanotoxicology and the manipulation of nanomaterials for in vivo theranostic applications. Bella has been using multimodal and multi-parametric in vivo imaging, of mainly preclinical animal models, to assess disease mechanisms and therapy accompa-

nied with screening of individual nanoparticle toxicity, the mechanisms involved and cellular–nanoparticle interaction kinetics. Bella's main interest is in developing non-invasive methods for the dual function of visualization and tracking of specific cell types with a strong focus on tumor cell, stem cells, immune cells and beta cells while simultaneously delivering therapeutic agents.



2. Nanoparticle-induced mechanisms for immunological alterations

Although the field of nanomedicine has made major advances, nanomaterials continue to cause concern due to their potential toxic effects following human exposure. In the past years, major research efforts have been undertaken to understand these toxic effects, and certain pathways, mechanisms and key influential parameters have been implicated as a consequence of cellular exposure to nanomaterials. These nanotoxicology evaluations have also shed light on the immunological alterations caused by these nanomaterials. In order to control the immunomodulatory effect of nanomaterials in applications, the mechanism by which they induce immunological reactions needs to be understood. Therefore, we discuss the main pathways that can lead to NP-induced immune alterations (Table 1). Additionally, we discuss how these mechanisms can be influenced by *e.g.* adjusting physicochemical parameters.

2.1. NP-induced stress

2.1.1. Oxidative stress. It is generally accepted that nanomaterials have a higher intrinsic reactivity compared to their bulk form, due to a larger surface area. This may lead to accelerated reactions in the biological environment. As such, exposure to some nanomaterials may lead to the (excessive) production of reactive oxygen species (ROS). Nanoparticle induced ROS leads to a cascade of pathophysiological consequences including inflammation caused by the activation of associated cell signaling pathways. This results in the release of pro-inflammatory mediators, such as TNF- α , IL-8, IL-2 and IL-6 through NF- κ B (Nuclear Factor- κ B), mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3-K) pathways.¹² Thus, various metal oxide nanoparticles including titanium dioxide, cerium oxide, iron oxide, *etc.*, have been reported, in *in vitro* and *in vivo* studies, to cause toxicity through the production of inflammatory cytokines.¹³

It is important to note that depending on the intrinsic material reactivity and possible surface modifications, the

Table 1 Nanoparticle-induced mechanisms leading to immunological alterations

Mechanism	NP-associated initiating effect	Cellular response	Immunological alteration	Examples
Stress mechanisms				
Oxidative stress	Intracellular release of reactive metal ions	ROS generation	MAPK and inflammasome activation	Silver; ZnO; CuO; TiO ₂
Lysosomal membrane permeabilization (LMP)	Increased cationic charge in lysosome	Proton sponge effect; lysosomal enlargement and pore formation	Inflammasome activation	Polystyrene; crystalline silica; MWCNTs; titanium nanobelts
Lysosomal alkalization	Dissociation of ATPase V ₁ protein complex from membrane-associated ion conductance V ₀ protein complex	Dysregulation of vacuolar H ⁺ (V)-ATPase; alkalization of the lysosome	No direct effect	Gold
Signalling pathways				
Toll-like receptors (TLR)	Binding of NP on TLR through <i>e.g.</i> hydrophobic effects	NA	TLR activation; increase or decrease of cytokines	CNTs; ZnO; silver; gold
Mitogen-activated protein kinases (MAPK)	ROS generation	NA	MAPK stimulates NF- κ B; increase of pro-inflammatory cytokines	Silica (colloidal and mesoporous)
Inflammasomes (NLRP3)	ROS generation; lysosomal cathepsin release	NA	NLRP3 activates caspase 1; production of IL-1 β and IL-18	Silver; AlO; MWCNT; TiO ₂
Pyroptosis	NLRP3 and caspase 1 activation; Cleavage of gasdermin D	Pore formation in cell membrane; cell death	Immunogenic cell death; release of intracellular contents <i>e.g.</i> IL-1 β	Mesoporous silica; La ₂ O ₃ and Gd ₂ O ₃
Necroptosis	Upregulation of ZBP1; activation of RIPK3	Pore formation in plasma membrane; cell death	Immunogenic cell death	Selenium; silica
Ferroptosis	Increased iron availability	Lipid peroxidation and glutathione depletion; cell death	Immunogenic cell death	Doxorubicin-loaded iron-saturated ferritin



induced oxidative stress varies for different nanomaterials. Redox-active nanomaterials for example, can either be antioxidant or prooxidant. Iron oxide is an example of a prooxidant nanomaterial and is heavily researched, especially superparamagnetic iron oxide nanoparticles (SPIONs), for their use in chemotherapy.¹⁴ Through Fenton and Haber-Weiss reactions, Fe^{2+} and Fe^{3+} ions can catalyze ROS generating reactions.¹⁵ When exposed to ultraviolet radiation, titanium oxide (TiO_2) is also prooxidant. UV exposure will lead to the formation of electron-hole pairs in the nanomaterial, which can react with oxygen to form ROS. This mechanism can be exploited in the photodynamic treatment of cancer.¹⁶ Cerium oxide (CeO) is an example of an antioxidative nanomaterial, that scavenges ROS through the Ce^{3+} and Ce^{4+} on the surface of the particles.¹⁷ An interesting study, performed by Dowding *et al.*, showed that the synthesis method of redox-reactive nanomaterials like CeO , can greatly influence the redox state of the material and thereby the anti- or prooxidative property of the material. This is a possible explanation for contradictory findings on toxicity in literature.¹⁸

Another way NPs can generate ROS is through oxidation of the nanomaterial itself, which subsequently leads to the release of (toxic) metal ions in a process called NP dissolution. A few, easily ionized nanomaterials (*e.g.* Ag , ZnO , CuO) have been described to release ions, and especially silver nanoparticles have been studied in detail, because of their popular use in consumer products leveraging their antimicrobial activity.¹⁹

However, AgNPs have been shown to induce toxicity upon *in vivo* exposure.²⁰ Multiple reports have indicated that this toxicity effect is mainly due to the release of ions during NP dissolution, although some reports indicate that NP-associated effects contribute to the toxicity of the particles as well.²¹ However, the most accepted mechanism for easily ionized metal nanoparticles is based on the so-called Trojan-horse mechanism.²² This mechanism was studied in more detail by Setyawati *et al.* and showed that particles are taken up *via* endocytosis by the cell and subsequently degraded in the lysosome, because the lower pH level accelerates NP dissolution. Ag^0 is then oxidized to Ag^+ , in a conversion step that includes ROS byproducts. The Ag^+ ions themselves interfere with the respiratory chain of the cell and lead to additional ROS formation.²³

ROS, either generated by redox-active materials or through NP dissolution, can elicit a variety of cellular processes with detrimental outcomes (Fig. 1). NP-induced ROS generation has, for example, been linked to mutagenic and carcinogenic effects and to induce lung fibrosis.²⁴ Additionally, ROS plays an important role in the induction of inflammation through the activation of oxidant-dependent mitogen-activated protein kinases (MAPKs) or the activation of the inflammasome. Murphy *et al.* investigated the pro-inflammatory effect of AgNP in THP-1 cells and results showed an increased gene expression of IL-1, IL-6 and $\text{TNF-}\alpha$. Additionally, a higher release of IL-1 β indicates the activation of the inflammasome.²⁵



Fig. 1 ROS generated oxidative stress elicit a variety of adverse, cellular processes.



Other metal NPs have shown to have a similar effect as well. In Brzicova *et al.*, it was shown that zinc oxide (ZnO) dissolution, and thus the release of Zn^{2+} , leads to the release of pro-inflammatory cytokines in THP-1 cells. Additionally, an enhanced expression of ICAM-1 and VCAM-1 was observed, which plays an important role in leukocyte adhesion.²⁶ The same inflammatory effect of ZnO was later shown *in vivo* and was proven to be regulated by the ROS-triggered activation of MAPKs.^{27,28} Similarly, Cu^+ ions were illustrated to contribute to ROS generation after copper oxide (CuO) NP dissolution,²⁹ and have shown to induce oxidative stress and trigger apoptosis in lymphocytes. ROS triggered lipid peroxidation, membrane potential collapse and lysosomal membrane leakage were all shown to contribute to the observed lymphocyte cell death.³⁰

Several parameters can influence oxidative stress and, therefore, the immunomodulatory effect of nanomaterials, *e.g.* by influencing their dissolution rate. Specific NP properties include composition of the metal core, size and surface coating. Size influences the dissolution rate, as more oxidation will take place on the larger reactive surface area of smaller NP.³¹ Park *et al.*, showed that 4 nm AgNPs induce a higher release of chemokines (IL-8) in comparison to larger AgNPs (20 and 70 nm) after *in vitro* exposure to macrophages.³² A similar size-dependent inflammatory effect was observed after *in vivo* pulmonary exposure to AgNPs with sizes 15 and 410 nm. Exposure to the smallest AgNPs led to a 5-fold increase in pro-inflammatory cytokines (IL-1 β and MCP-1) and a 175-fold increase in influx of neutrophils to the lungs.³³

A second way to influence dissolution and toxicity is the use of adequate coatings. Alcaron *et al.*, showed that type 1 collagen coated AgNPs are very stable and elicit no toxic effects in human fibroblasts and keratinocytes.³⁴ Similarly, Manshian *et al.* evaluated the effect of 3 different coatings on AgNP toxicity: mercaptoundecanoic acid (MUA), dodecylamine-modified poly(isobutylene-*alt*-maleic anhydride) (PMA) and polyethylene glycol (PEG). The different coatings were shown to have little effect on the intrinsic level of NP dissolution but did influence cellular NP uptake and thereby the level of Ag^+ in the cell. Additionally, different toxicity levels were observed for the different NPs, initiated by different toxicity pathways: PMA-coated NPs affected the cells through autophagy and cytoskeletal deformations, while MUA-NPs induce membrane damage because of agglomerate sedimentation. The difference in toxicity between the 3 different NPs indicates the importance of surface chemistry and proves that besides NP dissolution, also NP-associated effects contribute to ROS formation.²¹ The effect of surface chemistry was also illustrated for CuO NPs by Ilves *et al.*, *in vivo*. It was shown that inhalation of unmodified CuO lead to an exacerbation of allergic airway inflammation through an increased neutrophil influx. However, by coating the particles with PEG, this immune effect was suppressed.³⁵ The PEGylation effect on immune avoidance is commonly known. PEG-coating increases the hydrophilicity and neutralizes the surface charge on the particles. Without PEGylation, hydrophobic and cationic polymers show increased opsonization by serum proteins and as a result, a higher uptake by phagocytic cells.³⁶

2.1.2. Lysosomal membrane permeabilization. The accumulation of (mainly cationic) NPs in lysosomes can lead to a process called lysosomal membrane permeabilization or LMP. Although the mechanism that leads to LMP is not fully unraveled yet, it has been shown that the so-called proton sponge effect may play a significant role. Once accumulated in the lysosomes, cationic nanoparticles absorb free protons, resulting in the increased pumping of protons into the lysosomes, followed by Cl^- ions and water. Eventually, this leads to a significant lysosomal enlargement, which may lead to pore formation or physical rupture of the lysosomal membrane.³⁷ Wang *et al.* illustrated LMP after human astrocytoma 1321N1 cells were exposed to amine-modified polystyrene particles (NH_2 -PS), which eventually resulted in cell death. Additionally, the evolution of the different stages leading to cell death could be distinguished (Fig. 2). After 3 to 6 hours, an enlargement of the lysosomes and increased ROS levels could be observed. After 6 to 8 hours, leakage of lysosomal enzymes (mainly proteases like cathepsins) is observed, which damages the mitochondria. The loss of mitochondrial membrane potential leads to caspase 3/7 activation and cell death.³⁸

LMP has been reported to play a key role in NP-induced inflammation, more specifically, NLRP3 inflammasome activation. Jessop *et al.* illustrated that crystalline silica, multiwalled carbon nanotubes (MWCNTs) and titanium nanobelts induce acidification of the phagolysosome, which appeared to be critical in the eventually caused LMP in the exposed macrophages. This was proven by comparing silica exposure with or without Bafilomycin A1, a vATPase inhibitor which impedes proton influx. Results indicated that Bafilomycin A1 treatment inhibited lysosomal acidification and LMP.³⁹ Also, the cationic polymer poly(ethyleneimine) (PEI), which is mostly used as gene transfer vehicle, has been linked to induce LMP.⁴⁰ For example; Sang-Hyun Park and colleagues demonstrated that treating




Fig. 2 Lysosomal membrane permeabilization mechanism. Reproduced from ref. 38 with permission from The Royal Society of Chemistry.



HeLa cells with lysosomal membrane stabilization protein inhibitors resulted in a reduction in lysosomal Cl^- concentrations and the induction of LMP.⁴¹

2.1.3. Lysosomal alkalization. Contrary to the lysosomal acidification during LMP, NP-induced lysosomal alkalization is also possible. Gold (Au) nanoparticles have been shown to be taken up by a variety of cell lines, like; NRK rat kidney cells and dendritic cells.⁴² Ma *et al.* observed that this cellular uptake is characterized by a size-dependent endocytosis process, where, larger (50 nm) AuNPs showed higher cellular internalization than smaller (10 nm) particles. The internalized AuNPs eventually end up in the lysosome, which can lead to lysosomal alkalization. Normally, the vacuolar H^+ -(V)-ATPase is responsible for the regulation of lysosomal acidification and consist of a membrane-associated ion conductance V_0 protein complex and the peripherally associated ATPase V_1 protein complex. The AuNP-induced dissociation of V_1 from V_0 was observed to be responsible for this alkalization, which dysregulates the lysosomal degradation capacity.⁴³ Manshian *et al.* showed that this alkalization leads to an impeded clearance of autophagosomes and transient changes in cell functionality, like impeded cell migration and invasion.⁴⁴

2.2. Signaling pathways

Stress, generated by the exposure to nanoparticles, initiates (multiple) cell signaling pathways that eventually leads to immunological alterations. Several signaling molecules and pathways have been proposed to be involved and proven to be of importance for the different nanomaterials.

2.2.1. Toll-like receptors. Toll-like receptors (TLRs) are crucial in the recognition of intruding agents (pathogen-associated molecular patterns or PAMPs) by the innate immune system. Recognition of PAMPs, like NPs, can lead to the activation of NF- κ B, which subsequently activates a cascade of processes including upregulated cytokine production, increased macrophage phagocytosis and enhanced antigen presentation through upregulation of major histocompatibility complex (MHC), CD80 and CD86.⁴⁵ Although the mechanism behind the interaction between NPs and TLRs remains unknown, multiple NPs have been shown to induce immune responses *via* TLR signaling pathways (Fig. 3).⁴⁶ Turabekova *et al.* used computational methods to predict the immunotoxicity of carbon nanotubes (CNTs) and C_{60} fullerenes. They reported a strong binding affinity between the nanomaterials and TLRs, with higher values for CNT due to a higher surface area.




Fig. 3 Schematic illustration of the nanoparticle-induced signaling pathway regulated by TLRs. Reproduced from ref. 46 with permission of The Royal Society of Chemistry.



The hydrophobic pockets of TLR1/TLR2, TLR2/TLR6 extracellular domains and MD-2 were shown to be determining in the binding of CNTs and C₆₀ fullerenes.⁴⁶ The involvement of TLR signaling was also experimentally illustrated by Chang *et al.* for ZnO NP. Tracheal instillation in mice led to upregulation of the expression of TNF- α , IL-6, CXCL1 and MCP-1, and increased influx of neutrophils, lymphocytes and macrophages. A similar inflammation response was shown *in vitro* in MLE12 and RAW264.7 cells. The involvement of TLR signaling was proven by gene silencing of MyD88, a crucial adaptor protein in TLR signaling, which significantly reduced the ZnO-induced inflammation.⁴⁷ Similarly, by MyD88 silencing and TLR4 inhibition, Ho *et al.* proved quantum dot induced inflammation to be TLR4-dependent.⁴⁸

Interestingly, NP interaction with TLRs can also lead to an immunosuppressive effect. Gliga *et al.* recently showed that Ag nanoparticles reduce the LPS-induced release of pro-inflammatory cytokines in THP-1 cells (IL-1 β , TNF- α and IL-6). It was shown that co-treatment of LPS and AgNPs resulted in a dose-dependent inhibition of TLR2, which was suggested to be caused by the release of silver ions.⁴⁹ Tsai *et al.* illustrated that AuNPs can also lead to TLR-regulated immunosuppression. They showed that small AuNPs (4 nm) can inhibit TLR9 and, therefore, inhibit the production of pro-inflammatory cytokines.⁵⁰

2.2.2. MAPKs. Mitogen-activated protein kinases (MAPKs) are signaling molecules that play an important role in NP-induced inflammation. MAPKs are oxidant-dependent and will be influenced by the oxidative stress generated after NP exposure. MAPKs stimulate NF- κ B, which will activate expression of pro-inflammatory cytokines. The role of MAPK has been mainly illustrated for silica nanoparticles. Lee *et al.* evaluated inflammation difference between colloidal silica and mesoporous silica nanoparticles (MSNs) in murine macrophages. Keeping size, shape and concentration equal, it was demonstrated that mesoporous silica induced a significantly lower release of pro-inflammatory cytokines (TNF- α , IL-1 β and IL-6) compared to colloidal silica. Additionally, it was shown that colloidal silica nanoparticles strongly activated ERK, p38, JNK (3 types of MAPKs) and NF- κ B, while significantly less activation was shown for the mononuclear phagocytic system (MPS).⁵¹ The type of the meso-structure also plays a role. It was shown that cubic cage (AMS-8) meso-structures release more pro-inflammatory cytokines than cubic cylindrical (AMS-6) MSNs.⁵²

2.2.3. Inflammasomes. Caspase-1, the enzyme responsible for the proteolytic maturation and release of IL-1 β and IL-18, relies on the stimulation of the inflammasome NLRP3 (also called NALP3).⁵³ Zhou *et al.* showed that NLRP3 inflammasome is stimulated by ROS, and more specifically, superoxide from the mitochondrial complex I.⁵⁴ Yang *et al.* demonstrated the upregulated, simultaneous oligomerization of caspase-1 and NLRP3 after PBMC exposure to AgNPs. Additionally, they showed that, not only did, increased superoxide levels lead to NLRP3 activation, but also cathepsins released from the lysosome and cellular K⁺ efflux contributed to the inflammasome activation.⁵⁵ This is in agreement with the previously explained role of LMP in activating NLRP3 inflammasomes.³⁹

The role of NLRP3 is repeatedly shown in inflammatory responses to high aspect ratio nanomaterials. Manshian *et al.* illustrated the effect of aspect ratio for aluminum oxide (AlO) NPs in four different cell lines (KLN205, HeLa, A549 and SKOV3). The study showed that rod-like AlO NP resulted in higher toxicity, due to a higher cellular uptake, while wire-like particles showed higher activation of the NLRP3 inflammasome.⁴⁴ Hamilton *et al.* showed similar effects for TiO₂ by comparing nanospheres, 5 μ m and 20 μ m nanobelts in mouse alveolar macrophages. The longest nanobelts induced a significantly higher amount of pro-inflammatory cytokines (IL-1 β and IL-18).⁵⁶ Also, MWCNTs linked to inducing lung fibrosis, induce inflammation through the activation of NLRP3. Interestingly, Sun *et al.* showed the contribution of NADPH oxidase, able to generate an oxidative burst, for the MWCNT-induced inflammasome activation.⁵⁷

2.2.4. Immunogenic cell death mechanisms. Multiple cell death mechanisms are immunogenic and can thus contribute to inflammation. The most known immunogenic cell death mechanisms include pyroptosis, ferroptosis and necroptosis. Pyroptosis is a programmed, pro-inflammatory cell death and is dependent on caspase 1. It is characterized by a rapid plasma-membrane rupture and release of proinflammatory intracellular content. An important prerequisite of pyroptotic cell death is the activation of the inflammasome, *e.g.* the previously discussed NLRP3.⁵⁸ Which NLRs are responsible for pyroptosis and their exact role remains unclear. Note that the activation of NLRP3 and caspase 1 does not automatically implicate the induction of pyroptosis, as illustrated by previously explained examples.^{55,56}

Pyroptosis can be stimulated by multiple microbial infections, like *Salmonella* and *Legionella*, but also a few nanomaterials have been shown to induce pyroptotic cell death. Reissetter *et al.* showed that exposure of human alveolar macrophages to black carbon nanoparticles leads to the activation of the inflammasome and caspase 1, increased IL-1 β production and eventually pyroptosis. The distinction between pyroptosis and apoptosis was proven by the protective effect of treatment with YVAD, a caspase-1 inhibitor, and glycine, a pyroptosis inhibitor.⁵⁹ Furthermore, Zang *et al.* linked MSN to liver inflammation and hepatotoxicity. MSNs were shown to increase ROS levels, activate NLRP3 and subsequently initiate caspase 1-dependent pyroptosis in hepatocytes, both, *in vitro* and *in vivo*. The crucial role of NLRP3 was proven by the mitigation following NLRP3 knockdown or treatment with MCC950, a selective inhibitor of NLRP3.⁶⁰ A similar liver inflammation was observed in an interesting study evaluating the effect of 29 metal oxides. Of these metal oxides, only the rare-earth oxide (REO) NPs, *e.g.* La₂O₃ and Gd₂O₃, induced pyroptosis. However, pyroptosis was only observed in Kupffer cells, contrary to the observed apoptosis in hepatocytes. Lysosomal membrane permeabilization, induced by the lysosomal accumulation of REO NPs, was shown to play a key role in the activation of caspase 1. Caspase 1 subsequently cleaves Pro-IL-1 β and gasdermin D (GSDMD), resulting in N-GSDMD, which, after oligomerization in the cell membrane, leads to the formation of pores and the release of intracellular contents⁶¹ (Fig. 4).






Fig. 4 Mechanism of pyroptosis after uptake of nanoparticles. Reprinted with permission from ref. 61. Copyright (2018) American Chemical Society.

Necroptosis is another immunogenic cell death mechanism, regulated by 2 key components: (1) receptor-interacting serine-threonine kinase 3 (RIPK3) and (2) mixed lineage kinase domain-mike (MLKL). These 2 components are crucial in the characteristic plasma membrane permeabilization. RIPK3 is responsible for phosphorylation of serine and threonine residues on MLKL, which facilitates MLKL oligomerization, eventually leading to pore formation in the plasma membrane. Additionally, both RIPK3 and MLKL have been linked to the activation of the inflammasome, which leads to the pro-inflammatory potential associated with necroptosis.⁶² A few nanomaterials have been linked to necroptosis, for example, silica nanoparticles have been shown to induce necroptosis in hepatocellular carcinoma cells. Interestingly, it was shown that Z-DNA binding protein 1 (ZBP1), an RIPK3 activating protein, was upregulated after silica exposure and played a crucial role in necroptosis.⁶³ Additionally, Selenium nanoparticles were shown to induce necroptosis in PC-3 cancer cells.⁶⁴

A third immunogenic cell death pathway is ferroptosis. This regulated cell death mechanism is mediated by lipid peroxidation and iron availability and induced by glutathione depletion.⁶⁵ This type of cell death has been first proposed by Dixon *et al.* in 2012 and therefore nanomaterials linked to ferroptosis are limited at present.⁶⁶ Yang *et al.* designed doxorubicin loaded iron saturated ferritin nanoparticles that efficiently led to cell death of HT29 cells *via* ferroptosis. However, this was only seen for the drug loaded nanomaterials. Unloaded ferritin nanoparticles showed almost no cytotoxicity to HT29 and thus were unable to initiate ferroptosis.⁶⁷

3. Inorganic nanomaterials in immunological applications

The insights discussed above have allowed researchers to tune these nanomaterials in applications where an enhanced activation of the immune response is required. The most important applications where this is the case are nanovaccines. Nanoparticles can serve 3 purposes in vaccines: they can serve as

adjuvant, as an antigen carrier and as an adjuvant carrier. Beside applications in which NP-induced immune responses are desired, nanoparticles can also be used as delivery vehicles for the targeted delivery of compounds that interact with the immune system. In these applications, the goal of using nanomaterials is to enhance the efficiency of the active compound, while the toxic or immunogenic effect of the material is undesirable. At present, inorganic nanomaterials qualifying these criteria and used for immunological applications, are scarce.

3.1. Gold

Gold NPs are among the most popular nanoparticles, because they are considered bioinert, are easily synthesized and modified and have proven to be successful in a wide range of applications such as; biosensors, drug delivery and optical imaging applications.⁶⁸ In addition, their use as nanovaccines has shown to have potential in cancer therapy,⁶⁹ Influenza A⁷⁰ and Malaria,⁷¹ where they can serve as adjuvant, as antigen carrier, and adjuvant carrier. This was illustrated by Almeida and colleagues, who studied the use of AuNPs in peptide vaccines in anti-tumour immunotherapy. They showed that OVA-coated AuNPs, induce a higher systemic antigen-specific response compared to free OVA due to a facilitated delivery. This immune response translated in tumour growth reduction in a B16-OVA tumour mouse model. Also, the use of AuNPs as adjuvant carrier was shown by evaluating coupled CpG:AuNPs. Results show that a higher immune response is generated after administration of free OVA in combination with CpG:AuNPs compared to both free OVA and CpG. Interestingly, comparing the immune response to either OVA:AuNPs or to OVA:AuNPs in combination with CpG:AuNPs, was not significantly different.⁶⁹ However, the adjuvant effect of AuNP does not imply the uselessness of other adjuvants. Wang *et al.* showed, indeed, that the combination of influenza A hemagglutinin bound AuNPs (AuNP-HA) with flaggellin (Flic)-bound AuNPs (Flic-AuNP) was essential for the effectiveness of the vaccine. Without the adjuvant Flic-AuNP, the AuNP-HA induced a similar antigen-specific immune response, but was unable to effectively






Fig. 5 Self-assembly of peptides on gold nanoparticle surface.⁷³

induce a favorable IgG1/IgG2a ratio and, therefore, the promotion of cellular immunity.⁷²

Optimizing AuNPs as a vaccine delivery platform is possible by, for example, increasing the amount of peptides per particle, as illustrated by the bottom-up, self-assembling method proposed by Lin *et al.* (Fig. 5). By first coating the AuNPs with PEG-SH and subsequently conjugating the peptides using EDC/sulfo-NHS chemistry, multiple repeats of the peptide can be bound to the AuNP. This can enhance the efficiency of nanovaccines and deliver larger doses, resulting in stronger immunogenicity.⁷³ Another optimization method is choosing peptides that conjugate in a highly ordered, densely packed manner. Higher order organization of epitopes, similar to highly efficient surfaces of viruses, provokes a strong immune response. The coating order is influenced by the presence of the hydrophobic chains in the peptides.⁷⁴

Given the immunomodulatory effect of AuNPs, they have also been researched as potential anti-virals. The anti-viral effect of gold has been proven *in vivo* for respiratory syncytial virus (RSV) in Bawage *et al.* By stimulating the innate immune system through AuNP mediated TLR, NOD-like and RIG-1-like receptor signaling pathways, the production of cytokines and chemokines increases leading to an enforced defense mechanism and subsequently, a reduced replication of RSV.⁷⁵

3.2. Silica

Mesoporous silica nanoparticles have been heavily researched for their potential in nanovaccines.⁷⁶ The use of these hard, inorganic nanomaterials is especially interesting for oral vaccines. Despite the advantages of oral vaccination (ease of administration and increased patient compliance), poses the harsh gastrointestinal environment an enormous challenge for effective vaccination due to drug inactivation or degradation. For the purpose of developing novel oral vaccine adjuvants, Wang *et al.* investigated the potential use of mesoporous silica nanoparticles, serving as both the antigen carrier and as adjuvant. They designed 3 different particles with different particle sizes and pore diameter/geometry, which were loaded with BSA. Results of the systemic and humoral immune response in mice showed that the silica loaded nanoparticles induced a significant higher IgG production in comparison with the free BSA. Within different particle designs, a higher antibody titer can be obtained if the release of the antigen is prolonged. A larger pore diameter and particle size were shown to possibly prolong the

release of antigens. However, an optimal size range around 500 nm was reported, balancing the antigen release rate and the cellular uptake of the particles. Besides its clear antigen delivery potential, results showed that both the Th1 (cell-mediated) and Th2 (humoral) immune responses were induced upon administration of porous silica.⁷⁷ The self-adjuvant effect of MSN was strongly illustrated by Mahony *et al.*, were the adjuvant performance of AVO-loaded MSN was compared to the widely used adjuvant QuilA. Immunization results in mice showed that an MSN formulation with 10 μg of OVA resulted in a strong antibody and cell-mediated response, which was only slightly smaller than the OVA-QuilA formulation. The high immune response with a lower amount of antigen, together with the observation that MSN did not induce any toxic events, shows the potential of MSN as a self-adjuvant vaccine delivery platform.⁷⁸ Efforts have been made to optimize this platform further, for example by tuning the adjuvant potency by changing the surface chemistry of the MSN particles. Yang *et al.*, showed that a hydrophobic $-\text{C}_{18}$ modification, in comparison to $-\text{OH}$ and $-\text{NH}_2$ -groups, significantly enhances antigen uptake by APCs, macrophage maturation and antibody response in mice. Additionally, the positively charged $-\text{NH}_2$ particles showed a higher antibody response in comparison to the negatively charged $-\text{OH}$ particles.⁷⁹

Mesoporous silica is also one of the most interesting inorganic nanomaterials for drug delivery. The potential of MSN-based drug delivery is based on its large internal volume and high drug loading capacity. Additionally, as explained previously, physical properties of MSN can be tuned so that the immune response is limited. In Heidegger *et al.*, a pro-inflammatory drug (synthetic TLR7/8 ligand R848) was loaded in MSN particles and was shown, in contrast to empty MSN, to provoke a strong immune response in mice.⁸⁰ Additionally, anti-inflammatory agents can be loaded in MSN for drug delivery. Braz *et al.* loaded MSN with the anti-inflammatory drug indomethacin and showed that the MSN-drug complex significantly lowered the *in vitro* cytotoxicity compared to the free form of the drug.⁸¹

These MSN-based systems can be further improved, for example by using coatings such as ethylcellulose, which prolongs the drug release.⁸² Additionally, it can be modified for stimuli-responsive drug release by *e.g.* adding a lipid layer, which resolves in the reductive intracellular environment and subsequently sets the encapsulated drug free.⁸³ The drug



loading capacity and entrapment efficiency can be improved by using hollow MSNs, but these have the disadvantage that all pores are connected to one large reservoir and the drug can be released by any of the interconnected pores.^{84,85}

3.3. Silver

In the process of wound healing, the inflammatory stage is essential for a rapid clean-up of the tissue and the neutralization of invading agents.⁸⁶ Studies have shown that AgNPs induce an acute immune response, which normalizes over time.³³ This short-term inflammation has been found to be beneficial in wound healing. The initial rapid inflammation speeds up the wound healing process, eventually decreasing inflammation faster.⁸⁷ Tian *et al.*, demonstrated the beneficial effect of AgNPs in a thermal injury mouse model. By applying AgNP-coated dressings on the burn wound, an upregulation in mRNA levels of VEGF, IL-10 and IFN- γ was obtained, contributing to a fast wound healing process.⁸⁸ Additionally, Kwan *et al.* showed that using AgNPs for wound healing also leads to better restored functionality of the healed skin.⁸⁹

3.4. Aluminium

Aluminium salts (Alum) are widely used as adjuvants but have been shown not to be effective for several vaccine targets such as influenza, HPV and HBV, because alum mainly induces Th2 type immunity.⁹⁰ Orr *et al.* showed in their study that engineering the properties of Alhydrogel nanoparticles (nanoalum) can greatly influence their adjuvant properties. Results showed that, while the unbound formulation of poly(acryl) acid (PAA) and nanoalum promoted a Th2 immune response, PAA-coated nanoalum strongly promoted a Th1 immune response.⁹¹ The engineering of these nanoparticles has thus led to a possible new adjuvant class that can be used for diseases where Th1 immunity is important. In a follow-up study, Khandar *et al.* showed that the oxidative state of the core of the nanoalum influences its adjuvant capability. Nanoalum made from AlO(OH) did induce CD4⁺ T cells in mice, while the γ -Al₂O₃ derived particles did not.⁹⁰

3.5. Silicon

Porous silicon is a biodegradable and biocompatible material with a large drug loading capacity. In Gu *et al.*, porous silicon nanoparticles (SiNPs) were incorporated with multiple copies of the FGK45 antibody, an agonistic antibody to the APC receptor CD40. *In vitro* stimulation of mice B cells revealed 30–40-fold

activation level FGK-SiNP in comparison with free FGK45, while empty SiNP showed no B cell activation, indicating the immunological inertness of the nanomaterials. The increased activation was shown to be due to an increased potency of the conjugated FGK45 and not because of multivalency.⁹²

3.6. Others

Some inorganic nanomaterials have proven to be effective in interacting with microbes and viruses and can offer potential in therapeutics for infectious diseases. In this way, inorganic nanoparticles can impact indirectly the induced immune response. The most researched nanomaterial for this is silver, that has proven to act, both, as anti-microbial⁹³ and anti-viral.⁹⁴ Additionally, given the previously explained lysosomal alkalinization effect of gold nanoparticles, AuNPs might be of interest as less toxic variant for chloroquine in reducing replication of ACE2 receptor dependent viruses, like the coronaviruses SARS-Cov, NL63 and SARS-Cov-2.⁹⁵ A higher pH in lysosomes (and endosomes) reduces the rupture of the virus particle and therefore prevents the release of infectious viral nucleic acids.⁹⁶ Additionally, alkalization affects glycolisation of the ACE2 receptor and, therefore, the viral binding affinity of the receptor.⁹⁷ A detailed discussion of nanomaterials in infectious diseases falls outside the scope of this review. Finally, inorganic nanomaterials can be used in combination therapy, which will be discussed in a later chapter.

4. Organic nanoparticles in immunological applications

A plethora of organic nanocarriers have been reported as promising drug delivery systems including polymer-based nanoparticles, liposomes, dendrimers and protein nanoparticles (Fig. 6).^{98,99} Their advantages include: (1) the improved bioavailability of insoluble drugs and reduced side effects, (2) the protection of their cargo from degradation and rapid clearance, (3) specific tissue targeting using surface-coupled ligands, (4) controlled drug release and (5) co-delivery of agents for a synergistic therapeutic effect. Due to their preferable properties, such as their increased biodegradability, biocompatibility and stability,⁹⁸ organic nanomaterials have been extensively investigated as potential delivery vehicles of anti-inflammatory agents to inflamed tissues (Table 2), while they have also been explored as a cargo for vaccines and vaccine adjuvants (Table 3). Many studies have shown that the physicochemical characteristics and surface modifications of organic



Fig. 6 Classification of organic nanoparticles. Created with Biorender.com.



Table 2 Organic nanoparticles for the treatment of inflammation

Nanoparticle	Loaded anti-inflammatory agent	Modification	Application	System
Polymeric				
PLA-PEG ¹⁰⁵	TNF α -siRNA	Covalent surface Fab' attachment	Inflammatory bowel disease (IBD) treatment	Mouse model of colitis
PLGA-PEG-PLGA ¹¹⁰	Etoricoxib (NSAID)	NA	Osteoarthritis (OA) treatment	Intra-articular injection in rat OA model
PLA-PEG ¹¹¹	Curcumin	NA	Liver inflammation treatment	STZ-induced diabetic rats
PLA-PEG ¹¹⁵	NA	Surface coupled mAbs to E-selectin, VCAM-1, and ICAM-1	Inflamed endothelium targeting	<i>In vitro</i> : adhesion assay (HUVEC), <i>in vivo</i> : adhesion assay post TNF- α injection (mice)
PLGA-PEG ¹¹⁶	Genistein (protein tyrosine kinase inhibitor)	Surface coupled islet-homing peptide (CHVLWSTRC; Pep I)	Insulinitis therapy	Islet CE cells [leukocyte-endothelial cell adhesion assay]
PLGA ¹¹⁸	NA	Surface coupled α 2,8 N-acetylneuraminic acid (NANA)	Sepsis treatment	<i>In vitro</i> : LPS stimulated mice peritoneal macrophages, primary human monocyte derived macrophages and monocytes (MDMs), <i>in vivo</i> : mouse model of systemic inflammation, mouse model of lung injury, <i>ex vivo</i> : human lung perfusion model
PLGA ¹¹⁹	NA	Macrophage membrane coating	Sepsis treatment	<i>In vitro</i> : mouse TLR4 reporter cells, HUVECs, <i>in vivo</i> : mouse bacteraemia model, mouse endotoxemia model
PLGA ¹²⁰	NA	Human neutrophil membrane coating/mouse neutrophil membrane coating	Rheumatoid arthritis (RA) treatment	<i>In vitro</i> : human chondrocytes, HUVECs, <i>in vivo</i> : injured cartilage mouse model, inflamed cartilage mouse model, collagen-induced arthritis (CIA) mouse model, human transgenic mouse model of inflammatory arthritis
APN micelle ¹²¹	Prednisolone (PD) [glucocorticoid]	NA	Rheumatoid arthritis (RA) treatment	Mouse model of rheumatoid arthritis
PPS-PNIPAm (ROS-temperature responsive copolymer) ¹²²	DOX	NA	Inflammation and tumour targeting	MCF-7 cell line
Polyketal (PK) ¹²³	Superoxide dismutase (SOD)	NA	Interstitial lung diseases (ILD) treatment	Bleomycin mouse model of lung fibrosis
HPOX ¹²⁵	Biodegradable hydroxybenzyl alcohol (HBA)	NA	Airway inflammatory diseases treatment	Mouse model of allergic asthma
Liposomes				
DPPC/DPPG/Chol, 50/10/40 mol% (ref. 139)	Dexamethasone phosphate (DXM-P) (glycocorticoid)	NA	Rheumatoid arthritis (RA) treatment	Antigen-induced RA rat model
(NH ⁺)-DOPC/DOPE/DOTAP ¹⁴⁰	Guanosine 5'-diphosphate (GDP)	NA	Anaemia of inflammation (AI) treatment	<i>In vitro</i> : U937 monocytic cells and co-culture model consisting of HepG2 and Caco2 cells, <i>in vivo</i> : acute and chronic AI mouse model
LEC, F70101C-AL, FormuMax Scientific, Sunnyvale, CA, USA ¹⁴¹	Clodronate (LEC)	NA	Acute inflammation treatment	Carrageenan-induced inflammation model



Table 2 (Contd.)

Nanoparticle	Loaded anti-inflammatory agent	Modification	Application	System
DPPC, PEG-DSPE (1.85 : 0.15 : 1.0) ¹⁴⁸	Prednisolone phosphate (PP)	NA	Rheumatoid arthritis (RA) treatment	Adjuvant induced arthritis rat model
DPPC, PEG-(2000)-DSPE, NBD-PE, cholesterol (1.85 : 0.15 : 0 : 1) ¹⁵⁰	Dexamethasone phosphate	NA	Hepatitis and liver fibrosis treatment	Mouse models of acute concanavalin A (ConA)-based hepatitis and chronic toxic carbon tetrachloride (CCl ₄)-based liver injury
DSPE-PEG2000 (ref. 151)	Dexamethasone (Dex)	DC8,9 PC molecules crosslinked in the bilayer by UV irradiation	Rheumatoid arthritis (RA) treatment	<i>In vitro</i> : raw264.7 cell line, <i>in vivo</i> : adjuvant induced arthritis rat model
LipoCardium ¹⁵⁵	Cyclopentenone prostaglandin (PGA2)	Surface coupled anti-VCAM-1 antibodies	Atherosclerosis treatment	<i>In vitro</i> : U937pro-monocytic cell line, <i>in vivo</i> : atherosclerosis induced mouse model
DPPC 53% cholesterol 45%, DSPE-PEG2000 2% ¹⁵⁶	NA	Surface coupled anti-ICAM-1 antibodies	Intra-arterial drug delivery of CNS disorders	Brain inflammation mouse model induced by microinjection of TNF
DSPC : CH : SA (7.5 : 2.5 : 0.5) (inner liposome) ¹⁵⁸	Prednisolone (PRD) with methotrexate (MTX)	Folate-PEG-DSPE (outer liposome)	Rheumatoid arthritis (RA) treatment	Collagen-induced arthritis (CIA) rat model
Leukosome ¹⁵⁹	Dexamethasone (Dex)	Constituted by proteins derived from the leukocytes'	Targeting of inflamed endothelia	<i>In vitro</i> : HUVECs, <i>in vivo</i> : LPS induced murine ear inflammation
Dendrimers				
Polyamidoamine (PAMAM) (G2-G4) ¹⁷⁶	Ketoprofen, Ibuprofen, Diflunisal, Naproxen [NSAIDs]	NA	Improvement of NSAIDs solubility	NA
G4-NH2-PAMAM ¹⁷⁷	NA	NA	Inflammation treatment	<i>In vitro</i> : rat peritoneal macrophages, <i>in vivo</i> : adjuvant-induced arthritis rat model,
3.5 polyamidoamine (PAMAM) ¹⁷⁸	NA	Glucosamine and glucosamine 6-sulfate conjugation	Prevention of scar tissue formation after surgery	Carrageenan-induced edema rat model
Polyglycerol sulfates (dPGS) ¹⁸⁵	NA	Surface coupled E-, P- and L-selectin ligands	Blockade of leukocytes recruitment for therapeutic intervention in inflammatory disorders	PBMCs, HUVECs rabbit glaucoma filtration surgery model of excessive scar tissue formation
Protein				
HSA ¹⁹⁴	Methotrexate (MTX)	Chlorin e6 (Ce6) conjugation	SPARC targeting for rheumatoid arthritis (RA) treatment	Collagen-induced arthritis (CIA) mouse model
HSA ¹⁹⁵	5-Aminosalicylic acid (5-ASA)	Crosslinking with glutaraldehyde	MPO targeting for inflammatory bowel disease (IBD) treatment	DSS induced colitis mouse model
BSA ¹⁹⁶	Piceatannol (Syk inhibitor)	Crosslinking with glutaraldehyde	Inactivation of neutrophil transmigration and vascular inflammation mitigation	<i>In vitro</i> : isolated mouse neutrophils, <i>in vivo</i> : LPS-induced acute lung injury mouse model



Table 2 (Contd.)

Nanoparticle	Loaded anti-inflammatory agent	Modification	Application	System
Gelatin ²⁰³	Ibuprofen	PEGylation and CaCl ₂ crosslinking	Enhanced pharmacokinetics and bioavailability of ibuprofen for rheumatoid arthritis and chronic arthropathies treatment	<i>In vitro</i> : platelet rich plasma (PRP), platelet poor plasma (PPP) human peripheral blood mononuclear cells (PBMCs), RAW264.7 cells, <i>in vivo</i> : 5 week-old Sprague Dawley WT rats
Gelatin ²⁰⁴	Epigallocatechin gallate (EGCG)	Surface coupled hyaluronic acid (HA) NA	Dry-eye syndrome (DES) treatment	<i>In vitro</i> : HCECs, <i>in vivo</i> : DES induced rabbit model, Wistar rats
Lipoprotein-mimicking peptide-phospholipid scaffold (HPPS) ²⁰⁶	Curcumin		Autoimmune encephalomyelitis (EAE) treatment	<i>In vitro</i> : mouse isolated monocytes and neutrophils, <i>in vivo</i> : EAE mouse model
Elastin like particle (ELP) ²⁰⁷	Stromal cell-derived factor1 (SDF1)	Fusion of ELP with SDF1	Wound healing	Diabetic mice wound assay

nanoparticles moderate their immunological response. As has been well illustrated in the review of M. A. Dobrovolskaia and S. E. McNeil, different parameters, including size, shape, hydrophobicity, surface chemistry and functionalization as well as their route of administration have an essential role on the immunomodulatory effects of nanoparticles and consequently on their successive outcome, depending on the application used.¹⁰⁰ In this section, we focused on organic nanoparticle-based treatments for inflammatory diseases as well as on their role as vaccine delivery systems and vaccine adjuvants.

4.1. Polymer-based nanoparticles

4.1.1. Polymeric nanoparticles for the delivery of anti-inflammatory agents. Polymeric nanoparticles (NPs), such as poly(D,L-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(glutamic acid) (PGA), poly(caprolactone) (PCL), *N*-(2-hydroxypropyl)-methacrylate copolymers (HPMA), and poly(amino acids) have been widely used as drug delivery vehicles for several therapeutic applications. The advantage of polymeric NPs as drug delivery systems is based on their unique properties allowing for controlled drug release, increased blood circulation time and protection of the drug from biodegradation and rapid clearance.¹⁰¹ The most common methods for the fabrication of polymeric nanoparticles are (a) nanoprecipitation, and (b) emulsification-based techniques while the choice of the synthesis procedure is mainly based on the desired particle characteristics and drug properties.⁹⁹ Polymeric nanoparticles are classified based on their method of preparation into nanospheres, which are a matrix system with the drug dispersed within it, and nanocapsules, which consist of a polymer membrane surrounding the drug.¹⁰² Polymeric nanoparticles can be used as delivery vehicles of anti-inflammatory drugs that result in adverse side effects when administered systemically, such as non-steroidal anti-inflammatory drugs (NSAIDs).¹⁰³ In addition, they can facilitate the delivery of novel anti-inflammatory agents, such as siRNAs and peptides, which present poor solubility and stability.¹⁰⁴ For example, Laroui H. *et al.*, developed TNF α -siRNA-loaded PLA-PEG NPs in order to silence TNF- α critical chemo stimulating factor as a therapeutic approach for IBD and their results indicated a significant anti-inflammatory effect.¹⁰⁵ Tumour necrosis factor- α (TNF- α) is a pro-inflammatory cytokine and is thought to be involved in many inflammatory diseases and cancer.¹⁰⁶ There has been an increasing interest in delivering siRNA for inhibiting TNF- α production as a potential treatment for inflammatory diseases.¹⁰⁷⁻¹⁰⁹ Furthermore, block co-polymers containing PLGA and polyethylene glycol (PEG) blocks are attracted attention due to their sustained drug release and biocompatible properties. Liu P. *et al.*, developed PLGA-PEG-PLGA triblock copolymeric nanoparticles (NPs) as a drug delivery system to locally deliver etoricoxib, a COX-2 selective NSAID, into the articular cavity of osteoarthritis (OA) induced rats. The PLGA-PEG-PLGA NPs displayed a 28 days sustained release of etoricoxib *in vitro*, while *in vivo* they relieved the symptoms of osteoarthritis in rats.¹¹⁰ El-Naggar, M. *et al.*, successfully developed PLA-PEG copolymer nanoparticles with curcumin, an anti-





Table 3 Organic nanoparticles as vaccines and vaccine adjuvants

Nanoparticle	Loaded antigen	Properties	Application	System
Polymeric				
Delta-inulin (Advax™) ^{1,32}	NA	Complement activation	Improvement of recombinant hepatitis B virus (HBV) immunogenicity [vaccine adjuvant]	Mice and guinea pigs
Carboxylated polystyrene ^{1,33}	Ovalbumin (OVA)	Shape and size related immune response modulation (smaller spherical NPs produce a greater Th1 biased cell mediated immune response, while larger rod-shaped NPs a Th2 biased humoral immune response) Enhanced protein delivery to IDCs	Vaccine	<i>In vitro</i> : mouse dendritic cell line (DC2.4), <i>in vivo</i> : female Balb/c mice
Amphiphilic γ -PGA ¹²⁸	Ovalbumin (OVA) or recombinant human immuno-deficiency virus (HIV)-1		Vaccine/vaccine adjuvant	<i>In vitro</i> : murine iDCs, <i>in vivo</i> : female BALB/c mice
Cationicalginate-PEI nanogels ¹²⁹	Ovalbumin (OVA)	Enhanced MHC I presentation and IFN- γ production	Vaccine/vaccine adjuvant	<i>In vitro</i> : mouse splenocytes, mouse bone marrow dendritic cells (BMDCs), raw 264.7 mouse macrophages, <i>in vivo</i> : female C57BL/6 mice
CD205 and CD11c Ab functionalised poly (N-vinylpyrrolidone) (PVPON) ¹²⁷	NA	CD11c-NPs: Successful internalisation by DCs DC205-NPs: Unsuccessful internalization by DCs	Vaccine/vaccine adjuvant	Mouse spleen derived dendritic cells (DCs)
Anti-human DEC-205 functionalised PLGA ¹²⁶	MART-1peptide	DEC-205 receptor-mediated targeting of tumor Ag to DCs	Cancer vaccine	Human monocyte-derived DCs
Liposomes				
Mannosylated phosphatidylethanolamine (Man-PE) ¹⁶²	Neisseria meningitidis type B antigen PorA	Recognised by the DC surface molecule mannose receptor (MR), enhanced uptake by human DCs compared to unmannosylated liposomes	Vaccine/vaccine adjuvant	Human monocyte-derived DCs (MoDCs) and murine bone marrow-derived DCs (BMDCs)
Positively charged MLVs (PC/Chol/SA: molar ratio 4 : 5 : 1) ¹⁶³	Ovalbumin (OVA)	Efficient vectors to APC and antigen-depots	Vaccine/vaccine adjuvant	<i>In vitro</i> : C57BL/6 T lymphoma EG7 cell line, OVA-transfected clone of EL4 cell line, <i>in vivo</i> : male C57BL/6 mice, female BALB/c mice
Cationic PEGylated DDA: TDB ¹⁶⁴	Ag85B-ESAT-6	Size and % PEGylation controls depot formation and Th1/Th2 balance	Vaccine/vaccine adjuvant	Female BALB/c mice
ALF- and ALFQ ¹⁶⁷	NA	Enhanced anti-polysaccharide antibody responses	Vaccine adjuvants	Female BALB/c mice, female C57BL/6 mice
PLFE-based archaeosomes ¹⁶⁸	Ovalbumin (OVA)	Antigen specific both systemic immune response and mucosal immune response by oral administration	Oral vaccination	Female BALB/c mice



Table 3 (Contd.)

Nanoparticle	Loaded antigen	Properties	Application	System
Dendrimers Le ^b -conjugated poly(amido amine) (PAMAM) ¹⁸⁶ Dendritic FMDV peptide ¹⁸⁸	Ovalbumin (OVA) NA	G3 and G4: optimal size and multivalency to achieve the most efficient DC-SIGN targeting T-cell activation that efficiently contributes to FMDV protection	Antigen delivery to DCs Vaccination against foot-and-mouth disease virus (FMDV)	Human monocyte-derived dendritic cells Pigs
Protein Virus like particles (VLPs) ²⁰⁸	NA	Presentation of viral Env spikes in their natural conformation, efficient internalisation by APCs and strong humoral and cellular immune responses stimulation	Vaccination against hepatitis B, hepatitis E, HPV	Commercially available for humans

inflammatory, antioxidant, anti-cancer and anti-amyloidogenic agent. The formulations resulted in attenuation of hyperglycaemia and protective effects of rat liver from inflammation in STZ-induced diabetic rats.¹¹¹

4.1.1.1. PEGylation for escaping immune system recognition. Hydrophobic and cationic polymers present increased opsonization by serum proteins and as a result a higher uptake by phagocytic cells.¹⁰⁰ The uptake of nanoparticles usually increases with increasing the zeta potential values while excess of positive charge can induce toxicity and stimulate immune reactions.¹¹² When the goal is to avoid the immune system recognition, coating of NPs surface with polyethylene glycol (PEG) is thought to be a good strategy in order to increase the hydrophilicity and neutralise the surface charge of the particles.¹¹³ PEG generates a hydrated volume around the NPs, due to its hydrophilic nature, precluding NPs from steric interactions with other NPs and blood components. There are many factors that influence the interactions and circulation of PEGylated NPs in the blood, including PEG molecular weight, surface density and the physicochemical properties of NP core which should be taken into consideration for the optimal engineering of NP vehicles, in association with the targeting tissues, therapeutic application, loaded cargo and administration route.¹¹⁴

4.1.1.2. Ligand-targeted polymeric nanoparticles. Furthermore, polymeric NPs can be functionalized in order to target specific tissues by active targeting or escape the MPS. Several targeting ligands are used for drug delivery such as antibodies, peptides and lectins.^{115–118} Sakhalkar H. *et al.*, functionalized PLA-PEG NPs with monoclonal antibodies in order to target E-selectin, P-selectin, VCAM-1, and ICAM-1 on inflamed endothelium tissue. The targeted particles showed an increased adhesion to inflamed HUVEC cells (up to 33-fold) compared to non-inflamed and increased adhesion to cytokine (up to 6-fold) and trauma induced inflamed endothelium (up to 10-fold) compared to untreated endothelium.¹¹⁵ Apart from antibodies, peptides could also be used as targeting ligands to inflamed tissues. Ghosh K. *et al.*, coated PLGA-PEG NPs with an islet-homing peptide (CHVLWSTRC-Pep I) in order to target the endothelium of insulin-producing pancreatic islet β cells that are progressively destroyed by the body's immune cells in type 1 diabetes. The autoimmune destruction of islet β cells in insulinitis initiate with the adhesion of blood leukocytes to the inflamed islet vascular endothelium, followed by extravasation of the immune cells into the islet parenchyma where they attack the islet β cells. The Pep I functionalized PLGA-PEG NPs loaded with genistein (Gen), a protein tyrosine kinase inhibitor that is known to impair leukocyte binding to TNF-stimulated endothelial cells. The Pep I-Gen-PLGA-PEG NPs exhibited a 3-fold increased binding capability to islet endothelial cells *in vitro* compared to controls and a 200-fold inhibition of leukocyte adhesion to islet endothelial cells compared to free drug.¹¹⁶ Sialic acid-binding immunoglobulin-like lectins (Siglecs) are type I transmembrane proteins and are considered to be self-associated molecular patterns found on hemopoietic and immune cells which regulate immunity.¹¹⁷ Spence S. *et al.*, demonstrated that PLGA NPs conjugated with *N*-acetylneuraminic acid (NANA), a murine Siglec-E ligand, were able to

target Singlec-E receptors and exhibited a significant anti-inflammatory effect in murine and human inflammatory models.¹¹⁸

4.1.1.3. Biomimetic functionalization of polymeric nanoparticles. Another promising strategy seems to be the coating of nanoparticles with leukocytes' membranes in order to recapitulate their biological properties. For example, Thamphiwatana S. *et al.*, exploited the capability of macrophages to bind to endotoxins and pro-inflammatory cytokines in order to find a therapeutic effect against sepsis. They coated PLGA NPs with macrophage membranes which maintained their binding properties without retaining the inflammatory signals of macrophages. This resulted in the sequestering of bacterial endotoxin and inflammatory factors in a sepsis *in vivo* mouse model with a significant therapeutic potential.¹¹⁹ In a similar study, Zhang Q. *et al.*, used the membrane of neutrophils to coat PLGA NPs in order to target cytokines activated by chondrocytes in a rheumatoid arthritis mouse model which showed promising anti-arthritis effects.¹²⁰

4.1.1.4. Responsive polymeric micelles. Polymeric micelles are core-shell nanostructures that are formed by the self-assembly of amphiphilic block copolymers and can solubilize hydrophobic drug molecules that are not well dissolved in water.⁹⁸ Polymeric micelles with pH-, thermal and reactive oxygen species (ROS) responsiveness have also attracted a lot of attention due to their capabilities to target inflammation. Li C. *et al.*, synthesized a pH-sensitive amphiphilic NP by conjugating the glucocorticoid drug prednisolone (PD) with the polymer APN which is a branched derivative of PEG. The APN micelles were able to target the inflamed tissue of a rheumatoid arthritis mouse model, while the acidic environment at the sites of inflammation led to a targeted drug release, resulting in better therapeutic results than the free drug.¹²¹ In another study, Tang M. *et al.*, created a diblock copolymer combining poly(ϵ -propylene sulfide) (PPS) which is a ROS-sensitive polymer with PNIPAm, a thermo-sensitive polymer, in order to engineer a drug delivery vehicle which will release its cargo specifically in inflamed and cancerous tissues, characterized by increased ROS generation and higher temperatures.¹²²

4.1.1.5. Polymeric nanoparticles for pulmonary administration. The route of administration influences the toxicity profiles of NPs and should thus be tested for each administration route separately. For instance, although PLGA has been approved by United States-Food and Drug Administration (US-FDA) for biomedical and pharmaceutical applications, the use of PLGA NPs for pulmonary administration is not optional due to its acidic products and its slow degradation which results to an airway inflammatory response.¹²³ Springer S. *et al.*, instilled PLGA microspheres in the trachea of hamsters in order to investigate whether they are easily detectable within alveolar macrophages, which would constitute them as a possible marker for the diagnosis of respiratory lung disease. They noticed an acute inflammatory response on the instillation day of PLGA particles, demonstrated by an increase in neutrophils in whole-lung lavage and lung parenchyma of hamsters, that disappeared thereafter.¹²⁴ V. F. Fiore *et al.* compared the inflammatory response of polyketal (PK3) with PLGA

microparticles after intratracheal injection in mice in order to investigate their potential use as drug delivery vehicles for interstitial lung diseases (ILD). Their results showed that PLGA microparticles induced a significant macrophage infiltration starting at day 4 and continuing through day 7 and a transient lymphocyte infiltration at day 4, while PK3 particles did not exhibit any airway inflammation.¹²³ In addition, Yoo D. *et al.*, demonstrated the advantage of HPOX as a polymeric prodrug of HBA, as a potential therapeutic for treating airway inflammatory diseases compared to PLGA. The biocompatibility of HPOX in the lungs may be due to its rapid degradation rate (half-life of ~12 h) and the excellent antioxidant and anti-inflammatory activity of its degradation product, HBA.¹²⁵

4.1.2. Polymeric particles as vaccines and vaccine adjuvants. Different studies have shown that polymeric particles such as PLGA,¹²⁶ poly(*N*-vinylpyrrolidone) (PVPON),¹²⁷ poly(γ -glutamic acid) (γ -PGA)¹²⁸ and cationic polyethyleneimine (PEI) nanogels¹²⁹ can facilitate antigen delivery to the APCs such as DCs, an important target for vaccine delivery. Their surface functionalization with specific antibodies can increase targeting and uptake by APCs enhancing vaccine-mediated antibody production.¹²⁶ Complementary, polymeric particles can co-deliver molecular adjuvants to lymph nodes in order to enhance immunogenicity,^{130,131} while exhibiting adjuvant effects themselves. Advax™ is an adjuvant agent, composed of delta inulin, a natural polymer with complement activation properties which has been shown to improve the immunogenicity of recombinant hepatitis B virus (HBV) vaccines in mice and guinea pigs. Advax™ enhanced both IgG1 and IgG2 responses equally compared to alum adjuvants which causes a marked Th2 skew in immune response. Its efficacy is considered to result from the increased number of antibody-secreting cells (ASCs) rather than by increasing the amount of antibody secreted per ASC.¹³² The physicochemical characteristics of polymeric NPs, such as shape and size could be tuned to produce effective nanoparticulate vaccines. For example, Kumar S. *et al.* compared the production of IgG-1 and IgG-2a antibodies of ovalbumin presented polystyrene NPs of two different sizes (193 nm vs. 1530 nm) and two different shapes (spherical and rod-shaped), after mice immunization. Their results indicated a size and shape dependent antibody production with smaller spherical NPs producing a greater Th1 biased cell mediated immune response, while the larger rod-shaped NPs a Th2 biased humoral immune response.¹³³ Different sizes and shapes seem to have a different effect at different steps of immune response generation. These characteristics could lead to the antigen escape from the endosomal/lysosomal compartment or alternatively to the degradation of antigen within it, which has been shown to result in a T1-2 biased or TH-2 biased immune response respectively (Fig. 7).¹³³

4.2. Liposomes

Liposomes have been extensively investigated since 1965, when introduced first by Bangham *et al.*, for drug delivery applications.¹³⁴ Their unique properties such as their biocompatibility and biodegradability as well as their chemical structure that






Fig. 7 Schematic representation of intracellular trafficking of nanoparticles with different morphological features.¹³⁵

enable them to incorporate both hydrophilic and hydrophobic compounds make them suitable as drug delivery platforms.¹³⁵ Many liposomal particles have been approved for clinical practice such as Doxil®, Ambisome®, DepoDur™ *etc.*, while a lot of liposome formulations are currently in clinical trials for various therapeutic applications.¹³⁶

4.2.1. Liposomes for delivery of anti-inflammatory agents

4.2.1.1. Conventional liposomes. Liposomes are composed of phospholipid bilayers and are formed due to hydrophobic interactions which drive their hydrophobic carbon tails to cluster together while their polar groups interact with the aqueous media.¹³⁷ Liposomes have been extensively investigated as drug delivery systems of glucocorticoids (GC) in order to be specifically distributed in the inflamed tissues and reduce the out of target side effects of GC. Liposomal glucocorticoids have been evaluated for their therapeutic efficacy for various inflammatory diseases such as asthma, rheumatoid arthritis, multiple sclerosis and cancer and have been shown increased anti-inflammatory activity and/or prolonged therapeutic duration which make them promising agents for the treatment of inflammatory diseases.¹³⁸ As an example, Data C. *et al.*, demonstrated that liposomes (DPPC/DPPG/Chol, 50/10/40 mol%, size: 295 (SD 15) nm) loaded with glucocorticoid dexamethasone phosphate (DXM-P) showed an increased suppression of joint destruction compared to the free drug in rat antigen-induced arthritis.¹³⁹

Encapsulation of other anti-inflammatory strategies, using liposomes have also been investigated. Angmo S. *et al.*, developed cationic phospholipid mixture 1,2-Dioleoyl-*sn*-glycero-3-phosphocholine (DOPC), 1,2-Dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE) and DOTAP, with single positive surface charge (NH⁺) with the encapsulation of GDP, a natural compound which inhibits hepcidin action. Hepcidin is an hepatic peptide hormone, which present abnormally high levels in inflammation and inhibits iron transport by binding to the iron export channel ferroportin located on the basolateral surface of gut enterocytes and the plasma membrane of reticuloendothelial cells (macrophages). NH⁺-GPD liposomes demonstrated decreased hepcidin levels in hepatocytes and macrophages, indicating to be promising therapeutic for anaemia of inflammation (AI).¹⁴⁰ Macrophages are important

key players in initiation and progression of inflammation and their depletion is used as a strategy to manage inflammation. Clodronate (LEC)-encapsulated liposomes have been reported for the specific depletion of macrophages.¹⁴¹ Clodronate (LEC) belongs to the drug family of bisphosphonates and is used for the treatment of osteolytic bone disease and post-menopausal osteoporosis because of its ability to inhibit osteoclast function.¹⁴² Liposomes are undergone phagocytosis by macrophages (MΦ), while LEC is released into their cytosol causing their apoptosis. Mert *et al.*, investigated the effects of MΦ depletion using LEC-liposomes on a carrageenan-induced rat inflammation model and their results showed suppressive effects on inflammatory markers at the inflammation site and spinal cord level.¹⁴³

4.2.1.2. Stealth liposomes. One obstacle for the desired clinical efficacy of liposomes is thought to be their rapid clearance from the mononuclear phagocyte system (MPS). Blood circulating proteins can be absorbed to the surface of liposomes resulting to the formation of a protein corona which can lead to complement activation and phagocytic clearance.¹⁴⁴ It has been observed that PEGylation of liposomes results in decreased phagocytosis and enhanced circulation half-life.¹⁴⁵ Prolonged circulation time of liposomes when administered systemically can improve the pharmacokinetics of the encapsulated drugs and accumulate in the tumour tissues and sites of inflammation due to the “Enhanced Permeability and Retention Effect” (EPR).¹⁴⁶ Several studies have shown the advantage of PEGylated liposomes in glucocorticoid delivery.^{138,146,147} Several animal studies have shown that prednisolone containing long-circulating PEG-liposomes have higher therapeutic efficacy compared to the free drug administration.^{148,149} Bartneck M. *et al.*, evaluated PEG-liposomes loaded with dexamethasone for the treatment of experimental liver injury models, demonstrating the depletion of hepatic and systemic T cells, as well as polarization of macrophages towards an anti-inflammatory phenotype, which could be promising for the treatment of acute and chronic liver injury.¹⁵⁰

In addition, conventional liposomes present stability issues under physiological conditions which lead to the off-target leakage of encapsulated drug. An effective strategy for increasing liposomes' structural integrity is the polymerization



of lipids in their lipid bilayers. Recently, Wang Q. *et al.*, prepared polymerized stealth liposomes composed of 1,2-bis(10,12-tricosadiynoyl)-*sn*-glycero-3-phosphocholine (DC8,9PC) and 1,2-distearoyl-*sn*-glycero-3-phospho-ethanolamine-poly(ethyleneglycol) (DSPE-PEG2000) by a thin-film hydration method, in which DC8,9PC molecules were cross-linked in the bilayer by UV irradiation and PEG chains provided a stealth layer to enhance their blood circulation time. The polymerized stealth liposomes showed an increased blood circulation time compared to nonpolymerized stealth liposomes, while when loaded with dexamethasone (Dex) showed a significant suppression of proinflammatory cytokines (TNF- α and IL-1b) in joint tissues and reduction of inflamed joints' swelling, compared to free Dex, in RA induced rats.¹⁵¹

Liposomes have weak immunogenic response, however, there have been reported some unwanted immune reactions in several studies. It has been shown that exposure to liposomes can lead to complement activation which may result in some cases to a serious hypersensitivity reaction called complement activation-related pseudoallergy (CARPA).¹⁵² Although PEGylation reduces the RES clearance and increase the circulation lifetime, it may also lead to hypersensitivity responses.¹⁵³ It has been demonstrated that repeated injections of PEG-PE liposomes can generate anti-PEG antibodies which may lead to accelerated blood clearance (ABC) after prolonged administration.¹⁵⁴

4.2.1.3. Ligand targeted liposomes for active targeting of inflammation. Active targeting of liposomes to the inflamed tissues or inflammatory mediated cells can be facilitated by surface functionalization with specific ligands such as proteins, peptides, antibodies and antibody fragments.¹⁵⁵ Functionalization of liposomes with antibodies in order to target adhesion molecules of inflamed endothelium, such as ICAM-1, VCAM-1, E-selectin and P-selectin has been explored in liposomal technology as well, in order to deliver therapeutics to the inflamed sites. Homem P. *et al.*, targeted cyclopentenone prostaglandin (CP-PG) loaded liposomes using anti-VCAM antibodies to endothelial cells and foamy macrophages in atherosclerotic lesions of mice. CP-PGs inhibit the nuclear factor- κ B (NF- κ B) transcription factor, the activation of which leads to a cascade of inflammatory responses.¹⁵⁵ Their formulation resulted in enhanced targeting of endothelial cells and foamy macrophages in atherosclerotic lesions and indicated significant anti-inflammatory effects which rescued treated mice from death by myocardium infarction or stroke, compared to control ones. In a recent study, Marcos-Contreras O. *et al.*, showed that intraarterial administration of anti-ICAM functionalised liposomes exhibited superior targeting to inflamed brain vasculature compared to untargeted liposomes, implying their clinical potential in the treatment of cerebrovascular diseases.¹⁵⁶

Activated macrophages, which have an essential role in the development and maintenance of inflammatory diseases, have the folate receptor beta (FR-b) upregulated. Functionalized folate-linked PEG liposomes were demonstrated to specifically target sites of inflammation in colitis and atherosclerosis mouse models and deliver their anti-inflammatory cargo there (betamethasone) which led to the reduction of activated

macrophages.¹⁵⁷ In a similar study, Verma A. *et al.*, developed functionalized PEGylated double liposomes (DSPE and DSPC) with the vitamin folic acid (FA), which exhibits good affinity with the folate receptor. FA-PEG liposomes were loaded with the anti-inflammatory agent prednisolone (PRD) and methotrexate (MTX) (a disease modifying anti-rheumatoid agent, DMARDs) and their therapeutic effects evaluated in collagen-induced arthritis (CIA) rats. Their results indicated significantly higher edema inhibition compared to non-FA functionalized liposomes and free drugs.¹⁵⁸

4.2.1.4. Biomimetic functionalization of liposomes. Bio-inspired ligands on NPs' surface have been extensively investigated in order to mimic the functions of immune cells. The incorporation of cell membranes as coatings is a potential alternative in order to optimize targeting and therapeutic effects of liposomes. Molinaro R. *et al.*, first developed the so called "leukosomes", a novel vesicle constituted by cholesterol and phospholipids enriched with proteins derived from leukocytes' membranes. Leukosomes exhibited increased targeting efficiency of activated human endothelial cells *in vitro* as well as an enhanced accumulation in inflamed murine tissue *in vivo* compared to conventional liposomes. *In vivo* investigation of leukosomes in an ear inflamed mouse model showed increased accumulation of the leukosomes in the inflamed ears compared with control liposomes.¹⁵⁹

4.2.2. The role of liposomes as vaccines and vaccine adjuvants. The structure of liposomes allows them to interact with various cells and components of the immune system, rendering them ideal candidates for vaccine delivery.¹⁶⁰ Physicochemical properties of liposomes may affect their immunogenicity. Cationic liposomes seem to be internalized more by antigen presenting cells (APCs) than anionic or neutral liposomes. Foged C. *et al.*, studied the interactions of cationic and anionic liposomes with human and murine dendritic cells (DCs) and they observed that a much greater proportion of cationic liposomes were internalized by DCs compared to anionic liposomes. This could be explained by the favorable electrostatic interactions between the negative surface charge of DCs and the positively charged liposomes.¹⁶¹ The increased immunogenicity of antigen loaded cationic liposomes compared to neutral or negative charged liposomes has been related to non-specific cell damage at the site of infection (SOI). In addition, the enhanced absorption of the usually negative charged antigens to cationic liposomes increases the antigen presentation to APCs by forming an antigen depot at the SOI.¹⁶² Furthermore, the surface charge of the liposome vehicle has been demonstrated to have a significant effect on the antibody response. OVA-loaded positively charged liposomes exhibited a significant increase serum IgG1 response compared to neutral and negatively charged liposomes, after subcutaneous immunization of mice which lasted at least 60 days. These observations confirm that positively charged liposomes act not only as efficient vectors to APC but also as antigen-depots.¹⁶³ Kaur R. *et al.*, demonstrated that the types of T-cells response can be controlled by the PEGylation density of cationic liposomes. Highly PEGylated liposomes (containing 25 mol% PEG) presented a Th2 bias response, enhanced clearance and rapid



drainage to the local lymph node compared to 10% mol PEGylated liposomes, while non-PEGylated liposomes formed a depot at the site of injection inducing a Th1 based immune response. These results reveal that PEG density of cationic liposomes, alters how the liposome surface interacts with antigen presenting cells when remained at the SOI or accumulated to the lymph nodes, leading to a TH1 or TH2 bias response respectively.¹⁶⁴

Although cationic liposomes have shown an increased antigen presentation when administered intramuscularly, it was reported that their positive charge blocks DNA vaccine activity after intradermal administration. This was explained by the immobilization of the positively charged nanoparticles in the negatively charged extracellular matrix (ECM), preventing the particles to reach their target. PEGylation of these particles resulted in shielding of their surface charge and a significant 55-fold increase *in vivo* antigen expression.¹⁶⁵ Therefore, the administration route and desired immune responses should be taken into consideration when PEG coated cationic liposomes engineered as vaccines adjuvants. Combination of antigens with various immunostimulators, as ligands for pattern recognition receptors (PRRs) of APCs, have been investigated as cargos of cationic liposomes vaccine adjuvants. Differences in the signaling pathways induced by the different receptors can lead towards Th1 or Th2 biased immune responses. Therefore, the choice and combination of immunostimulators play an important role in controlling the type of immune response whereas different strategies can be employed for their engineering depending on the type of molecules and purpose of

their use (Fig. 8). For example, PRRs recognizing ligands of bacterial origin often induce a Th1 response, which is suitable for fighting certain bacterial infections, while (ds)RNA derived from virus induces cytotoxic T-lymphocyte (CTL) immune responses, capable of combatting a virus infection.¹⁶⁶ Ramakrishnan A. *et al.*, developed two novel liposome-based adjuvant systems, the Army Liposome Formulation (ALF), containing synthetic monophosphoryl lipid A, and ALF plus QS-21 (ALFQ), in order to enhance immunogenicity of capsule conjugate vaccine against *C. jejuni* strain 81-176 (CPS-CRM). Both liposome adjuvants exhibited enhanced immunity in mice and nonhuman primates compared to alum, providing promising evidence that these adjuvant formulations may enhance immunogenicity in humans as well.¹⁶⁷ In the case of hydrophobic immunostimulators, they can be incorporated in the liposomal bilayer. For example, the use of archaeal lipids, can increase the immunogenicity of liposomes (“archeosomes”) and was demonstrated by Li Z. *et al.*, that were significantly more potent than liposomes made with Egg phosphatidylcholine (EPC)/Chol at inducing ovalbumin- (OVA-) specific IgG and IgA antibodies following oral administration in a mouse model.¹⁶⁸

4.3. Dendrimers

Dendrimers belong to another category of nanoformulations with promising biomedical applications, due to their unique properties of low polydispersity, low viscosity, multifunctionality and biocompatibility.¹⁶⁹ They are hyperbranched molecules which are generally prepared using either a divergent




Fig. 8 Different strategies for incorporating antigens and immunostimulators into liposomes.¹⁶⁶






Fig. 9 Representation of dendrimers of generations 1–4. The n denotes number of terminal functional groups.¹⁷⁴

method or a convergent one. In the divergent method, dendrimers are built up from a multifunctional core molecule on which successive series of branches are attached with repeated reactions on activated end groups, while in the convergent method the synthesis starts from exterior branches and ends to the core.¹⁷⁰ The total number of series of branches determines the generation of the dendrimer (Fig. 9).¹⁷¹ Their molecular weight and number of terminal groups are determined by the dendrimer generation. Conformational changes occur when dendrimers reach a specific generation, with low generation dendrimers (G0–G3) presenting ellipsoidal shapes without an interior cavity, while high-generation dendrimers (G4–G10) have spherical shapes and well-defined interior cavities.¹⁷² It is shown that higher generation and positive charged dendrimers result in higher cytotoxicity and immunogenicity and for that reason different chemical groups are attached on their surface in order to increase their biocompatibility.¹⁷³ The end groups on their outer shell could be also functionalized in order to enhance their targeting capability.

4.3.1. Dendrimers for delivery of anti-inflammatory agents.

Dendrimers are attractive candidates as drug delivery vehicles, because drugs can be loaded either in their inner core or covalently conjugated to their surface.¹⁷⁵ Dendrimers can be easily loaded with non-steroidal anti-inflammatory drugs (NSAIDs), which are mostly hydrophobic, either through encapsulation by hydrophobic interactions in their core or attachment on their surface by electrostatic interactions.¹⁷² Several studies have shown that PAMAM dendrimers improve solubility and intracellular accumulation of NSAIDs such as indomethacin, ketoprofen, Ibuprofen, Diflunisal and Naproxen. It has been demonstrated that the solubility of the drugs is increased in a concentration and generation dependent manner. The enhanced solubility was attributed to the increased number of surface amines and internal cavities that are available to interact with NSAID molecules for increasing concentration and generation of PAMAM dendrimers.¹⁷⁶

4.3.2. Dendrimers as anti-inflammatory agents.

In addition to their role as delivery vehicles, dendrimers without any drug cargo, have shown therapeutic potential as anti-inflammatory agents. PAMAM dendrimers were first reported by Tomalia *et al.*, to exhibit significant anti-inflammatory activity, by the inhibition of the pro-inflammatory mediators COX-1, COX-2, and NO in rat peritoneal macrophages. The anti-inflammatory activity of the PAMAM dendrimers was depended on their generation and functional surface groups, with amine and hydroxyl groups exhibiting an enhanced anti-inflammatory effect compared to carboxylate groups.¹⁷⁷ Since then, various types of dendrimers have been investigated for their anti-inflammatory effects. Different physicochemical properties of these formulations, such as structure, surface charge, functional groups and size, seem to affect their immunomodulatory response. It has been shown that glucosamine residues conjugated to the surface of carboxylic acid groups of 3.5 Poly-AMidoAMine (PAMAM) dendrimer are essential for its specific anti-inflammatory properties inhibiting pro-inflammatory cytokines from bacterial lipopolysaccharides (LPS) activated macrophages and dendritic cells. In addition, G4.5-CO₂H PAMAM dendrimer has been found to be more efficient than G5-OH PAMAM dendrimer in inhibiting the production of nitric oxide (a pro-inflammatory agent) by LPS activated peritoneal macrophages.¹⁷⁸ Their branched nature provides a better *in vivo* application profile than their linear polymeric analogues. For instance, dendrimers with increased number of branches present an enhanced blood circulation half-life, as a result of a reduced interaction with MPS cells. This is attributed to their decreased flexibility resulting in a difficulty in passing through glomerular pores. Furthermore, the more branched structures provide increased levels of steric protection for the drug payload at the core of the molecule.¹⁷⁹ Although PAMAM polymers have been investigated for their anti-inflammatory effects, contradictory results related to their immunomodulatory effects have been reported. Chauhan *et al.*, showed that functionalized dendrimers with anionic groups such as $-\text{NH}_2$, $-\text{OH}$ and $-\text{COOH}$ have shown to inhibit iNOS and COX-2,¹⁷⁷ while Durocher I. *et al.*, demonstrated that PAMAM dendrimers with anionic $-\text{NH}_2$ functional groups exhibited pro-inflammatory activity *in vivo* by leukocyte infiltration enhancement and a local increased expression of the pro-inflammatory mediators MIP-2, TNF- α and IL-6. More research is needed to understand the immunomodulatory effect, the properties influencing this effect and the mechanism behind it, before conclusions can be made on the immune response of PAMAM dendrimers.¹⁸⁰

In addition to PAMAM dendrimers, other types of dendrimers have also been reported to possess anti-inflammatory properties. Azabisphosphonate (capped by amino-bisphosphonate groups) (ABP) anionic dendrimers have shown to increase the production of the immunomodulatory cytokine IL10 *via* the activation of different immune cells, such as monocytes, macrophages and CD4⁺ T lymphocytes. In addition, they seem to selectively amplify Natural Killer (NK) cells, which could lead to promising applications in cancer immunotherapy.^{181,182} Molecular dynamic simulations have shown



that ABP dendrimers with low flexibility and more directional surface groups leads to enhanced anti-inflammatory properties.^{183,184} Adhesive interactions of leukocytes and endothelial cells initiate leukocyte migration to inflamed tissue which can lead to acute and chronic inflammatory diseases. Selectin receptors on endothelial cells facilitate the adhesion of leukocytes and it is proposed that pharmacological inhibitors of those molecules, such as heparin, could lead to an effective treatment for inflammatory diseases. Dervede J. *et al.*, investigated the role of synthetic dendritic polyglycerol sulphates (dPGs) as inhibitors of the cell adhesion molecules E-, L- and P-selectin. Using Surface Plasmon Resonance (SPR) in order to evaluate the selectin binding potential of dPGs *in vitro*, they showed that L- and P-selectin were efficiently inhibited, with IC₅₀ values of 30 and 90 nM, whereas E-selectin binding was not affected. The number of sulphate groups per molecule and the core size of dPGs determined the selectin inhibition efficacy. Their results indicated that the larger is the core of the dendritic NPs the more effectively shields the selectin binding sites.¹⁸⁵

4.3.3. Dendrimers as vaccines and vaccine adjuvants.

Dendrimers exhibit a highly multivalent surface which increases their potential for interactions with biological entities. This property can be exploited for antigen delivery to antigen presenting cells (APCs) for immunotherapy applications against cancer, autoimmune and infectious diseases. Antigen delivery to dendritic cells (DCs), the professional APCs, is among the most preferred strategies in immunotherapy. For an effective targeting of DCs it is essential to use an antigen delivery vehicle which recognizes a specific marker on DCs' surface. Unique glycan epitopes on foreign pathogens appear to be strong epitopes when presented in high density to DCs. García-Vallejo J. *et al.*, engineered multivalent PAMAM dendrimers conjugated with Lewis^b (Le^b) glycopeptides in order to target a glucan-specific C-type lectin (CLR) receptor of dendritic cells (DCs), called DC-specific ICAM-3-grabbing non-integrin (DC-SIGN). Generations 0–7 of PAMAM dendrimers with 4–512 reactive groups were developed in order to compare the effects of the increased ligand density. The glycopeptide dendrimers were able to target DC-SIGN receptors and internalized by the DCs demonstrating an enhanced induction of CD4 and CD8T cells. Generations 3 and 4 of the PAMAM dendrimers, with diameters similar to the distance between the carbohydrate recognition domains of DC-SIGN, exhibited the optimal size and multivalency to achieve the most efficient DC-SIGN targeting.¹⁸⁶

Multiple antigenic peptides (MAPS) with a dendrimer-structure are able to present multiple copies of an antigen or multiple antigens to the immune system at the same time and are thought as promising formulations in vaccine development.¹⁸⁷ Mimicking protective responses using synthetic peptides has attracted a lot of attention due to their advantages such as ease of production, thermal stability and safety. However, the complexity of the interactions between pathogens and host immune responses have limited the development of successful peptide vaccines. The multivalency of dendrimers can be exploited for the presentation of multiple peptides through the

enhancement of peptide immunogenicity. Cubillos C. *et al.*, demonstrated the increased efficiency of peptide dendrimeric vaccines against foot-and-mouth disease virus (FMDV) in pigs, containing T-cell and B-cell epitopes for an enhanced immune reactivity. The pigs did not develop significant clinical signs upon FMDV challenge, while a potent anti-FMDV immunoglobulin A response (local and systemic) was observed, despite the parenteral administration of the peptide, which constitute MAPs dendrimers as promising vaccine candidates.¹⁸⁸

4.4. Protein nanoparticles

4.4.1. Protein nanoparticles for delivery of anti-inflammatory agents. Protein-based nanoparticles have also been extensively investigated as drug delivery vehicles, thank to their biodegradability, biocompatibility, amphiphilicity and ease of functionalization.¹⁸⁹ They have attracted a lot of attention as they are relatively safe and easy to prepare, while their size distribution can be easily modified. The FDA approval of Abraxane®, a paclitaxel (PTX) albumin-bound nanoparticle formulation for the treatment of metastatic breast cancer and non-small-cell lung carcinoma (NSCLC) shows the clinical potential of such formulations.¹⁹⁰

4.4.1.1. Albumin. Human serum albumin (HSA) is the most abundant protein in blood plasma which has a critical role as a pH and osmotic pressure determinant while it facilitates the transport of many substances (endogenous or exogenous) inside the body due to its high affinity to many ligands.¹⁹¹ SPARC (secreted protein acidic and rich in cysteine) is an extracellular glycoprotein involved in tissue development, wound healing and angiogenesis. It has been observed that various tumour tissues present an overexpression of SPARC which is associated with metastasis and poor prognosis.¹⁹² Albumin has a high affinity for SPARC which has led to the success of Abraxane® to enhance the targeting of the chemotherapeutic drug PTX to metastatic tumour tissues.¹⁹³ Bottini N. *et al.*, showed that SPARC is overexpressed in the synovial fluid and joint tissues in patients with RA as well as RA induced mice. Therefore, they aimed to target the antirheumatic drug methotrexate (MTX) to the arthritic joints of RA induced mice using MTX-loaded HSA nanoparticles, exploiting the high affinity of albumin for SPARC. In addition, arthritic joints seemed to metabolize more albumin than healthy tissues which enhanced the delivery of albumin NPs to these tissues. They demonstrated that the MTX-albumin bound NPs increased the therapeutic effects of MTX with no significant side effects compared to free MTX due to the greater accumulation of MTX-albumin NPs to the arthritic joints of mice.¹⁹⁴ In another innovative study, Iwao Y. *et al.*, exploited the affinity of albumin to myeloperoxidase (MPO) which is reported to be elevated and cause damage to the sites of inflammation, in IBD patients. In order to deliver the anti-inflammatory drug, 5-aminosalicylic acid (5-ASA), to the inflamed colon, they prepared 5-ASA-HSA NPs by a desolvation technique in which the active site for enzymatic degradation of HSA was internalized inside the NPs in order to protect it from the proteolytic enzymes in the gastrointestinal tract. 5-ASA-HSA NPs were shown to have a significant therapeutic effect in



a mouse model of ulcerative colitis (UC) with the delivery of a lower drug dose needed, compared to the dose of the free drug, in order to cause similar therapeutic effects.¹⁹⁵ Wang Z. *et al.*, demonstrated that bovine serum albumin (BSA) NPs are preferentially internalized by activated neutrophils *in vivo*, through FcγR signaling. As neutrophil infiltration and activation at the vessel wall is the primary cause of vascular inflammation which leads to various diseases such as acute lung injury and ischaemic tissue injury, the targeting of neutrophils in order to block their adhesion to endothelial cells seems to be a promising approach. In this study, BSA NPs were prepared using a desolvation technique and loaded with piceatannol, a tyrosine kinase inhibitor which blocks outside-in integrin signaling of neutrophils. Piceatannol loaded BSA NPs showed a significantly reduced neutrophil sequestration in acute lung injury induced mice compared to piceatannol alone, confirming the specific targeting of albumin NPs to activated neutrophils.¹⁹⁶

4.4.1.2. Gelatin. Gelatin is another biocompatible and biodegradable protein which can be used for the fabrication of nanomaterials. It is obtained by controlled hydrolysis of collagen, which is a major component of the skin, bones, and connective tissues.¹⁹⁷ There are two different types of gelatin, A and B, which can be produced following either acid or base hydrolysis, resulting in proteins with different isoelectric point (pI), molecular weight, amino acid composition, and viscosity.¹⁹⁸ Gelatin NPs can be prepared by several different techniques, including desolvation, coacervation-phase separation, emulsification-solvent evaporation, reverse phase microemulsion, and nanoprecipitation.¹⁹⁹ Various cross-linking agents such as glutaraldehyde, glycerinaldehyde *etc.* could be used for the cross-linking of gelatin in order to provide stability and enhance the circulation lifetime of nanoparticles (Fig. 10).^{197,198} Gelatin particles have been used effectively as drug delivery vehicles as they demonstrate a controlled drug release profile by the manipulation of their size, cross-linker density, and PIs of the particles.²⁰⁰ Wang E. *et al.*, showed that the crosslinking density of gelatin nanoparticles affects the degradability of the gelatin polymers and their drug release.²⁰¹ Gelatin nanoparticles are easily functionalized with ligands in order to enhance their targeting and have been used for the targeted delivery of inflammatory drugs, siRNAs and DNA. IBS, the sodium salt of Ibuprofen, is a NSAID drug used for the

treatment of rheumatoid arthritis and chronic arthropathies, but its short plasma half-life demands multiple administrations in order to maintain a therapeutic dose.

In general, positively charged nanoparticles more readily interact with cells due to the negatively charged cell membranes, resulting in their rapid clearance by the reticulo-endothelial system upon intravenous administration.²⁰² Narayanan D. *et al.*, showed that PEGylated gelatin nanoparticles loaded with IBS, improved the *in vivo* pharmacokinetics of the drug, exhibiting a sustained drug release and prolonged blood circulation, whereas gelatin nanocarriers did not exhibit any significant immunotoxicity even at high doses.²⁰³ In another study, Huang *et al.*,²⁰⁴ functionalized gelatin nanoparticles with the mucoadhesive hyaluronic acid (HA) in order to increase the interaction of particles on the corneal surface for the treatment of dry-eye syndrome (DES), which is characterized by inflammation of the ocular surface and lacrimal glands.²⁰⁵ Epigallocatechin gallate (EGCG), a polyphenol of green tea with anti-inflammatory properties, encapsulated inside the HA coated gelatin particles (GEH NPs) as an ocular drug delivery system and was administered to DES induced rabbits. GEH NPs exhibited an enhanced therapeutic outcome compared to EGCG alone and gelatin nanoparticles without HA coating, due to their slow drug release and prolonged ocular retention.²⁰⁴

4.4.1.3. Recombinant proteins. The biomimetic characteristics of recombinant proteins could also be exploited for engineering of NP vehicles when the availability of the natural proteins is limited or has undesired immunogenic response. In a recent study, Lu L. *et al.*, developed high-density lipoprotein-mimicking peptide-phospholipid scaffold (HPPS) nanoparticles loaded with curcumin, as an anti-inflammatory agent, in order to target monocytes, which are thought to play an important role in the initiation and development of multiple sclerosis (MS). Thus, the group has designed HPPS to target high-density lipoprotein (HDL) receptor of monocytes. Curcumin loaded HPPS NPs were specifically taken up by inflammatory monocytes hindering their crossing of the blood brain barrier (BBB). The internalised curcumin NPs inhibited NF-κB activation which led to the downregulation of intercellular adhesion molecules 1 (ICAM-1) and macrophage-1 antigen (MAC-1) expression in the monocytes with a significant therapeutic outcome in mice with autoimmune encephalomyelitis (EAE).²⁰⁶




Fig. 10 Protein nanoparticles formed by crosslinking.¹⁹⁸



Elastin like peptides (ELPs) are recombinant peptides with structural and functional properties similar to elastin, which is a component of extracellular matrix and promotes tissue repair. Above a transition temperature ELPs form self-assemble nanoparticles which can be used as drug delivery vehicles.¹⁹⁷ ELP fusion proteins, with a nanoparticulate form, have been shown to protect biomolecules from proteolysis. Yeboah A. *et al.*, engineered stromal cell-derived factor1 (SDF1)-ELP fusion protein NPs, in order to increase stability of SDF1, a key mediator of the wound healing response. The SDF1-ELP NPs showed accelerated wound healing compared to SDF1 alone after treatment of diabetic mice with skin wounds, which was attributed to the increased stability and half-life of SDF1-ELP NPs.²⁰⁷

4.4.2. Protein nanoparticles as vaccines. Engineering of virus-like particles (VLPs) emerged as an alternative for attenuating live viruses for vaccination purposes. VLPs are self-assemble particles made from capsid proteins derived from viruses. They can induce immune responses without being infectious. VLP vaccine formulations against Hepatitis B, Hepatitis E and human papillomavirus (HPV) subtypes 16 and 18, which account for approximately 70% of all cervical cancer cases, are commercially available.²⁰⁸ VLPs are also investigated as delivery vehicles for various cargos such as antigens, adjuvants, nucleic acids, peptides, proteins and drugs.²⁰⁹ The natural tropism of VLPs provides the advantage of targeting without further engineering and seems to have the potential for gene delivery applications and cancer antigen delivery systems.²¹⁰

5. Combination therapy: immunotherapy combined with nanoparticle treatment

5.1. Cancer immunotherapy

Immunotherapeutic agents for the treatment of cancer have provided limited evidence of clinical success until recently. In 2010, FDA approved Provenge (sipuleucel-T), a cell-based immunotherapy for advanced prostate cancer. It followed the approval of ipilimumab in 2011, an anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody, the programmed cell death protein 1 (PD-1) antibodies pembrolizumab and nivolumab in 2014 for the treatment of melanoma, and the PD-1 ligand (PD-L1) antibody atezolizumab in 2015 for the treatment of bladder cancer.²¹¹ Cancer immunotherapy can be classified into the active and passive type. Active immunotherapy stimulates endogenous immune system using prophylactic or therapeutic vaccines, immune adjuvants or cytokines, while passive immunotherapy uses engineered cells or antibodies which are administered to patients in order to enhance immunity against cancer.²¹²

Although promising, Immunotherapies can be problematic due to undesired side effects that can lead to autoimmune diseases. In addition, they seem to be more effective against lymphoma than solid tumours while the immunosuppressive tumour microenvironment hinders their effectiveness.²¹¹ The emerging field of nanomedicine seems to be promising for

overcoming the current shortcomings of cancer immunotherapy. Nanoparticles could have different roles in cancer immunotherapy (Fig. 16) which are in-detailed discussed in the following sections.

5.2. NPs for checkpoint blockade immunotherapy and immune-suppressive TME modulation

The effectiveness of cancer immunotherapy is challenging, due to the immunosuppressive properties of cancerous cells. Tumours express ligands that bind to inhibitory receptors of tumour-specific T cells and downregulate their immune response. Such examples are the CTLA-4 receptor, an inhibitory receptor that down-regulates the initial stages of T cell activation, and PD1 receptor, which binds to PD-L1 and PD-L2 ligands expressed by tumours and leads to the inhibition of T-cell proliferation, cytokine release and cytotoxicity.²¹² Cancer immunotherapeutic agents, using immune checkpoint inhibitors, such as CTLA-4 antibody (Ab) (ipilimumab), PD-L1 Ab (atezolizumab), and two PD-1 Abs (nivolumab and pembrolizumab) have been FDA approved, but seem to be effective only in a minority of patients while are associated with adverse side effects.²¹² Nanoparticles can be used for the delivery of immune checkpoint inhibitors in order to enhance their efficiency. Zhang X. *et al.*, generated membrane derived nanovesicles (NVs) with PD-1 receptors tagged with DsRed protein. The membrane of transfected HEK 293T cells was used for the engineering of PD1-NVs (Fig. 11a), while 1-methyl-tryptophan (1-MT), an inhibitor of indoleamine 2,3-dioxygenase IDO, which is an immunosuppressive molecule overexpressed by tumour and DC cells (IDO + DCs), was encapsulated inside the NVs. The PD-1 NVs could bind to the surface of tumour cells and achieve PD-L1 blockade while the encapsulated 1-MT inhibited IDO which is induced by Treg cells (Fig. 11b and c). The 1-MT loaded PD1-NVs significantly suppressed the tumour growth in melanoma bearing mice compared to the treatment with 1-MT or PD-1 NVs alone, by the disruption of the dual immune tolerance mechanisms in the tumours.²¹³

Furthermore, tumour microenvironment (TME) infiltrates cells with an immunosuppressive activity. Regulatory T-cells (Tregs) are chemoattracted to the TME and suppress immune functions through various mechanisms such as CTLA-4-mediated suppression of APC function, consumption of IL-2, production of immunosuppressive cytokines, and immune suppressive metabolites.²¹⁴ Tumour associated macrophages (TMA) are frequently found in the TME exhibiting two opposing phenotypes, either tumour-supportive (M2-like cells) or tumour-icidal (M1-like cells). In most tumours the M2 phenotype dominates, producing high levels of IL-10 and TGF- β immunoregulatory cytokines, inhibiting immune cell activation, maturation, and differentiation. In addition, myeloid derived suppressor cells (MDSCs) are tumour infiltrated cells which release IL-10, ARG1, NOS2, and IDO activating Tregs and suppress other immune cells.²¹² Nanoparticles that can target these immunosuppressive cells in TME and inhibit their action or re-educate them are promising agents for cancer immunotherapy. Rodell C. *et al.*, engineered β -Cyclodextrin nanoparticles






Fig. 11 (a) Schematic representation of the preparation of PD-1 NVs loaded with 1-MT. (i) Engineering of HEK 293T cell line stably expressing mouse PD-1 receptors on the cell membranes. (ii) Harvesting of the cell membrane expressing PD-1 receptors. (iii) Preparation of PD-1 NVs through extrusion. (iv) Loading 1-MT into PD-1 NVs. (b) PD-L1 downregulates CD8⁺ T cells by interacting with their PD-1 receptors. The expression of IDO is induced by Treg cells, which inhibits the activity of CD8⁺ T cells. (c) PD-L1 blockade by PD-1 NVs lead to the activation of CD8⁺ cells to attack tumour cells. The inhibition of IDO by the 1-MT inhibitor also reverts the immunosuppressive activity of the DCs to CD8⁺ T cells. © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Reproduced from ref. 213 with permission from John Wiley and Sons.

(CDNPs) with R848 entrapment in order to re-educate TAMs. R848 is an inhibitor of the macrophage colony-stimulating factor 1 receptor (CSF1R), the activation of which leads to M2-like polarization. Colorectal cancer (MC38) bearing mice treated with CDNP-R848 demonstrated nanoparticle accumulation in TAMs and a significant decrease in the tumour growth rates compared to R848 and CDNP alone and a vehicle control.²¹⁵ In another study, Ou W. *et al.*, demonstrated Treg cell targeting using PLGA NPs coated with polyethylene glycol-distearoyl-phosphatidylethanolamine (PEG-DSPE) and 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC). NPs were loaded with imatinib (IMT), a tyrosine kinase inhibitor that blocks STAT3 and STAT5 signalling and impairs their immunosuppressive functions. In addition, the surface of the NPs functionalized with tLyp1 peptide for targeting the Nrp1 receptor on Treg cells and an anti-CTLA4 immuno-checkpoint inhibitor for a combined immunosuppressive effect (imatinib loaded tLyp1-hNPs). Their results indicated a strong immune response against B16/BL6 melanoma tumours in mice by down-regulating immunosuppressive Treg cells while activating CD8⁺ T cells. The antitumour capability of IMT was enhanced by tLyp1 and anti-CTLA4 antibody functionalization of the NPs inhibiting the tumour cell proliferation and decrease angiogenesis.²¹⁶

5.3. Targeting immune cells resident in lymph nodes

Nanoparticles are exploited as vehicles of tumour-specific antigens (TSAs) in order to APCs and specifically DCs.

Administration of free antigens does not lead to an effective immune response due to their enzymatic degradation, low cellular uptake by APCs and insufficient delivery to the lymph nodes. Nanoparticles can be functionalized with ligands in order to target DCs resident in lymph nodes, such as; mannose, DEC-205, and CD40. In addition, the size of NPs is also an important factor for their accumulation in the lymph nodes. Smaller NPs, in a size range of 10–50 nm exhibit higher accumulation in the lymph nodes, whereas larger particles are taken up by macrophages.²¹⁷ DCs exhibit pattern recognition receptors (PRRs) in order to scavenge pathogens, such as Toll-like receptors (TLRs). Using ligands for TLRs as adjuvants, could lead to the activation of DCs and upregulation of co-stimulatory factors such as CD40, CD80, and CD86.²¹⁹ Adjuvants could be loaded in the NPs, linked to their surface or co-administered with them. Rosalia R. *et al.*, developed PLGA NPs loaded with the ovalbumin tumour associated antigen and the adjuvants Pam3Csk4 (TLR2L) and poly(I:C) (TLR3L), for DCs' TLR receptors activation. Furthermore, NPs were surface functionalised with DC40 monoclonal antibodies for the specific targeting of DCs. CD40 is a highly expressed surface receptor on DCs which plays a crucial role in the maturation of DCs and T-cell signalling. The multi-compound nanoparticulate vaccine resulted in selective delivery to DCs *via* CD40 targeting and efficient T-response through the synergistic effect of TLR2-and TLR3-adjuvants.²²⁰ In another study, Kakwere H. *et al.*, synthesized amphiphilic polymeric NPs, conjugated with the tumour-






Fig. 12 Schematic representation of the antigen-conjugated nanoparticles and their immunogenic action. Reprinted from ref. 221. Copyright 2017 American Chemical Society.

associated antigen peptide derived from tyrosinase-related protein 2 (TRP2) and functionalized with mannose for the specific targeting of DCs (Fig. 12). *In vitro* immunogenicity assay of bone marrow derived mouse DCs treated with the antigen conjugated NPs showed poor immunogenicity indicating the necessity of adjuvant co-administration. Treatment of mice with melanoma (B16-F10) tumours, using CpG, a TLR9 agonist that can stimulate the immune system, as an adjuvant, showed that antigen conjugated NPs in combination with an adjuvant

resulted in an improved survival (up to 24 days) compared to the untreated group (14 days).²²¹

Using another approach, Noh Y. *et al.*, generated immunostimulatory liposomes, named “tumosomes”, by the reconstitution of tumour cell membranes containing tumour-associated antigens and the incorporation of two immunomodulatory adjuvants, 3-*O*-desacyl-4'-monophosphoryl lipid A (MPLA) and dimethyldioctadecylammonium bromide (DDA) (Fig. 13). After an intranodal injection of the tumosomes in B16-



Fig. 13 Schematic representation of the generation of the antigenic liposomes “tumosomes” as cancer immunotherapeutic agents. Reproduced from ref. 218. Copyright WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.



F10 melanoma tumour-bearing mice, the results indicated a significant inhibition of tumour growth compared to injections of antigen or liposomes alone. The treatment with tumosomes increased the proliferation of immune cells from lymph nodes and spleen, while lymph nodes cells and splenocytes produced a higher amount of IFN- γ levels resulting in an enhanced antitumour immunogenicity.²¹⁸ The cytosolic nucleotide sensor stimulator of IFN genes (STING), has attracted a lot of attention as a target of potential adjuvants. Cyclic dinucleotides (CDNs) are ubiquitous small molecule second messengers synthesized by bacteria which activate innate immunity by binding to the endoplasmic reticulum-resident receptor STING, activating a signalling pathway that induces the expression of interferon- β (IFN- β).²²² Hanson M. *et al.*, used a PEGylated liposomal carrier to transfer chemically synthesized CDNs, called cdGMP, to lymphoid tissues in order to enhance their potency as immune stimulators and decrease their side effects. Mice immunization with cdGMP-liposomes demonstrated enhanced CD4⁺ and CD8⁺ T cell responses, with a 30-fold higher potency and 15-fold increased accumulation in the lymph nodes compared to free CDNs.²²³

5.4. Immunogenic cell death induction

There is evidence that tumour cell death promotes an anti-tumour immune response known as immunogenic cell death (ICD). Dying cells release or express molecules, which are referred to as damage-associated molecular patterns (DAMPs) and can act as danger signals for the innate immune system. Some known DAMPs are ATP, high mobility group protein B1 (HMGB, also known as amphoterin), calreticulin (CRT) and heat shock protein 90 (HSP90).²²⁴ Consequently, anticancer agents which cause toxicity and cell death in cancerous cells could be used as a combination treatment with immunotherapy, acting as adjuvants and enhancing the therapeutic outcome.

However, effectively inducing ICD is challenging and so nanomaterials are attractive modalities to promote ICD, as they specifically concentrate cytotoxic agents in tumour cells,

thereby reducing common systemic side effects.²²⁵ They can be designed to directly interact with external energy sources, allowing for targeted radiotherapy, magnetic hyperthermia, photothermal and photodynamic therapy, or deliver a toxic therapeutic agent combined with immunotherapeutic strategies. Additionally, as previously explained in the section on nanoparticle-induced mechanisms, ICD can be induced by the intrinsic properties of nanomaterials.

5.4.1. Photothermal therapy. Photothermal therapy (PTT) is a tumour ablation method that inflicts cell death due to heat generation of nanoparticles after exposure to near-infrared radiation. Additionally, PTT can trigger ICD and limit the damage to nontargeted tissues. Bear *et al.* showed that combining gold nanoshells with the infusion of tumour-directed, activated, T cells (ATCT) led to eradication of local and metastatic melanoma tumours in mice. PTT alone resulted in a priming antitumour immune response (increased expression of pro-inflammatory cytokines), facilitated the infiltration of MDSCs and accelerated the growth of the metastatic tumours. ATCT alone exhibited a modest tumour reduction. However, the stimulatory immune environment induced by PTT, enhanced the efficiency of ATCT by promoting the activation and function of transferred tumour-specific T cells.²²⁶

PTT can also be combined with chemotherapy which can lead to enhanced anti-cancer effects exploiting ICD triggering. Wen *et al.* co-delivered the chemotherapeutic agent Doxorubicin (Dox) with photothermal reactive palladium nanoparticles (PDNPs) in amphiphile triglycerol monostearates (TGMs). Chemotherapy and PTT proved to effectively kill mouse colon cancer (CT26) cells, but additionally promoted the release of 'eat-me' signals like calreticulin (CRT) and adenosine triphosphate (ATP). This improved immunogenicity led to an improved T-lymphocyte infiltration and eventually better treatment efficacy.²²⁷ Ma *et al.* achieved similar effects with gold nanoparticle irradiation using the second near-infrared bio window NIR(II), with wavelengths between 950 and 1350 nm. This window is more preferred as it reduces photon scattering, has a low tissue background and most importantly, allows a deeper penetration




Fig. 14 Calreticulin (CALR) exposure at different depths using different laser irradiation wavelengths. (A) Schematic representation of the experiment. (B) Percentage of CALR positive areas at different depths in dissected 4T tumours (C) immunohistochemical staining of CALR exposure in tumours. Reprinted from ref. 228. Copyright 2019 American Chemical Society.



depth in comparison to NIR(I). This was proven by measuring the different levels of calreticulin (CALR) in mouse breast cancer (4T1) tumours after intratumoural injection of Au-DOPC (gold nanoparticles absorbed on liposomes) and treatment with 3 different laser irradiations. NIR(I) irradiation led to ICD up until 3 mm into the tumour, while NIR(II) reached significantly further up until 6 mm (Fig. 14). Additionally, the researchers illustrated that using this technique after administration of erythrocyte membrane-coated 2D polypyrrole nanosheets, an anti-tumour immunity can be elicited that prevents tumour metastasis.²²⁸

Further optimization research for PTT was performed by Sweeney *et al.*, which revealed the importance of the correct thermal dose that is generated. Results indicated that a thermal window between 50 and 60 °C is optimal for the immunogenicity of the tumour cell death, and thus, critical for generating an anti-tumour immunity.²²⁹ Therefore, optimization of appropriate nanoparticle dose as well as radiation intensity, has to be performed on an individual application level.

5.4.2. Photodynamic therapy. Photodynamic therapy (PDT) is based on the high ROS generation in the endoplasmic reticulum (ER) through the accumulation of a photosensitizer under illumination. The production of ER ROS subsequently activates the signaling pathways for induction of ICD. In order to target the photosensitizer specifically to the ER, Li and colleagues encapsulated ICG in hollow gold nanospheres, modified with FAL peptides. Additionally, in order to avoid hypoxia during exposure hemoglobin was encapsulated in FAL-modified liposomes. After exposure to NIR (808 nm) light, ROS-based ER stress was generated, followed by an upregulation of Calreticulin, which, similar to previous examples, upregulated the immune response and inhibited tumour growth.²³⁰ Enhancing of PDT therapies implies fully overcoming the strong immunosuppressive tumour environment. Therefore, Liu *et al.* developed a redox-activatable liposome from phospholipid-porphyrin conjugates for the codelivery of an indoleamine 2,3-dioxygenase (IDO) inhibitor (NLG-8189). This achieves inhibition of IDO, which normally impairs the activity of CD8⁺ T cells, as NLG8189 is quickly released in the reductive tumour micro-environment. The combination of PDT-induced ICD with IDO inhibition significantly improved the efficiency of metastasis prevention in a 4T1 breast cancer mouse model.²³¹

5.4.3. Photoporation. Next to thermal generation, irradiation of NPs can be applied to increase porosity of the cell membrane through vapor nanobubble photoporation. This allows the intracellular delivery of a variety of macromolecules, like CRISPR ribonucleoproteins or antibodies.²³² However, also ICD inducing macromolecules can be transfected, like MLKL, the terminal mediator for necroptosis. Van Hoecke *et al.* showed that MLKL transfection resulted in 62% cell death characterized with cell swelling and cell membrane rupture, typical for necroptosis (as explained previously).²³³

5.4.4. Targeted delivery of ICD inducing agents. Furthermore, some chemotherapeutic agents have been shown to be proinflammatory and capable of inducing immunogenic cell death (ICD). Therefore, Duan X. *et al.*, developed self-assembled nanoscale coordination polymer (NCP) core-shell nanoparticles

loaded with oxaliplatin (OxPt), which was identified as an ICD inducer agent and the particles were functionalized with dihydroartemisinin (DHA), an active metabolite of artemisinin derivative which interacts with iron in tumours and causes oxidative stress.²³⁴ NPs with the dual ICD activity enabled their selective targeting in colorectal cancer (CRC) tumours in mice, causing immunogenic apoptosis and release of HMGB-1, which facilitates the engulfment of dying tumour by APCs and optimal antigen presentation to T cells. Supplemental treatment with α -PD-L1 inhibited T-cell deactivation and lead to complete eradication of the tumours and long-term tumour-specific immune memory response. Similar immune vaccination type effects were achieved by Naatz *et al.*, where the group demonstrated that 6% Fe-doped CuO NPs showed a selective ROS generation and cell death in cancerous cell lines *in vitro*. Administration of the NPs in KLN-205 mouse xenograft models resulted in incomplete tumour remission. However, exploiting the ICD induction capability of 6% Fe-doped CuO NPs, the scientists administered the NPs in combination with epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor which prevents immunosuppression through myeloid-derived suppressor cells (MDSCs). The combination treatment resulted in enhanced therapeutic efficacy and complete tumour remission showing the potential of nanoparticles in combination with cancer immunotherapy. Furthermore, reinjecting the tumour cells to the same mice did not generate a new tumour suggesting the successful induction of long term immune memory response.²³⁵

Recently, Ploetz E. *et al.*, demonstrated that hybrid metal-organic framework (MOF) nanoparticles loaded in liposomes (Lip-MOFs) could create a controllable platform for intracellular iron delivery. The high amount of realized ions by the internalized particles induced pyroptosis, a highly inflammatory form of programmed cell death, which occurred only in slightly acidic extracellular environments. This unique property of Lip-MOFs and similar nanostructures could be exploited in cancer immunotherapy, as the particles could result in the cell death of targeted cells in the acidic tumour microenvironment, *via* pyroptosis, inducing a significant immune response at the same time.²³⁶

Finally, activation of the stimulator of interferon gene (STING) pathway leads to increased IFN-I production and induction of ICD. Activator molecules are cyclin dinucleotides (CDNs) such as cGAMP.²³⁷ Nanoparticles can be used for the optimal and effective delivery of CDNs. Cheng *et al.* showed that the encapsulation of cGAMP in liposomal nanoparticles significantly upregulates IFN-I levels and suppress tumour growth, compared to free cGAMP.²³⁸ A similar approach was taken by Shae *et al.* using polymersomes as delivery vehicles.²³⁹ In another study, Hoang M. *et al.* investigated the antigen production from human B-lymphocytic (U266) cells using bPEI-SPIONs combined with ultraviolet B (UVB) irradiation. Superparamagnetic iron oxide nanoparticles (SPIONs) are known to produce high amounts of ROS and induce an immunogenic response. Apoptotic U266 cells can be used as antigens in order to induce antitumour induction of DCs to T-cells. Two hours post irradiation U266 cells with b-PEI-SPIONs demonstrated increased ROS production, extracellular release of surface Heat Shock Proteins 70 and 90 (Hsp70, Hsp90), and high mobility group box 1 protein (HMGB1). DCs



were loaded with the antigenic cells which showed an enhanced expression of IFN- γ , a Th-1 polarizing cytokine promoting Th1 polarization of T-cells.²⁴⁰

5.5. Adoptive cell therapy (ACT)

Adoptive cell therapy (ACT) is a promising strategy for cancer immunotherapy. Tumour-specific lymphocytes are isolated from patients' blood, tumour draining lymph nodes, or tumour tissues, and expanded *ex vivo* before reinfusion, in order to express high reactivity against tumour antigens and overcome the immunosuppressive tumour microenvironment. T-cells can be engineered in order to express antitumour receptors. The first engineered T-cells were designed to express T-cell receptors (TCRs) with affinity to a tumour antigen. TCRs were activated only when they recognized peptides bound to major histocompatibility complex (MHC) on tumours and antigen presenting cells. However, many tumours exhibit a downregulation of the MHC constituting TCR-T cells ineffective. In order to overcome this limitation, artificial chimeric antigen receptors (CARs) have been engineered which combine the high affinity of antibody binding, without the need for antigen expression through MHC, with the intracellular signalling domains of TCRs.²⁴¹ CAR-T cell-based agents were FDA approved in 2017 exhibiting significant antitumour activity against CD19-positive B-cell leukaemia and lymphoma in humans.²⁴² However, the therapeutic efficacy of CAR-T therapies in the treatment of solid tumours is low, mainly, due to the immunosuppressive tumour microenvironment.²⁴³ Nanoparticles can be loaded with supporting drugs or chemokines and conjugated with the adoptively transferred cells (cellular backpacks) or functionalised with ligands in order to target adoptive T-cells *in vivo* enhancing ACT effects. For example, Zheng *et al.*, studied the effect of TGF- β inhibitor loaded liposomes on ACT T-cell therapy. They investigated whether T-cells preloaded *ex vivo* with liposomes targeting an internalizing receptor (CD90, or Thy1) *versus* a non-internalizing receptor (CD45) were more efficient compared to antibody-functionalized liposomes that target TGF- β directly to T-cells *in vivo* (Fig. 15). They showed that *in vitro* loaded T-cells with CD45 functionalized liposomes exhibited an enhanced tumour infiltration and therapeutic efficacy, while anti-Thy1.1 internalizing liposomes,

targeting T-cells *in vivo*, demonstrated a better therapeutic outcome. These results indicated that Thy1 exhibits an increased specificity to the donor T-cells compared to CD45. Targeted liposomes to T-cells *in vivo* could have a preferable clinical application, as liposomes can be administered repeatedly compared to the limitations exhibited in T-cell infusions.²⁴⁴

The targeted delivery of supporting cytokines and tumour-microenvironment-modulating factors using nanoparticles conjugated to adoptive T-cells (backpacks) has been explored in order to enhance ACT effectiveness and avoid systemic side effects. However, low drug loading capacity and leakiness of the drug from the backpacks before reaching their target limit their therapeutic effect. Tang L. *et al.*, addressed these challenges using nanogels (NGs), as adoptive T-cell backpacks, synthesized with a disulphide cross-linker which was designed to be cleaved in response to reducing conditions at the T cell surface, allowing TCR activation *in vivo*. NGs were loaded with a human interleukin-15 super-agonist (IL-15 α), a potent cytokine that increases CD8⁺ T and NK cell numbers and function.²⁴⁵ The NGs were functionalized with anti-CD45 antibodies in order to be conjugated to T-cell surfaces, avoiding their internalization inside the cell cytoplasm. Their results showed that T cells backpacked with TCR-responsive NGs expanded 16-fold more in B16F10 mouse melanoma tumours compared to T cells supported by systemic cytokine injections. Furthermore, they evaluated whether NG-backpacked CAR-T cells targeting epidermal growth factor receptor (EGFR) in a human glioblastoma model in immunodeficient mice could enhance the impact of CAR-T cell therapy. Treatment with NG-backpacked CAR-T cells lead to an increased therapeutic outcome, with the complete eradication of tumours in 4 or 5 mice, compared to CAR-T cells alone or CAR-T cells with an equivalent systemic dose of free IL-15 α .²⁴⁶ Nanoparticles can be used as DNA delivery vehicles in order to introduce leukaemia-targeting CAR genes into circulating T cells *in vivo*. Smith *et al.*, synthesized poly(β -amino ester) polymeric NPs, functionalized with T-cell-targeting anti-CD3e f(ab')₂ fragments which enabled their receptor-mediated endocytosis by lymphocytes and peptides containing microtubule-associated sequences (MTAS) and nuclear localization signals (NLS) in order to import their DNA cargo into T-cell nuclei *via* the microtubule transport machinery. NPs were loaded with a plasmid DNA, encoding the leukaemia-specific 194-1BBz CAR and they exhibited selective targeting and reprogramming of T-cells *in vivo* with leukaemia regression in mice at efficacies comparable to conventional adoptive transfer of laboratory-manufactured CAR T-cells.²⁴⁷

Despite the advantages of CAR-T therapy, the elaborate procedures needed to isolate, engineer, selectively expand and reinfuse patient derived T-lymphocytes can only be performed at a few specialized centres worldwide, preventing their use as standard-of-care treatment for cancer.

5.6. The role of nanoparticles for the treatment of allergy and auto-immune diseases

Immunotherapy for the treatment of cause-oriented allergy involves the gradually increased dose administration of allergen




Fig. 15 Schematic representation of the fate of Anti-Thy1.1 and Anti-CD45 targeted liposomes after T-cell targeting. Reprinted from ref. 244. Copyright 2017 American Chemical Society.






Fig. 16 Schematic representation of the different roles of nanoparticles used in cancer immunotherapy. Created with BioRender.com.

natural extracts. Administration of high-dose of allergen leads to a shift from allergic Th2 inflammation toward Th1 inflammation and the generation of suppressive “regulatory” immune cells with the decrease of allergen-specific IgE and an increase of protective IgG antibodies. In addition, the infiltration and activation of eosinophils, mast cells, and basophilic leukocytes is reduced.^{248,249} Despite the promising therapeutic outcome of allergen-specific immunotherapy (AIT), it has some limitations, including potential systemic side-effects, long-term duration of the treatment needed and, in some cases, limited treatment effect. Nanoparticles can be used as allergen delivery vehicles, with potential adjuvant effects, in order to target their cargo, specifically, to the site of action avoiding their recognition by IgEs on the surface of mast cells or basophils, which would lead to adverse systemic side effects (Fig. 17).²⁴⁹

Various types of NPs have been investigated as antigen delivery vehicles with potential therapeutic use.²⁴⁵ For example, Smarr C. *et al.*, demonstrated that PLGA NPs loaded with the OVA antigen [PLG(Ag) NPs] effectively inhibited Th2 responses and airway inflammation in an allergic airway inflammation mouse model without inducing adverse side effects.²⁵⁰ Allergen-specific immunotherapy (AIT) using NPs could be a potential treatment strategy for food allergies, which currently remains challenging due to high rates of allergic side effects and no evidence of long-term efficacy.²⁴⁹ Kawakita A. *et al.*, investigated whether intranasal administration of oligomannose-coated liposomes (OML), loaded with the OVA food allergen, could induce immune tolerance in OVA-sensitized mice. Their results

indicated that OVA-OML induced regulatory CD8⁺ T cells and antigen-specific secretory IgA in localized tissues of OVA-sensitized mice and inhibited the development of allergic diarrhea.²⁵¹ Furthermore, inorganic nanoparticles and specifically gold nanoparticles exhibiting immunomodulatory effects have been investigated for their impact on allergic diseases. Baretto E. *et al.*, demonstrated that intranasal installation of gold nanoparticles inhibited allergen-induced airway hyperactivity in asthma mouse models. The treatment with gold nanoparticles blocked the Th2 pro-inflammatory cytokine production and reduced ROS and MDA production, resulting in protective effects against asthma allergen sensitization.²⁵²

It is known that autoimmune diseases result from an attack of the immune system against specific tissues, compromising their function. In the context of an autoimmune disease, self-peptide antigens displayed by APCs activate T-cells, instead of promoting their tolerance, resulting in auto-immune response.²⁵³ Currently, the treatment of autoimmune diseases relies mostly on total immunosuppression, which, in the long term, leads to adverse side effects. Therefore, new approaches need to be developed that could target only the disease mediating cells. Altered peptide ligands (APLs) of autoantigens have been used to induce antigen-specific tolerance in animal models of autoimmune diseases exploiting the specificity of the TCR–pMHC interaction in order to modulate the function of autoreactive T-cells. However, the immune response to a specific APL cannot be predicted and the suppression of the autoreactive T-cells without affecting the systemic immunity is







Fig. 17 Schematic representation of allergen-specific immunotherapy using (A) soluble allergen and (B) allergen encapsulated in nanoparticles (NPs). Reproduced from ref. 249. Copyright 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

not currently possible. Nanoparticle based approaches are investigated for the treatment of autoimmune diseases, in order to achieve specific targeting and avoid systemic side effects. One approach is the use of NPs as delivery vehicles of autoantigens to tolerogenic APCs.²⁵⁴ Getts D. *et al.*, showed that polystyrene microparticles coupled to encephalitogenic myelin epitopes induced T-cell tolerance in multiple sclerosis mouse models, alleviating the clinical symptoms of experimental autoimmune encephalomyelitis (EAE). They demonstrated that the beneficial effect of the particles required expression of the 'macrophage receptor with collagenous structure' (MARCO), a scavenger receptor expressed on splenic marginal zone macrophages that contributes to the uptake and clearance of particulate debris.²⁵⁵ Another approach involves the delivery of tolerogenic substances to T-cells. Naive CD4⁺ T lymphocytes in the periphery, recognize self-peptides on APCs with the concurrent stimulatory or inhibitory signals in the microenvironment playing an important role to their transformation to effector T-cells (Teff) or regulatory T-cells (Treg), respectively. Park J. *et al.*, demonstrated that CD4-targeted PLGA nanoparticles loaded

with the inflammatory cytokine interleukin-6 (IL-6) led to inappropriate Th17 cell activity enhancing ROR γ T expression and inflammatory activity. On the contrary, NPs loaded with leukemia inhibitory factor (LIF), a tolerogenic cytokine, enhanced Foxp3⁺ expression which led to Treg lineage development and immune tolerance (Fig. 18).²⁵⁶

Adoptive transfer of polyclonal FOXP3⁺CD4⁺CD25⁺ regulatory T (Treg) cells has been proposed as a therapeutic approach for autoimmune diseases. However, there are currently no effective strategies for expanding antigen specific Treg cells *in vitro*. Clemente-Casares X. *et al.*, discovered a new strategy for the expansion of Treg cells *in vivo*. They showed that systemic therapy with nanoparticles coated with autoimmune-disease-relevant peptides bound to major histocompatibility complex class II (pMHCII) molecules triggered the generation and expansion of antigen-specific regulatory CD4⁺ T cells in different autoimmune disease mouse models *in vivo*, leading to the resolution of inflammation. Their data suggests that the use of any single pMHC, involved in a given autoimmune disease, could promote the differentiation of disease autoreactive T cells into Treg which,






Fig. 18 (A) Schematic model of the LIF and IL-6 cytokine loaded antibody (anti-CD4)-targeted PLGA nanoparticle and their modulation of CD4⁺ T cell differentiation. Nanoparticles encapsulating LIF (LIF-nano) were found to enhance Foxp3 expression leading to Treg lineage development, while nanoparticles encapsulating IL-6 (IL-6-nano) enhanced ROR γ T expression leading to Th17 lineage development. (B) Schematic representation of the PLGA anti-CD4 PLGA NPS used. Reprinted from ref. 256. Copyright 2011 American Chemical Society.

in turn, suppress autoantigen-loaded APCs and lead to the differentiation of B cells into disease-suppressing regulatory B cells. Therefore, pMHC-based nanomedicines represent a new class of therapeutics in the treatment of autoimmune diseases, without compromising systemic immunity.²⁵⁷

6. Clinical trials

The current understanding of the immune alterations induced by nanomaterials, together with optimized strategies for their use in drug delivery or vaccines, allowed multiple products to reach clinical trials. In Table 4 we review clinical trials of nanoparticles in immunotherapy that have a start and/or end date in the past 10 years. Not surprisingly, more trials are found using organic based NP-strategies, in contrast to only 3 trials using inorganic NPs. This trend is in accordance with current approved nanoparticle-based therapeutics, with iron oxide applications, *e.g.* as contrast agents for MRI, one of the few inorganic examples.²⁵⁸ The hafnium oxide nanoparticle-based strategy (NBTXR3) of Nanobiotix is another example and has been approved (CE mark) for its radio enhancing effect for the treatment of locally advanced soft tissue sarcoma.²⁵⁹ Additionally, promising preclinical *in vivo* results for its use in combination with anti-PD-1 immunotherapy, show potential for the treatment of lung cancer and has led to the initiation of a new clinical trial (NCT03589339).²⁶⁰

For organic nanoparticles, we divided the trials based on their type of application; nanoparticles as adjuvants, nanoparticles as immunotherapeutic delivery vehicles or nanoparticles in combination therapy. Within the first category, adjuvants, the clinical trials (NCT02030301 and NCT02837575) for VCL-HB01, a plasmid DNA vaccine formulated with Vaxfectin (cationic lipid-based adjuvant), were completed. Although promising results from the phase 1/2A showed significant lowering of lesion rates after 9 months, Vical completely shut down the HSV-2 program following unsatisfactory results in the

phase 2 trial. The disappointing results were allocated to a limited recurrence rate in the placebo group.²⁶¹

Within the second category, nanoparticles as immunotherapeutic delivery vehicles, the clinical trial for RGI-2001 (NCT01379209) was finalized in April 2017. RGI-2001 is a liposomal formulation of KRN700, an α -galactosylceramide, and is intended to prevent Graft-versus-Host-Disease (GVHD) after allogeneic bone marrow transplantation. In pre-clinical studies in a murine model, RGI-2001 was shown to prevent GVHD, due to an increased number of naturally occurring CD4⁺Foxp3⁺ Tregs, while retaining the intended Graft-versus-Leukemia effect of the transplantation.²⁶² In the phase 2A clinical trial, 29 patients were enrolled, of which 14 patients received a dose of 1 $\mu\text{g kg}^{-1}$ and 15 patients a dose of 100 $\mu\text{g kg}^{-1}$ on day 0 of transplantation. Results show that the treatment was well tolerated and led to an increase in Tregs in 8 out of 29 patients. Of these 8 responders, 6 had received sirolimus, an immunosuppressant, and appeared to result in a synergetic effect on the total Treg number. Additionally, the incidence of grade 2 to 4 and of grade 3 or 4 of GVHD was respectively, 12.5% and 0% in the responder group, contrary to 52.4% and 9.5% in non-responders. Although results are promising, it should be noted that no control group was included in the study, and no definitive conclusion can be made regarding the potential of RGI-2001.²⁶³ Further studies are needed to clarify the precise effect of RGI-2001 and to understand the lack of effect in non-responders. In another completed clinical trial (NCT03140657), the use of nanocurcumin (curcumin encapsulated in biodegradable polymer nanoparticles) for the treatment of ankylosing spondylitis, a chronic autoimmune disease, was evaluated. In this phase 2 trial, 12 patients were given a daily dose of 80 mg kg^{-1} nanocurcumin for 4 months. The study showed a significant increase of Treg cells and higher expression levels of FoxP3, TGF- β and IL-10, while the expression of IL-6 was significantly suppressed. Therefore, nanocurcumin shows potential as therapeutic agent for ankylosing spondylitis.²⁶⁴






Table 4 Clinical translation of nanomedicines for immunological applications^a

Name	Nanoparticle	Intervention	Immunotherapeutic indication	Disease application	Phase	Start date	Status	Clinical trials.gov identifier
Inorganic NBFXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy	Hafnium oxide (HfO ₂) nanoparticle activated by radiotherapy	Combination of NBFXR3 with anti-PD-1 therapy	Combination with immune checkpoint inhibitors to convert checkpoint inhibitor non-responders into responders	Locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and lung and liver metastases from any primary cancer eligible for anti-PD-1 therapy	1	16/01/2019	Recruiting	NCT03589339
Enhanced epidermal antigen specific immunotherapy trial-1 (EE-ASI-1)	Human C19A3 proinsulin derived peptide coupled to gold nanoparticles	Intradermal micro-injectable solution of C19-A3 GNP	Induce peptide-specific IL-10 secreting T cells to modify the autoimmune response and the switching off the white blood cells causing damage to the pancreatic islet cells	Diabetes type 1	1A	29/09/2016	Active	NCT02837094
Study to assess the impact of inhaled silver nanoparticles on lung cell immune response	Silver nanoparticles	Inhalation of nanosilver	Inhaled nanosilver can affect the lungs immune system and enter the bloodstream	Toxicity screening on healthy adults	0	03/04/2015	Withdrawn	NCT02408874
Organic <i>Nanoparticles as adjuvants</i> Safety and efficacy trial of DNA vaccines to treat Genital Herpes in Adults	Liposome (Vaxfectin)	VCL-HB01: Plasmid DNA vaccine encoding two HSV-2 proteins formulated with Vaxfectin	Cationic lipid-based adjuvant Vaxfectin to improve vaccine efficiency	Genital Herpes Simplex type 2	1/2A	December 2013	Completed (February 2016)	NCT02030301
<i>Nanoparticles as delivery vehicle for immunotherapy</i> RNA-immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (TNBC-MERIT)	Liposomes containing RNA for patient-specific tumour-associated antigens and p53 RNA	Individualized cancer immunotherapy with immunogenic RNA vaccines IVAC_W_bre1_uID vaccination JVRS-100 therapy	Induction of T-cell memory against patient specific tumour-associated antigens	Triple negative breast cancer	1	October 2016	Active	NCT02316457
JVRS-100 for the treatment of patients with relapsed or refractory leukemia	Cationic liposome loaded with plasmid DNA complex	JVRS-100 therapy	Immune stimulation	Relapsed or refractory leukemia	1	01/03/2009	Completed (February 2017)	NCT00860522




Table 4 (Contd.)

Name	Nanoparticle	Intervention	Immunotherapeutic indication	Disease application	Phase	Start date	Status	Clinical trials.gov identifier
Intravenous administration of RGI-2001 in patient undergoing allogeneic hematopoietic stem cell transplantation (AH SCT)	Liposomal formulation of α -galactosylceramide	IV-injection of RGI-2001 after completion of transplant	Mitigation of graft <i>versus</i> host disease by increasing immune tolerance	Patients undergoing allogeneic hematopoietic stem cell transplantation with or without radiation myeloablative preparative treatment	1/2	September 2011	Completed (April 2017)	NCT01379209
The effects of oral nanocurcumin on expression levels of microRNAs and Treg cells and Th17 cells development factors in ankylosing spondylitis patients	Curcumin in nanomicelles	Oral nano-curcumin application in patients with ankylosing spondylitis (AS)	Curcumin induces down-regulation of various inflammatory cytokines including TNF- α and IL 1	Ankylosing spondylitis	2	29/04/2017	Completed (January 2018)	NCT03140657
<i>Combination therapy: immunotherapy in combination with nanoparticle treatment</i> Nab-paclitaxel and durvalumab with or without neoantigen vaccine in treating patients with metastatic triple negative breast cancer	Nab-paclitaxel	Combination of nab-paclitaxel and durvalumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine)	Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 leading to immune cell activation. Vaccines made from peptides may help to build an effective immune response to kill tumor cells	Metastasized triple negative breast cancer	2	15/12/2018	Not yet recruiting	NCT03606967
Nab-paclitaxel and atezolizumab before surgery in treating patients with triple negative breast cancer	Nab-paclitaxel	Atezolizumab and Nab-paclitaxel	Combination of anti-PD-L1 antibody with nab-paclitaxel to reduce tumour size before surgery	Primary invasive adenocarcinoma of triple negative breast cancer with no prior treatment	2	04/02/2016	Recruiting	NCT02530489
Safety, tolerability and immunogenicity of EGFR(V)-EDV-Dox in subjects with recurrent glioblastoma multiforme (GBM) (CerebralEDV)	EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology	EGFR(V)-EDV-Dox is a bacterially derived minicell with encapsulated doxorubicin, which targets specific cancer cells using bispecific antibodies (BsAb)	The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immunosuppression caused by the tumor	Recurrent glioblastoma multiforme	1	25/10/2016	Recruiting	NCT02766699

Table 4 (Contd.)

Name	Nanoparticle	Intervention	Immunotherapeutic indication	Disease application	Phase	Start date	Status	Clinical trials.gov identifier
Atezolizumab with chemotherapy in treating patients with anaplastic or poorly differentiated thyroid cancer	Nab-paclitaxel	Combination of atezolizumab with chemotherapy (Cobimetinib, nab-paclitaxel, paclitaxel, vemurafenib)	Atezolizumab is a monoclonal antibody which will bind with PD-L1 and lead to immune cell activation. Combining it with chemotherapy may improve how immune cells respond and attack tumor cells	Anaplastic or poorly differentiated thyroid cancer	2	27/07/2017	Recruiting	NCT03181100
A study to evaluate safety/tolerability of immunotherapy combinations in participants with triple-negative breast cancer and gynecologic malignancies	Nab-paclitaxel pegylated liposomal doxorubicin (PLD)	AB928 in combination with PLD with or without IPI-549, or AB928 in combination with nanoparticle albumin-bound-paclitaxel	Enhancing the tumour-infiltrating lymphocytes and myeloid cells in combination with anthracycline topoisomerase II inhibitor with or without PIK3 inhibitor or enhancing the tumour-infiltrating lymphocytes and myeloid cells in combination with microtubules stabilizers	Triple negative breast cancer or ovarian cancer	1/1B	15/10/2018	Recruiting	NCT03719326
Dose escalation study of mRNA-2752 for intratumoral injection to patients with advanced malignancies	Lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ	Intratumoral injections of mRNA-2752 alone and in combination with intravenously administered durvalumab (immune checkpoint blockade therapy)	mRNA-2752 in combination with durvalumab, enhances the immune response at the tumour site	Relapsed/refractory solid tumor malignancies or lymphoma	1	27/11/2018	Recruiting	NCT03739931
Nab-paclitaxel/rituximab-coated nanoparticle AR160 in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma	Nab-paclitaxel/rituximab-coated nanoparticle AR160	Combination treatment of paclitaxel albumin-stabilized nanoparticle formulation and rituximab	Rituximab is a monoclonal antibody which binds to the cell surface protein CD20 of B cells forming a cap which triggers natural killer cells to destroy these B-cells	Non-Hodgkin lymphoma	1	25/4/2019	Recruiting	NCT03003546
Durvalumab in combination with chemotherapy in treating patients with advanced solid tumors, (DURVA + study)	Nab-paclitaxel-pegylated liposomal doxorubicin hydrochloride 1	Combination of durvalumab with chemotherapy (capecitabine, nab-paclitaxel, paclitaxel, carboplatin, gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride)	Durvalumab is a monoclonal antibody which will bind with PD-1 and lead to immune cell activation. Combining it with chemotherapy may improve how immune cells respond and attack tumor cells	Advanced solid tumors (spread to other places in the body)	2	25/06/2019	Recruiting	NCT03907475





Table 4 (Contd.)

Name	Nanoparticle	Intervention	Immunotherapeutic indication	Disease application	Phase	Start date	Status	Clinical trials.gov identifier
Evaluation of IPI-549 combined with front-line treatments in Pts. With triple-negative breast cancer or renal cell carcinoma (MARIO-3)	Nab-paclitaxel	Combination of IPI-549 with atezolizumab and nab-paclitaxel	IPI-549 targets immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma. In combination with immune therapy, it may enhance immune cell activation against the tumour cells	Triple negative breast cancer and renal cell cancer	2	17/12/2019	Recruiting	NCT03961698
Cryoablation, Atezolizumab/Nab-paclitaxel for locally advanced or metastatic triple negative breast cancer	Nab-paclitaxel	Atezolizumab (humanized monoclonal antibody against PD-L1), Cryosurgery (cryoablation of the primary tumour), Nab-paclitaxel	Cryoablation in combination with anti-PD-L1 antibody and Nab-paclitaxel	PD-L1 positive triple negative metastatic breast cancer or breast cancer spread into neighboring tissue or lymph nodes	Early 1	23/01/2020	Recruiting	NCT04249167
A single-arm, phase II study of neoadjuvant MPDL3280A, Nab-paclitaxel and carboplatin (MAC) in resectable non-small cell lung cancer (NSCLC)	Nab-paclitaxel	Combination of chemotherapeutic agents with immune-based therapy	MPDL3280A (atezolizumab) is an immune checkpoint inhibitor which will bind to PD-1 and activate the immune cells	Non-small cell lung cancer	2	07/06/2016	Active	NCT02716038
Neoadjuvant pembrolizumab (Pbr)/Nab-paclitaxel followed by Pbr/epirubicin/cyclophosphamide in TNBC (NIB)	Nab-paclitaxel	Pembrolizumab in combination with Nab-paclitaxel	Combination of anti-PD-L1 antibody with nab-paclitaxel to reduce tumour size before surgery	Triple negative breast cancer	2	23/03/2018	Active	NCT03289819
S0800, Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer	Nab-paclitaxel	IV injection of nab-paclitaxel with or without intravenous injection of bevacizumab	Comparison of treating efficiency of	HER2/NEU negative breast cancer	2	04/2010	Completed (December 2015)	NCT00856492

Table 4 (Contd.)

Name	Nanoparticle	Intervention	Immunotherapeutic indication	Disease application	Phase	Start date	Status	Clinical trials.gov identifier
Nab-paclitaxel and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery	Nab-paclitaxel	Combination of Nab-paclitaxel with bevacizumab in patients with stage IV melanoma	Bevacizumab is a monoclonal antibody that can bind to vascular endothelial growth factor and prevent the growth of new blood vessels that tumours need to grow	Stage IV melanoma	2	18/10/2013	Completed (October 2019)	NCT02158520
Safety and feasibility study of AGS-003-LNG for the treatment of stage 3 non small cell lung cancer	Nab-paclitaxel	AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of nano-particle albumin-bound paclitaxel chemotherapy & radiation therapy	Effects of combination treatment of autologous dendritic cell immunotherapy (AGS-003-LNG) and nanoparticle albumin-bound paclitaxel in patients with resectable non-small cell lung cancer	Resectable non-small cell lung cancer	2	March 2016	Withdrawn	NCT02662634
MM-398 and ramucirumab in treating patients with gastric cancer or gastroesophageal junction adenocarcinoma	Encapsulating irinotecan within long-circulating liposome-based nanoparticles	MM-398: interrupts cell reproduction ramucirumab: anti-VEGFR2	Treating patients with ramucirumab to enhance body's immune system to attack cancer cells and the combination with MM-398 for treating patients by interrupting cell reproduction	Gastric cancer or gastroesophageal junction adenocarcinoma	1/2	06/04/2020	Withdrawn (PI left)	NCT03739801

^a PIK3 (phosphoinositide 3-kinases); PD-L1 (programmed death-ligand 1); VEGFR2 (vascular endothelial growth factor 2); AHSCT (autologous hematopoietic stem cell transplantation).



After the successful use of liposome and albumin nanoparticles in current chemotherapies, like Doxil® and Abraxane®, similar strategies have been used in combination treatment with immunotherapy, the third category of clinical trials. Abraxane® (albumin-bound paclitaxel) is a very promising strategy with, currently, 10 ongoing clinical trials evaluating its potential for treating Triple Negative Breast Cancer (NCT03606967, NCT02530489, NCT03961698, NCT03719326, NCT04249167 and NCT03289819), thyroid cancer (NCT03181100), Non-Hodgkin lymphoma (NCT03003546), Non-small cell lung cancer (NCT02716038) and advanced solid tumours (NCT03907475). It was also used in the completed SWOG S0800 clinical trial, in which the addition of bevacizumab to a neo-adjuvant chemotherapy (Nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide) was shown to enhance the cytotoxicity of the therapy.²⁶⁵

7. Future prospects and conclusions

Nanoparticles have gained increasing interest over the years and are being explored for enhancing therapies of a variety of diseases and disorders. Here, we have provided an overview of the current research and understanding of the immunological alterations induced by nanomaterials and how this has allowed researchers to design nanomaterials suitable for drug delivery, immunostimulation and immunotherapy. Inorganic nanomaterials, like gold and mesoporous silica, were shown to have excellent adjuvant properties, and thus, could be used as self-adjuvant vaccine carriers. Additionally, porous inorganic materials can leverage their high internal volumes for enhanced drug delivery.

Organic nanomaterials exhibit considerable potential as delivery vehicles of anti-inflammatory agents, genetic material like DNA or RNA, antibodies and antigens, as they can protect their cargo from degradation and target specifically the inflamed tissues without inducing adverse side effects. Their physicochemical characteristics have significant effects on their therapeutic efficacy and should be modulated accordingly, taking into consideration their intended application. For example, cationic liposomes are recommended to be used for antigen presentation due to their immunostimulatory effects, whereas neutral and anionic liposomes would be preferable as drug delivery vehicles due to their prolonged circulation lifetime. Furthermore, surface functionalization of the NPs has a critical role on their site-specific targeting. Various ligands have been used for targeting enhancement while their specificity to the diseased site is essential for engineering safe and efficient nanotherapeutics. As discussed in this review, nanomaterial-based immunotherapy has shown great promise in the treatment of cancer, allergies and autoimmune diseases. Several approaches have been proposed in order to overcome the limitations of conventional immunotherapy strategies. Nanomaterials are able to deliver antigens specifically to antigen presenting cells (APC) in the lymph nodes, regulate Tregs, and TAMs, activate T cells and enhance adoptive cell therapies. In addition, nanoparticles could be harnessed as

immunogenic cell death (ICD) inducers, in combination with immunotherapy for an enhanced therapeutic efficacy.

The findings, discussed in this review, illustrate that research efforts on nanomaterial-based therapies have spiked and have made rapid progress. Progress in this field has largely been pushed by research for cancer therapies and, although translation is still relatively low,²⁶⁶ more and more nanoparticle strategies reach clinical trials. Enhancing translation ability of nanomedicine research will be one of the key challenges in the coming years. Upcoming strategies, such as cell-based nanoparticle delivery, functionalization with elaborating ligands with specific microenvironment responsiveness, and co-delivery of agents with synergistic immunomodulatory effects, are promising ideas for tackling this challenge.

The second major challenge is to assure safety of nanomaterials in the human body. Although multiple mechanisms have been suggested and indicated to contribute to the toxicological and immunological effect of nanomaterials, the exact pathways are still not fully unraveled. Additionally, tuning influential physicochemical parameters requires a time consuming, systematic experimental optimization. Computational methods are upcoming in bionanotechnology research and might facilitate optimization steps. For example, artificial neural network modelling has been used to fully evaluate the effect of PEG chain length, chitosan/PEG ratio and pH of the solution on the size and zeta potential of PEGylated Chitosan NPs.²⁶⁷ Additionally, computational fluid dynamics (CFD) has been used to predict the distribution and targeting efficiencies of nanoparticles.²⁶⁸ Further integration of computational models in bionanotechnology could accelerate nanoparticle designs.

Despite the major accomplishments over the past years, it is clear that we are only at the beginning of exploiting the potential of nanotechnology to its fullest and that a deeper understanding of the interactions of nanomaterials within the human body will lead to safer and more efficient immunological applications.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the European Commission under the Horizon 2020 framework for ERC (ERC StG 750973), FWO research project (GOB2919N) and KU Leuven Internal Funds C2 (C24/18/101).

References

- 1 G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old and R. D. Schreiber, *Nat. Immunol.*, 2002, **3**, 991, DOI: 10.1038/ni1102-991.
- 2 P. J. Delves, in *Encyclopedia of Immunology*, 2nd edn, 1998.
- 3 C. G. Drake, E. Jaffee and D. M. Pardoll, *Adv. Immunol.*, 2006, **90**, 51–81.



- 4 A. N. Ilinskaya and M. A. Dobrovolskaia, *Br. J. Pharmacol.*, 2014, **171**, 3988–4000.
- 5 S. Farkona, E. P. Diamandis and I. M. Blasutig, *BMC Med.*, 2016, **14**, 1–18.
- 6 X. Feng, W. Xu, Z. Li, W. Song, J. Ding and X. Chen, *Adv. Sci.*, 2019, **6**, DOI: 10.1002/advs.201900101.
- 7 S. Musetti and L. Huang, *ACS Nano*, 2018, **12**, 11740–11755.
- 8 A. K. Jain, K. Thanki and S. Jain, *Mol. Pharmaceutics*, 2013, **10**, 3459–3474.
- 9 P. I. Sifaka, N. Üstündag Okur, E. Karavas and D. N. Bikiaris, *Int. J. Mol. Sci.*, 2016, **17**, 1440, DOI: 10.3390/ijms17091440.
- 10 R. Pati, M. Shevtsov and A. Sonowane, *Front. Immunol.*, 2018, **9**, 2224, DOI: 10.3389/fimmu.2018.02224.
- 11 M. Saeed, J. Gao, Y. Shi, T. Lammers and H. Yu, *Theranostics*, 2019, **9**, 7981–8000.
- 12 M. Poljak-Blaži, M. Jaganjac and N. Žarković, *Cell Oxidative Stress: Risk of Metal Nanoparticles*, CRC Press Taylor, London, UK; New York, NY, USA, 2010.
- 13 I. Pujalte, I. Passagne, B. Brouillaud, M. Treguer, E. Durand, C. Ohayon-Courtes and B. L'Azou, *Part. Fibre Toxicol.*, 2011, **8**, 10.
- 14 M. Licciardi, C. Scialabba, R. Puleio, G. Cassata, L. Cicero, G. Cavallaro and G. Giammona, *Int. J. Pharm.*, 2019, **556**, 57–67.
- 15 R. J. Wydra, C. E. Oliver, K. W. Anderson, T. D. Dziubla and J. Z. Hilt, *RSC Adv.*, 2015, **5**, 18888–18893.
- 16 Z. Hou, Y. Zhang, K. Deng, Y. Chen, X. Li, X. Deng, Z. Cheng, H. Lian, C. Li and J. Lin, *ACS Nano*, 2015, **9**, 2584–2599.
- 17 F. Caputo, M. De Nicola, A. Sienkiewicz, A. Giovanetti, I. Bejarano, S. Licoccia, E. Traversa and L. Ghibelli, *Nanoscale*, 2015, **7**, 15643–15656.
- 18 J. M. Dowding, S. Das, A. Kumar, T. Dosani, R. McCormack, A. Gupta, T. X. T. Sayle, D. C. Sayle, L. Von Kalm, S. Seal and W. T. Self, *ACS Nano*, 2013, **7**, 4855–4868.
- 19 G. Benetti, E. Cavaliere, R. Brescia, S. Salassi, R. Ferrando, A. Vantomme, L. Pallecchi, S. Pollini, S. Boncompagni, B. Fortuni, M. J. Van Bael, F. Banfi and L. Gavioli, *Nanoscale*, 2019, **11**, 1626–1635.
- 20 N. Leynen, F. G. A. J. Van Belleghem, A. Wouters, H. Bove, J.-P. Ploem, E. Thijssen, S. A. S. Langie, R. Carleer, M. Ameloot, T. Artois and K. Smeets, *Nanotoxicology*, 2019, **13**, 476–491.
- 21 B. B. Manshian, C. Pfeiffer, B. Pelaz, T. Heimeri, M. Gallego, M. Möller, P. del Pino, U. Himmelreich, W. J. Parak and S. J. Soenen, *ACS Nano*, 2015, **9**, 10431–10444.
- 22 S. Sabella, R. P. Carney, V. Brunetti, M. A. Malvindi, N. Al-Juffali, G. Vecchio, S. M. Janes, O. M. Bakr, R. Cingolani, F. Stellacci and P. P. Pompa, *Nanoscale*, 2014, **6**, 7052–7061.
- 23 M. I. Setyawati, X. Yuan, J. Xie and D. T. Leong, *Biomaterials*, 2014, **35**, 6707–6715.
- 24 X. Lai, H. Zhao, Y. Zhang, K. Guo, Y. Xu, S. Chen and J. Zhang, *Sci. Rep.*, 2018, **8**, 4499.
- 25 A. Murphy, A. Casey, G. Byrne, G. Chambers and O. Howe, *J. Appl. Toxicol.*, 2016, **36**, 1311–1320.
- 26 T. Brzicova, E. Javorkova, K. Vrbova, A. Zajicova, V. Holan, D. Pinkas, V. Philimonenko, J. Sikorova, J. Klema, J. Topinka and P. Rossner, *Nanomaterials*, 2019, **9**, 687, DOI: 10.3390/nano9050687.
- 27 A. Pal, S. Alam, L. K. S. Chauhan, P. N. Saxena, M. Kumar, G. N. Ansari, D. Singh and K. M. Ansari, *Toxicol. Res.*, 2016, **5**, 1066–1077.
- 28 H. Attia, H. Nounou and M. Shalaby, *Toxics*, 2018, **6**(2), 29, DOI: 10.3390/toxics602029.
- 29 C. Angelé-Martínez, K. V. T. Nguyen, F. S. Ameer, J. N. Anker and J. L. Brumaghim, *Nanotoxicology*, 2017, **11**, 278–288.
- 30 E. Assadian, M. Zarei, A. Gilani, M. Farshin, H. Degampanah and J. Pourahmad, *Biol. Trace Elem. Res.*, 2018, **184**, 350–357.
- 31 J. Y. Ma, H. Zhao, R. R. Mercer, M. Barger, M. Rao, T. Meighan, D. Schwegler-Berry, V. Castranova and J. K. Ma, *Nanotoxicology*, 2011, **5**, 312–325.
- 32 J. Park, D.-h. Lim, H.-j. Lim, T. Kwon, J.-s. Choi, S. Jeong, I.-h. Choi and J. Cheon, *Chem. Commun.*, 2011, **47**, 4382–4384.
- 33 H. M. Braakhuis, I. Gosens, P. Krystek, J. A. F. Boere, F. R. Cassee, P. H. B. Fokkens, J. A. Post, H. van Loveren and M. V. D. Z. Park, *Part. Fibre Toxicol.*, 2014, **11**, 1743–8977.
- 34 E. I. Alarcon, K. Udekwu, M. Skog, N. L. Pacioni, K. G. Stampelcoskie, M. González-Béjar, N. Poliseti, A. Wickham, A. Richter-Dahlfors, M. Griffith and J. C. Scaiano, *Biomaterials*, 2012, **33**, 4947–4956.
- 35 M. Ilves, P. A. S. Kinaret, J. Ndika, P. Karisola, V. Marwah, V. Fortino, Y. Fedutik, M. Correia, N. Ehrlich, K. Loeschner, A. Besinis, J. Vassallo, R. D. Handy, H. Wolff, K. Savolainen, D. Greco and H. Alenius, *Part. Fibre Toxicol.*, 2019, **16**(28), 1–21.
- 36 S. Haque, V. M. McLeod, S. Jones, S. Fung, M. Whittaker, M. McIntosh, C. Pouton, D. J. Owen, C. J. H. Porter and L. M. Kaminskas, *Eur. J. Pharm. Biopharm.*, 2017, **119**, 408–418.
- 37 J.-P. Behr, *CHIMIA*, 1997, **51**, 34–36.
- 38 F. Wang, M. G. Bexiga, S. Anguissola, P. Boya, J. C. Simpson, A. Salvati and K. A. Dawson, *Nanoscale*, 2013, **5**, 10868–10876.
- 39 F. Jessop, R. F. Hamilton, J. F. Rhoderick, P. Fletcher and A. Holian, *Toxicol. Appl. Pharmacol.*, 2017, **318**, 58–68.
- 40 R. Benjaminsen, M. A. Mettebjerg, J. Henriksen, S. M. Moghimi and T. Andresen, *Mol. Ther.*, 2013, **21**, 149–157.
- 41 S.-H. Park, J. Y. Hyun and I. Shin, *Chem. Sci.*, 2018, **10**, 56–66.
- 42 X. Le Guével, M. Perez Perrino, T. D. Fernández, F. Palomares, M.-J. Torres, M. Blanca, J. Rojo and C. Mayorga, *ACS Appl. Mater. Interfaces*, 2015, **7**, 20945–20956.
- 43 J. Y. Ma, H. Zhao, R. R. Mercer, M. Barger, M. Rao, T. Meighan, D. Schwegler-Berry, V. Castranova and J. K. Ma, *Nanotoxicology*, 2011, **5**, 312–325.



- 44 B. B. Manshian, J. Poelmans, S. Saini, S. Pokhrel, J. J. Grez, U. Himmelreich, L. Mädler and S. J. Soenen, *Acta Biomater.*, 2018, **68**, 99–112.
- 45 Y.-H. Luo, L. W. Chang and P. Lin, *BioMed Res. Int.*, 2015, **2015**, 143720, DOI: 10.1155/2015/143720.
- 46 M. Turabekova, B. Rasulev, M. Theodore, J. Jackman, D. Leszczynska and J. Leszczynski, *Nanoscale*, 2014, **6**, 3488–3495.
- 47 H. Chang, C.-C. Ho, C. S. Yang, W.-H. Chang, M.-H. Tsai, H.-T. Tsai and P. Lin, *Exp. Toxicol. Pathol.*, 2013, **65**, 887–896.
- 48 C.-C. Ho, Y.-H. Luo, T.-H. Chaung, C.-S. Yang and P. Lin, *Toxicology*, 2013, **308**, 1–9.
- 49 A. R. Gliga, J. De Loma, S. Di Bucchianico, S. Skoglund, S. Keshavan, I. O. Wallinder, H. L. Karlsson and B. Fadeel, *Nanoscale Adv.*, 2020, **2**, 648–658.
- 50 C. Y. Tsai, S. L. Lu, C. W. Hu, C. S. Yeh, G. B. Lee and H. Y. Lei, *J. Immunol.*, 2012, **188**, 68–76.
- 51 S. Lee, H.-S. Yun and S.-H. Kim, *Biomaterials*, 2011, **32**, 9434–9443.
- 52 A. Gallud, O. Bondarenko, N. Feliu, N. Kupferschmidt, R. Atluri, A. Garcia-Bennett and B. Fadeel, *Biomaterials*, 2017, **121**, 28–40.
- 53 O. Kepp, L. Galluzzi and G. Kroemer, *Nat. Immunol.*, 2011, **12**, 199–200.
- 54 R. Zhou, A. S. Yazdi, P. Menu and J. Tschopp, *Nature*, 2011, **469**, 211–215.
- 55 C. S. Yang, D. M. Shin and E. Jo, *Int. Neurol. J.*, 2012, **16**, 2–12.
- 56 R. F. Hamilton, N. Wu, D. Porter, M. Buford, M. Wolfarth and A. Holian, *Part. Fibre Toxicol.*, 2009, **6**, 35.
- 57 B. Sun, X. Wang, Z. Ji, M. Wang, Y. P. Liao, C. H. Chang, R. Li, H. Zhang, A. E. Nel and T. Xia, *Small*, 2015, **11**, 2087–2097.
- 58 S. L. Fink and B. T. Cookson, *Cell. Microbiol.*, 2006, **8**, 1812–1825.
- 59 A. Reisetter, L. V. Stebounova, J. Baltrusaitis, L. Powers, A. Gupta, V. Grassian and M. M. Monick, *J. Biol. Chem.*, 2011, **286**, 21844–21852.
- 60 X. Zhang, J. Luan, W. Chen, J. Fan, Y. Nan, Y. Wang, Y. Liang, G. Meng and D. Ju, *Nanoscale*, 2018, **10**, 9141–9152.
- 61 V. Mirshafiee, B. Sun, C. H. Chang, Y.-P. Liao, W. Jiang, J. Jiang, X. Liu, X. Wang, T. Xia and A. E. Nel, *ACS Nano*, 2018, **12**, 3836–3852.
- 62 Q. Remijns, V. Goossens, S. Grootjans, C. V. D. Haute, N. Vanlangenakker, Y. Dondelinger, R. Roelandt, I. Bruggeman, A. Goncalves, M. J. M. Bertrand, V. Baekelandt, N. Takahashi, T. V. Berghe and P. Vandenebeele, *Cell Death Dis.*, 2014, **5**, e1004, DOI: 10.1038/cddis.2013.531.
- 63 Y. Niu, E. Tang and Q. Zhang, *Toxicol. Res.*, 2019, **8**, 1042–1049.
- 64 P. Sonkusre and S. S. Cameotra, *J. Nanobiotechnol.*, 2017, **15**, 43, DOI: 10.1186/s12951-017-0276-3.
- 65 T. T. Mai, A. Hamai, A. Hienzsch, T. Caneque, S. Müller, J. Wicinski, O. Cabaud, C. Leroy, A. David, V. Acevedo, A. Ryo, C. Ginestier, D. Birnbaum, E. Charafe-Jauffret, P. Codogno, M. Mehrpour and R. Rodriguez, *Nat. Chem.*, 2017, **9**, 1025–1033.
- 66 S. Dixon, K. Lemberg, M. Lamprecht, R. Skouta, E. Zaitsev, C. Gleason, D. Patel, A. Bauer, A. Cantley, W. Yang and B. Morrison, *Cell*, 2012, **149**, 1060–1072.
- 67 R. Yang, Y. Li, X. Wang, J. Yan, D. Pan, Y. Xu, L. Wang and M. Yang, *RSC Adv.*, 2019, **9**, 28548–28553.
- 68 H.-H. Jeong, E. Choi, E. Ellis and T.-C. Lee, *J. Mater. Chem. B*, 2019, **7**, 3480–3496.
- 69 J. P. M. Almeida, A. Y. Lin, E. R. Figueroa, A. E. Foster and R. A. Drezek, *Small*, 2015, **11**, 1453–1459.
- 70 W. Tao, K. S. Ziemer and H. S. Gill, *Nanomedicine*, 2014, **9**, 237–251.
- 71 R. Kumar, P. C. Ray, D. Datta, G. P. Bansal, E. Angov and N. Kumar, *Vaccine*, 2015, **33**, 5064–5071.
- 72 C. Wang, W. Zhu, Y. Luo and B.-Z. Wang, *Nanotechnol. Biol. Med.*, 2018, **14**, 1349–1360.
- 73 A. Y. Lin, J. Lunsford, A. S. Bear, J. K. Young, P. Eckels, L. Luo, A. E. Foster and R. A. Drezek, *Nanoscale Res. Lett.*, 2013, **8**, 72.
- 74 N. G. Bastús, E. Sánchez-Tilló, S. Pujals, C. Farrera, C. López, E. Giralt, A. Celada, J. Lloberas and V. Puntès, *ACS Nano*, 2009, **3**, 1335–1344.
- 75 S. S. Bawage, P. M. Tiwari, A. Singh, S. Dixit, S. R. Pillai, V. A. Dennis and S. R. Singh, *Nanotechnol. Biol. Med.*, 2016, **12**, 2299–2310.
- 76 K. T. Mody, A. Popat, D. Mahony, A. S. Cavallaro, C. Yu and N. Mitter, *Nanoscale*, 2013, **5**, 5167–5179.
- 77 T. Wang, H. Jiang, Q. Zhao, S. Wang, M. Zou and G. Cheng, *Int. J. Pharm.*, 2012, **436**, 351–358.
- 78 D. Mahony, A. S. Cavallaro, F. Stahr, T. J. Mahony, S. Z. Qiao and N. Mitter, *Small*, 2013, **9**, 3138–3146.
- 79 Y. Yang, M. Jambhrunkar, P. L. Abbaraju, M. Yu, M. Zhang and C. Yu, *Adv. Healthcare Mater.*, **6**, 1700466, DOI: 10.1002/adhm.201700466.
- 80 S. Heidegger, D. Gl, A. Schmidt, S. Niedermayer, C. Argyo, S. Endres, T. Bein and C. Bourquin, *Nanoscale*, 2015, **8**, 938–948.
- 81 W. R. Braz, N. L. Rocha, E. H. de Faria, M. L. A. e. Silva, K. J. Ciuffi, D. C. Tavares, R. A. Furtado, L. A. Rocha and E. J. Nassar, *Nanotechnology*, 2016, **27**, 385103, DOI: 10.1088/0957-4484/27/38/385103.
- 82 Y. C. Hacene, A. Singh and G. Van Den Mooter, *Int. J. Pharm.*, 2016, **506**, 138–147.
- 83 N. Han, Q. Zhao, L. Wan, Y. Wang, Y. Gao, P. Wang, Z. Wang, J. Zhang, T. Jiang and S. Wang, *ACS Appl. Mater. Interfaces*, 2015, **7**, 3342–3351.
- 84 B. G. Trewyn, S. Giri, I. I. Slowing and V. S. y. Lin, *Chem. Commun.*, 2007, 3236–3245.
- 85 H. Geng, Y. Zhao, J. Liu, Y. Cui, Y. Wang, Q. Zhao and S. Wang, *Int. J. Pharm. Res.*, 2016, **1**, 184–194.
- 86 S.-K. Min, S.-C. Lee, S.-D. Hong, C.-P. Chung, W. H. Park and B.-M. Min, *Biomaterials*, 2010, **31**, 4725–4730.
- 87 S. J. Cameron, F. Hosseinian and W. G. Willmore, *Int. J. Mol. Sci.*, 2018, **19**, 2030, DOI: 10.3390/ijms19072030.



- 88 J. Tian, K. K. Y. Wong, C. M. Ho, C. N. Lok, W. Y. Yu, C. M. Che, J. F. Chiu and P. K. H. Tam, *ChemMedChem*, 2007, **2**, 129–136.
- 89 K. H. L. Kwan, X. Liu, M. K. T. To, K. W. K. Yeung, C.-M. Ho and K. K. Y. Wong, *Nanotechnol. Biol. Med.*, 2011, **7**, 497–504.
- 90 A. P. Khandhar, H. Liang, A. C. Simpson, S. G. Reed, D. Carter, C. B. Fox and M. T. Orr, *Nanoscale*, 2020, **12**, 2515–2523.
- 91 M. T. Orr, A. P. Khandhar, E. Seydoux, H. Liang, E. Gage, T. Mikasa, E. L. Beebe, N. D. Rintala, K. H. Persson, A. Ahniyaz, D. Carter, S. G. Reed and C. B. Fox, *npj Vaccines*, 2019, **4**, 1.
- 92 L. Gu, L. E. Ruff, Z. Qin, M. Corr, S. M. Hedrick and M. J. Sailor, *Adv. Mater.*, 2012, **24**, 3981–3987.
- 93 U. Ikoba, H. Peng, H. Li, C. Miller, C. Yu and Q. Wang, *Nanoscale*, 2015, **7**, 4291–4305.
- 94 J. L. Elechiguerra, J. L. Burt, J. R. Morones, A. Camacho-Bragado, X. Gao, H. H. Lara and M. J. Yacaman, *J. Nanobiotechnol.*, 2005, **3**, 6, DOI: 10.1186/1477-3155-3-6.
- 95 H. P. Jia, D. C. Look, L. Shi, M. Hickey, L. Pewe, J. Netland, M. Farzan, C. Wohlford-Lenane, S. Perlman and B. McGray, *J. Virol.*, 2005, **23**, 14614–14621.
- 96 C. Devaux, J.-M. Rolain, P. Colson and D. Raoult, *Int. J. Antimicrob. Agents*, 2020, 105938, DOI: 10.1016/j.ijantimicag.2020.105938.
- 97 M. A. A. Al-Bari, *Pharmacol. Res. Perspect.*, 2017, **5**(1), e00293, DOI: 10.1002/prp2.293.
- 98 M. J. R. Virlan, D. Miricescu, R. Radulescu, C. M. Sabliov, A. Totan, B. Calenic and M. Greabu, *Molecules*, 2016, **21**, 207, DOI: 10.3390/molecules21020207.
- 99 R. Kumar and S. Lal, *J. Nanomater. Mol. Nanotechnol.*, 2014, **3**(4), 1000150, DOI: 10.4172/2324-8777.1000150.
- 100 M. A. Dobrovolskaia and S. E. McNeil, *Nat. Nanotechnol.*, 2007, **2**, 469–478.
- 101 N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Morenob and O. C. Farokhzad, *Chem. Soc. Rev.*, 2012, **41**, 2971–3010.
- 102 H. K. S. Yadav, A. A. Almokdad, S. I. M. Shaluf and M. S. Debe in *Nanocarriers for Drug Delivery: Polymer-Based Nanomaterials for Drug-Delivery Carriers*, ed. S. S. Mohapatra, S. Ranjan, N. Dasgupta, R. K. Mishra and S. Thomas, Elsevier Inc., 2019, pp. 531–556.
- 103 D. Dupeyrón, M. Kawakami, A. M. Ferreira, P. R. Cáceres-Vélez, J. Rieumont, R. B. Azevedo and J. C. T. Carvalho, *Int. J. Nanomed.*, 2013, **8**, 467–3477.
- 104 K. Tatiparti, S. Sau, S. K. Kashaw and A. K. Iyer, *Nanomaterials*, 2017, **7**, 77, DOI: 10.3390/nano7040077.
- 105 H. Laroui, E. Viennois, B. Xiao, B. S. B. Canup, D. Geem, T. L. Denning and D. Merlin, *J. Controlled Release*, 2014, **186**, 41–53.
- 106 N. Parameswaran and S. Patial, *Crit. Rev. Eukaryotic Gene Expression*, 2010, **20**(2), 87–103.
- 107 A. M. Aldayel, H. L. O'Mary, S. A. Valdes, X. Li, S. G. Thakkar, B. E. Mustafa and Z. Cui, *J. Controlled Release*, 2018, **283**, 280–289.
- 108 M. A. A. Jansen, L. H. Klausen, K. Thanki, J. Lyngsø, J. S. Pedersen, H. Franzky, H. M. Nielsen, W. van Eden, M. Dong, F. Broere, C. Foged and X. Zeng, *Eur. J. Pharm. Biopharm.*, 2019, **142**, 38–48.
- 109 S. J. Lee, A. Lee, S. R. Hwang, J. Park, J. Jang, M. S. Huh, D. Jo, S. Yoon, Y. Byun, S. H. Kim, I. C. Kwon, I. Youn and K. Kim, *Mol. Ther.*, 2014, **22**(2), 397–408.
- 110 P. Liu, L. Gu, L. Ren, J. Chen, T. Li, X. Wang, J. Yang, C. Chen and L. Sun, *Am. J. Transl. Res.*, 2019, **11**(11), 6775–6789.
- 111 M. E. El-Naggar, F. Al-Joufi, M. Anwar, M. F. Attia and M. A. El-Bana, *Colloids Surf., B*, 2019, **177**, 389–398.
- 112 M. Elsabahy and K. L. Wooley, *Chem. Soc. Rev.*, 2012, **41**, 2545–2561.
- 113 M. Üner and G. Yener, *Int. J. Nanomed.*, 2007, **2**(3), 289–300.
- 114 J. S. Suk, Q. Xu, N. Kim, J. Hanes and L. M. Ensign, *Adv. Drug Delivery Rev.*, 2016, **99**, 28–51.
- 115 H. S. Sakhalkar, M. K. Dalal, A. K. Salem, R. Ansari, J. Fu, M. F. Kiani, D. T. Kurjiaka, J. Hanes, K. M. Shakesheff and D. J. Goetz, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**(26), 15895–15900.
- 116 K. Ghosh, M. Kanapathipillai, N. Korin, J. R. McCarthy and D. E. Ingber, *Nano Lett.*, 2012, **12**, 203–208.
- 117 H. Läubli and A. Varki, *Cell. Mol. Life Sci.*, 2020, **77**, 593–605.
- 118 S. Spence, M. K. Greene, F. Fay, E. Hams, S. P. Saunders, U. Hamid, M. Fitzgerald, J. Beck, B. K. Bains, P. Smyth, E. Themistou, D. M. Small, D. Schmid, C. M. O'Kane, D. C. Fitzgerald, S. M. Abdelghany, J. A. Johnston, P. G. Fallon, J. F. Burrows, D. F. McAuley, A. Kissenpfennig and C. J. Scott, *Sci. Transl. Med.*, 2015, **7**, 303, DOI: 10.1126/scitranslmed.aab3459.
- 119 S. Thamphiwatana, P. Angsantikul, T. Escajadillo, Q. Zhang, J. Olson, B. T. Luk, S. Zhang, R. H. Fang, W. Gao, V. Nizet and L. Zhang, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**(43), 11488–11493.
- 120 Q. Zhang, D. Dehaini, Y. Zhang, J. Zhou, X. Chen, L. Zhang, R. H. Fang, W. Gao and L. Zhang, *Nat. Nanotechnol.*, 2018, **13**, 1182–1190.
- 121 C. Li, H. Li, Q. Wang, M. Zhou, M. Li, T. Gong, Z. Zhang and X. Sun, *J. Controlled Release*, 2017, **246**, 133–141.
- 122 M. Tang, P. Hu, Q. Zheng, N. Tirelli, X. Yang, Z. Wang and Y. Wang, *J. Nanobiotechnol.*, 2017, 1–11.
- 123 V. F. Fiore, M. C. Lofton, S. Roser-Page, S. C. Yang, J. Roman, N. Murthy and T. H. Barker, *Biomaterials*, 2010, **31**, 810–817.
- 124 C. Springer, S. Benita, Y. Sherman, N. Gursoy and D. Gilhar, *Pediatr. Res.*, 2005, **58**(3), 537–541.
- 125 D. Yoo, K. Guk, H. Kim, G. Khang, D. Wu and D. Lee, *Int. J. Pharm.*, 2013, **450**, 87–94.
- 126 D. J. Hanlon, F. A. Sharp, D. Khalil, E. Robinson, R. Tigelaar and T. M. Fahmy, 2014, 5231–5246.
- 127 J. D. Mintern, C. Percival, M. M. J. Kamphuis, W. J. Chin, F. Caruso and A. P. R. Johnston, *Adv. Healthcare Mater.*, 2013, **2**, 940–944.
- 128 T. Akagi, X. Wang, T. Uto, M. Baba and M. Akashi, *Biomaterials*, 2007, **28**, 3427–3436.



- 129 P. Li, Z. Luo, P. Liu, N. Gao, Y. Zhang, H. Pan, L. Liu, C. Wang, L. Cai and Y. Ma, *J. Controlled Release*, 2013, **168**, 271–279.
- 130 M. Diwan, P. Elamanchili, M. Cao and J. Samuel, *Curr. Drug Delivery*, 2004, **1**(4), 405–412.
- 131 P. J. Tacken, I. S. Zeelenberg, L. J. Cruz, M. A. van Hout-Kuijter, G. van de Glind, R. G. Fokkink, A. J. Lambeck and C. G. Figdor, *Blood*, 2011, **118**(26), 6836–6844.
- 132 N. P. F. Saade, Y. Honda-Okubo and S. Trec, *Vaccine*, 2013, **31**(15), 1999–2007.
- 133 S. Kumar, A. C. Anselmo, A. Banerjee, M. Zakrewsky and S. Mitragotri, *J. Controlled Release*, 2015, **220**, 141–148.
- 134 A. D. Bangham, M. M. Standish and J. C. Watkins, *J. Mol. Biol.*, 1965, **13**, 238–252.
- 135 Z. Chu, S. Zhang, B. Zhang, C. Zhang, C. Fang, I. Rehor, P. Cigler, H. Chang, G. Lin, R. Liu and Q. Li, *Sci. Rep.*, 2014, **4**, 4495, DOI: 10.1038/srep04495.
- 136 T. M. Allen and P. R. Cullis, *Adv. Drug Delivery Rev.*, 2013, **65**, 36–48.
- 137 U. Bulbake, S. Doppalapudi, N. Kommineni and W. Khan, *Pharmaceutics*, 2017, **9**, 12, DOI: 10.3390/pharmaceutics9020012.
- 138 B. Ozbakir, B. J. Crielaard, J. M. Metselaar, G. Storm and T. Lammers, *J. Controlled Release*, 2014, **190**, 624–636.
- 139 C. Data, *Ann. Rheum. Dis.*, 2009, **68**, 12, DOI: 10.1136/ard.2009.108985.
- 140 S. Angmo, S. Rana, K. Yadav, R. Sandhir and N. K. Singhal, *Sci. Rep.*, 2018, **8**, 17684, DOI: 10.1038/s41598-018-35992-2.
- 141 M. Ponzoni and F. Pastorino, *Int. J. Mol. Sci.*, 2018, **19**, 1953, DOI: 10.3390/ijms19071953.
- 142 T. M. Drake, L. B. Clarke and S. Khosla, *Mayo Clin. Proc.*, 2008, **83**, 1032–1045.
- 143 T. Mert, M. Sahin, E. Sahin and S. Yaman, *Inflammopharmacology*, 2019, **27**, 603–612.
- 144 N. M. La-Beck, X. Liu and L. M. Wood, *Front. Pharmacol.*, 2019, **10**, 220, DOI: 10.3389/fphar.2019.00220.
- 145 R. Nisini, N. Poerio, S. Mariotti, F. De Santis and M. Fraziano, *Front. Immunol.*, 2018, **9**, 155, DOI: 10.3389/fimmu.2018.00155.
- 146 R. M. Schifflers, M. Banciu, J. M. Metselaar, G. Storm, R. M. Schifflers, M. Banciu and J. M. Metselaar, *J. Liposome Res.*, 2006, **16**(3), 185–194.
- 147 A. Gauthier, A. Fisch, K. Seuwen, B. Baumgarten, H. Ruffner, A. Aebi, M. Rausch, F. Kiessling, M. Bartneck, R. Weiskirchen, F. Tacke, G. Storm, T. Lammers and M. Ludwig, *Biomaterials*, 2018, **178**, 481–495.
- 148 J. M. Metselaar, W. B. van den Berg, A. Wagenaar-hilbers, O. C. Boerman and G. Storm, *Arthritis Rheum.*, 2003, **48**(7), 2059–2066.
- 149 J. M. Metselaar, W. B. van den Berg, A. E. Holthuysen, M. H. Wauben, G. Storm and P. L. van Lent, *Ann. Rheum. Dis.*, 2004, **63**(4), 348–353.
- 150 M. Bartneck, K. M. Scheyda, K. T. Warzecha, L. Y. Rizzo, K. Hittatiya, T. Luedde, G. Storm, C. Trautwein, T. Lammers and F. Tacke, *Biomaterials*, 2015, **37**, 367–382.
- 151 Q. Wang and J. Fang, *J. Mater. Chem. B*, 2020, **8**(9), 1773–1982.
- 152 J. Szebeni and G. Storm, *Biochem. Biophys. Res. Commun.*, 2015, **468**, 490–497.
- 153 E. Wenande and L. H. Garvey, *Clin. Exp. Allergy*, 2016, 907–922.
- 154 J. J. F. Verhoef and T. J. Anchordoquy, *Drug Delivery Transl. Res.*, 2013, **3**(6), 499–503.
- 155 P. I. Homem de Bittencourt Jr, D. J. Lagranha, A. Maslinkiewicz, S. M. Senna, A. M. V. Tavares, L. P. Baldissera, D. R. Janner, J. S. Peralta, P. M. Bock, L. L. P. Gutierrez, G. Scola, T. G. Heck, M. S. Krause, L. A. Cruz, D. S. P. Abdalla, C. J. Lagranha, T. Lima and R. Curi, *Atherosclerosis*, 2007, **193**, 245–258.
- 156 O. A. Marcos-contreras, J. S. Brenner, R. Y. Kiseleva, V. Zuluaga-ramirez, C. F. Greineder, C. H. Villa, E. D. Hood, J. W. Myerson, S. Muro, Y. Persidsky and V. R. Muzykantov, *J. Control Release*, 2019, **301**, 54–61.
- 157 S. Poh, V. Chelvam, W. Ayala-lópez, K. S. Putt and P. S. Low, *Nanomedicine*, 2018, **14**(3), 1033–1043.
- 158 A. Verma, A. Jain, A. Tiwari, S. Saraf and P. K. Panda, *Pharm. Res.*, 2019, **36**, 123, DOI: 10.1007/s11095-019-2653-0.
- 159 R. Molinaro, C. Corbo, J. O. Martinez, F. Taraballi, M. Evangelopoulos, S. Minardi and I. K. Yazdi, *Nat. Mater.*, 2016, **15**, 1037–1047.
- 160 M. Henriksen-lacey, K. S. Korsholm, P. Andersen, Y. Perrie and D. Christensen, *Expert Opin. Drug Delivery*, 2011, **8**(4), 505–519.
- 161 C. Foged, C. Arigita, A. Sundblad, W. Jiskoot, G. Storm and S. Frokjaer, *Vaccine*, 2004, **22**, 1903–1913.
- 162 M. Henriksen-lacey, D. Christensen, V. W. Bramwell, T. Lindenstrøm, E. Marie, P. Andersen and Y. Perrie, *J. Controlled Release*, 2010, **145**, 102–108.
- 163 T. Nakanishi, J. Kunisawa, A. Hayashi, Y. Tsutsumi, K. Kubo, S. Nakagawa, H. Fujiwara, T. Hamaoka and T. Mayumi, *Biochem. Biophys. Res. Commun.*, 1997, **797**, 793–797.
- 164 R. Kaur, V. W. Bramwell, D. J. Kirby and Y. Perrie, *J. Controlled Release*, 2012, **164**, 331–337.
- 165 J. H. van den Berg, K. Oosterhuis, W. E. Hennink, G. Storm, L. J. van der Aa, J. F. J. Engbersen, J. B. A. G. Haanen, J. H. Beijnen, T. N. Schumacher and B. Nuijen, *J. Controlled Release*, 2010, **141**, 234–240.
- 166 S. T. Schmidt, C. Foged, K. S. Korsholm, T. Rades and D. Christensen, *Pharmaceutics*, 2016, **8**, 7, DOI: 10.3390/pharmaceutics8010007.
- 167 A. Ramakrishnan, N. M. Schumack, C. L. Garipey, H. Eggleston, G. Nunez, N. Espinoza, M. Nieto, R. Castillo, R. J. Rojas, A. J. McCoy, Z. Beck, G. R. Matyas, C. R. Alving, P. Guerry, F. Poly and R. M. Laird, *mSphere*, 2019, **4**(3), e00101.
- 168 Z. Li, L. Zhang, W. Sun, Q. Ding, Y. Hou and Y. Xu, *Vaccine*, 2011, **29**, 5260–5266.
- 169 R. H. J. Khandare, M. Calderon and N. M. Dagia, *Chem. Soc. Rev.*, 2012, **41**, 2824–2848.
- 170 R. K. Kesrevani and A. K. Sharma, in *Nanoarchitectonics for Smart Delivery and Drug Targeting: Present Status and Future Prospects in Drug Delivery*, ed A. M. Holban and A. M. Grumezescu, William Andrew, Oxford, UK, 2016.



- 171 S. Fruchon and R. Poupot, *Nanomaterials*, 2017, **7**, 251, DOI: 10.3390/nano7090251.
- 172 Y. Cheng, J. Wang, T. Rao, X. He and T. Xu, *Front. Biosci.*, 2008, **13**, 1447–1471.
- 173 A. Janaszewska, J. Lazniewska, P. Trzepiński, M. Marcinkowska and B. Klajnert-Maculewicz, *Biomolecules*, 2019, **9**, 330.
- 174 S. Biswas and V. P. Torchilin, *Pharmaceuticals*, 2013, **6**, 161–183.
- 175 H. Yang, *Nanomedicine*, 2016, **12**, 309–316.
- 176 C. Yiyun and X. Tongwen, *Eur. J. Med. Chem.*, 2005, **40**(12), 1384–1389.
- 177 A. S. Chauhan, P. V. Diwan, N. K. Jain and D. A. Tomalia, *Biomacromolecules*, 2009, **10**, 1195–1202.
- 178 S. Shaunak, S. Thomas, E. Gianasi, A. Godwin, E. Jones, I. Teo, K. Mireskandari, P. Luthert, R. Duncan, S. Patterson, P. Khaw and S. Brocchini, *Nat. Biotechnol.*, 2004, **22**, 977–984.
- 179 E. R. Gillies, J. M. J. Fréchet and F. C. Szoka, *Mol. Pharm.*, 2005, **2**, 129–138.
- 180 I. Durocher and D. Girard, *Inflammation Res.*, 2016, **65**, 745–755.
- 181 L. Griffe, M. Poupot, P. Marchand, A. Maraval, C. Turrin, O. Rolland, P. Møtvierv, G. Bacquet, J. Fourniø, A. Caminade, R. Poupot and J. Majoral, *Angew. Chem., Int. Ed.*, 2007, **46**, 2523–2526.
- 182 S. Fruchon and R. Poupot, *Molecules*, 2018, **23**(6), 1272, DOI: 10.3390/molecules23061272.
- 183 L. Griffe, M. Poupot, P. Marchand, A. Maraval, C. Turrin, O. Rolland, P. Møtvierv, G. Bacquet, J. Fourniø, A. Caminade, R. Poupot and J. Majoral, *Angew. Chem., Int. Ed.*, 2007, **46**, 2523–2526.
- 184 G. M. Hayder, M. Garzoni, D. Bochicchio, A. Caminade, F. Couderc, V. Ong-Meang, J. L. Davignon and C. Turrin, *Biomacromolecules*, 2018, **19**, 712–720.
- 185 J. Dervede, A. Rausch, M. Weinhart, S. Enders, R. Tauber, K. Licha, M. Schirner, U. Zügel, A. Von Bonin and R. Haag, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 19679–19684.
- 186 J. J. García-Vallejo, M. Ambrosini, A. Overbeek, W. E. van Riel, K. Bloem, W. W. J. Unger, F. Chiodo, J. G. Bolscher, K. Nazmi, H. Kalay and Y. van Kooyk, *Mol. Immunol.*, 2013, **53**, 387–397.
- 187 F. S. Tabatabaei Mirakabad, M. S. Khoramgah, K. F. Keshavarz, M. Tabar zad and J. Ranjbari, *Life Sci.*, 2019, **233**, 116754.
- 188 C. Cubillos, G. Beatriz, A. Jakab, G. Clementi, E. Borrás, J. Bárcena, D. Andreu, F. Sobrino and E. Blanco, *J. Virol.*, 2008, **82**(14), 7223–7230.
- 189 D. Verma, N. Gulati, S. Kaul, S. Mukherjee and U. Nagaich, *J. Pharm.*, 2018, **2018**, 9285854, DOI: 10.1155/2018/9285854.
- 190 A. Sparreboom, C. D. Scripture, V. Trieu, P. J. Williams, T. De, A. Yang, B. Beals, W. D. Figg, M. Hawkins and N. Desai, *Clin. Cancer Res.*, 2005, **11**, 4136–4144.
- 191 G. Fanali, V. Trezza, M. Marino, M. Fasano and P. Ascenzi, *Mol. Aspects Med.*, 2012, **33**, 209–290.
- 192 F. Zhang, Y. Zhang, J. Da, Z. Jia, H. Wu and K. Gu, *J. Cancer*, 2020, **11**, 414–420.
- 193 N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins and P. Soon-shiong, *Clin. Cancer Res.*, 2006, **12**, 1317–1325.
- 194 L. Liu, F. Hu, X. Wu, A. S. Eltahan, S. Stephanie, N. Bottini, H. Xiao, M. Bottini, W. Guo and X. Liang, *ACS Nano*, 2019, **13**, 5036–5048.
- 195 Y. Iwao, I. Tomiguchi, A. Domura, Y. Mantaira and A. Minami, *Eur. J. Pharm. Biopharm.*, 2018, **125**, 141–147.
- 196 Z. Wang, J. Li, J. Cho and A. B. Malik, *Nat. Nanotechnol.*, 2014, **9**, 204–210.
- 197 A. Verma, A. Jain, A. Tiwari, S. Saraf and P. K. Panda, *ACS Biomater. Sci. Eng.*, 2018, **4**, 3939–3961.
- 198 W. Lohcharoenkal, L. Wang, Y. C. Chen and Y. Rojanasakul, *BioMed Res. Int.*, 2014, **2014**, 180549, DOI: 10.1155/2014/180549.
- 199 A. O. Elzoghby, *J. Controlled Release*, 2013, **172**, 1075–1091.
- 200 M. Santoro, A. M. Tataro and A. G. Mikos, *J. Controlled Release*, 2014, **190**, 210–218.
- 201 H. Wang, Q. Zou, O. C. Boerman, A. W. G. Nijhuis, J. A. Jansen, Y. Li and S. C. G. Leeuwenburgh, *J. Controlled Release*, 2013, **166**, 172–181.
- 202 M. Bartneck, K. T. Warzecha and F. Tacke, *Hepatobiliary Surg Nutr*, 2014, **3**, 364–376.
- 203 D. Narayanan, M. G. Geena, H. Lakshmi, M. Koyakutty, S. Nair and D. Menon, *Nanomedicine*, 2013, **9**, 818–828.
- 204 H. Y. Huang, M. C. Wang, Z. Y. Chen, W. Y. Chiu, K. H. Chen, I. C. Lin, W. C. V. Yang, C. C. Wu and C. L. Tseng, *Int. J. Nanomed.*, 2018, **13**, 7251–7273.
- 205 M. Javadi and S. Feizi, *J. Ophthalmic Vision Res.*, 2011, **6**, 192–198.
- 206 L. Lu, S. Qi, Y. Chen, H. Luo, S. Huang, X. Yu, Q. Luo and Z. Zhang, *Biomaterials*, 2020, **245**, 119987, DOI: 10.1016/j.biomaterials.2020.119987.
- 207 A. Yeboah, R. I. Cohen, R. Faulknor, R. Schloss, M. L. Yarmush and F. Berthiaume, *J. Controlled Release*, 2016, **232**, 238–247.
- 208 Y. Gao, C. Wijewardhana and J. F. S. Mann, *Front. Immunol.*, 2018, **9**, 1–18.
- 209 J. Yoo, D. J. Irvine, D. E. Discher and S. Mitragotri, *Nat. Rev. Drug Discovery*, 2011, **10**, 521–535.
- 210 Y. Seow and M. J. Wood, *Mol. Ther.*, 2009, **17**, 767–777.
- 211 M. A. Buabeid, E. S. A. Arafa and G. Murtaza, *J. Immunol. Res.*, 2020, **2020**, 9624532, DOI: 10.1155/2020/9624532.
- 212 S. Farkona, E. P. Diamandis and I. M. Blasutig, *BMC Med.*, 2016, **14**, 73, DOI: 10.1186/s12916-016-0623-5.
- 213 X. Zhang, C. Wang, J. Wang, Q. Hu, B. Langworthy, Y. Ye, W. Sun, J. Lin, T. Wang, J. Fine, H. Cheng, G. Dotti, P. Huang and Z. Gu, *Adv. Mater.*, 2018, **30**, 1707112, DOI: 10.1002/adma.201707112.
- 214 Y. Ohue and H. Nishikawa, *Cancer Sci.*, 2019, **110**, 2080–2089.
- 215 C. B. Rodell, S. P. Arlauckas, M. F. Cuccarese, C. S. Garris, R. Li, M. S. Ahmed, R. H. Kohler, M. J. Pittet and R. Weissleder, *Nat. Biomed. Eng.*, 2018, **2**, 578–588.
- 216 W. Ou, R. Kumar, L. Jiang, Z. Chi, M. Gautam and J. Chang, *J. Controlled Release*, 2018, **281**, 84–96.



- 217 H. Zhang, M. T. Silvestrini, J. S. Lewis and K. W. Ferrara, *Bioconjugate Chem.*, 2018, **28**, 2756–2771.
- 218 Y. W. Noh, S. Y. Kim, J. E. Kim, S. Kim, J. Ryu, I. Kim, E. Lee, S. H. Um and Y. T. Lim, *Adv. Funct. Mater.*, 2017, **27**, 1605398, DOI: 10.1002/adfm.201605398.
- 219 N. I. Ho, L. G. M. Huis, T. K. Raaijmakers and G. J. Adema, *Front. Immunol.*, 2018, **9**, 2874, DOI: 10.3389/fimmu.2018.02874.
- 220 R. A. Rosalia, L. J. Cruz, S. Van Duikeren, A. T. Tromp, J. Oostendorp, A. L. Silva, W. Jiskoot, T. De Gruijl, L. Clemens, S. H. Van Der Burg and F. Ossendorp, *Biomaterials*, 2015, **40**, 88–97.
- 221 H. Kakwere, E. S. Ingham, R. Allen, L. M. Mahakian, S. M. Tam, H. Zhang, M. T. Silvestrini, J. S. Lewis and K. W. Ferrara, *Bioconjugate Chem.*, 2017, **28**, 2756–2771.
- 222 T. W. Dubensky, D. B. Kanne and M. L. Leong, *Ther. Adv.*, 2013, **1**, 131–143.
- 223 M. C. Hanson, M. P. Crespo, W. Abraham, K. D. Moynihan, G. L. Szeto, S. H. Chen, M. B. Melo, S. Mueller and D. J. Irvine, *J. Clin. Invest.*, 2015, **125**, 2532–2546.
- 224 D. J. Irvine and E. L. Dane, *Nat. Rev. Immunol.*, 2020, **20**, 321–334.
- 225 D. V. Krysko, A. D. Garg, A. Kaczmarek and O. Krysko, *Nat. Rev. Cancer*, 2012, **12**, 860–875.
- 226 A. S. Bear, L. C. Kennedy, J. K. Young, S. K. Perna, J. P. Mattos, A. Y. Lin, P. C. Eckels, R. A. Drezek and A. E. Foster, *PLoS One*, 2013, **8**, 69073, DOI: 10.1371/journal.pone.0069073.
- 227 Y. Wen, X. Chen, X. Zhu, Y. Gong, G. Yuan, X. Qin and J. Liu, *ACS Appl. Mater. Interfaces*, 2019, **11**, 43393–43408.
- 228 Y. Ma, Y. Zhang, X. Li, Y. Zhao, M. Li, W. Jiang, X. Tang, J. Dou, L. Lu, F. Wang and Y. Wang, *ACS Nano*, 2019, **13**, 11967–11980.
- 229 E. E. Sweeney, J. Cano-Mejia and R. Fernandes, *Small*, 2018, **14**(20), 1800678, DOI: 10.1002/smll.201800678.
- 230 W. Li, J. Yang, L. Luo, M. Jiang, B. Qin, H. Yin, C. Zhu, X. Yuan, J. Zhang, Z. Luo, Y. Du, Q. Li, Y. Lou, Y. Qiu and J. You, *Nat. Commun.*, 2019, **10**, 3349, DOI: 10.1038/s41467-019-11269-8.
- 231 D. Liu, B. Chen, Y. Mo, Z. Wang, T. Qi, Q. Zhang and Y. Wang, *Nano Lett.*, 2019, **19**, 6964–6976.
- 232 L. Raes, C. Van Hecke, J. Michiels, S. Stremersch, J. C. Fraire, T. Brans, R. Xiong, S. De Smedt, L. Vandekerckhove, K. Raemdonck and K. Braeckmans, *Crystals*, 2019, **9**, 411, DOI: 10.3390/cryst9080411.
- 233 L. Van Hoecke, L. Raes, S. Stremersch, T. Brans, J. C. Fraire, R. Roelandt, W. Declercq, P. Vandenabeele, K. Raemdonck, K. Braeckmans and X. Saelens, *Int. J. Mol. Sci.*, 2019, **20**, e4254, DOI: 10.3390/ijms20174254.
- 234 X. Duan, C. Chan, W. Han, N. Guo, R. R. Weichselbaum and W. Lin, *Nat. Commun.*, 2019, **10**, 1899, DOI: 10.1038/s41467-019-09221-x.
- 235 H. Naatz, B. B. Manshian, C. R. Luci, V. Tsikourkitoudi, Y. Deligiannakis, J. Birkenstock, S. Pokhrel, M. Lutz and S. J. Soenen, *Angew. Chem., Int. Ed.*, 2020, **59**, 1828–1836.
- 236 E. Ploetz, A. Zimpel, V. Cauda, D. Bauer, D. C. Lamb, C. Haisch, S. Zahler, A. M. Vollmar, S. Wuttke and H. Engelke, *Adv. Mater.*, 2020, 1907267, DOI: 10.1002/adma.201907267.
- 237 L. W. Bishop, M. Wehbe, D. Shae, J. James, B. C. Hacker, K. Garland, P. P. Chistov, M. Rafat, J. M. Balko and J. T. Wilson, *J. Immunotherapy Cancer*, 2020, **8**(1), e000282, DOI: 10.1136/jitc-2019-000282.
- 238 N. Cheng, R. Watkins-Schulz, R. D. Junkins, C. N. David, B. M. Johnson, S. A. Montgomery, K. J. Peine, D. B. Darr, H. Yuan, K. P. McKinnon, Q. Liu, L. Miao, L. Huang, E. M. Bachelder, K. M. Ainslie and J. P. Y. Ting, *JCI Insight*, 2018, **3**(22), e120638, DOI: 10.1172/jci.insight.120638.
- 239 D. Shae, K. W. Becker, P. Christov, D. S. Yun, A. K. R. Lytton-Jean, S. Sevimli, M. Ascano, M. Kelley, D. B. Johnson, J. M. Balko and J. T. Wilson, *Nat. Nanotechnol.*, 2019, **14**, 269–278.
- 240 M. Hoang, H. Lee, H. Lee, S. Jung, N. Choi, M. Vo, H. Kim, I. Park and J. Lee, *J. Immunol. Res.*, 2015, **2015**, 706379, DOI: 10.1155/2015/706379.
- 241 T. R. Abreu, N. A. Fonseca, N. Gonçalves and J. N. Moreira, *J. Controlled Release*, 2020, **319**, 246–261.
- 242 J. N. Kochenderfer, W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. N. Nathan, B. J. Lanier, R. A. Morgan and S. A. Rosenberg, *Blood*, 2010, **116**, 4099–4102.
- 243 K. Newick, E. Moon and S. M. Albelda, *Mol. Ther.–Oncolytics*, 2016, **3**, 16006, DOI: 10.1038/mto.2016.6.
- 244 Y. Zheng, L. Tang, L. Mabardi, S. Kumari and D. J. Irvine, *ACS Nano*, 2017, **11**, 3089–3100.
- 245 L. Tang, Y. Zheng, M. B. Melo, L. Mabardi, A. P. Castaño, Y. Xie, N. Li, S. B. Kudchodkar, H. C. Wong, E. K. Jeng, M. V. Maus and D. J. Irvine, *Nat. Biotechnol.*, 2018, **36**(8), 707–716, DOI: 10.1038/nbt.4181.
- 246 C. P. Bailey, T. Budak-Alpdogan, C. T. Sauter, M. M. Panis, C. Buyukgoz, E. K. Jeng, H. C. Wong, N. Flomenberg and O. Alpdogan, *Oncotarget*, 2017, **8**, 44366–44378.
- 247 T. T. Smith, S. B. Stephan, H. F. Moffett, L. E. Mcknight, W. Ji, D. Reiman, E. Bonagofski, M. E. Wohlfahrt, S. P. S. Pillai and M. T. Stephan, *Nat. Nanotechnol.*, 2017, **12**, 813–822.
- 248 N. C. Gunawardana and S. R. Durham, *Ann. Allergy, Asthma, Immunol.*, 2018, **121**, 293–305.
- 249 H. Pohlitz, I. Bellinghausen, H. Frey and J. Saloga, *Allergy*, 2017, **72**, 1461–1474.
- 250 C. B. Smarr, W. Teck, T. P. Neef, R. M. Pearson, Z. N. Hunter, I. Ifergan and D. R. Getts, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 5059–5064.
- 251 A. Kawakita, H. Shirasaki, M. Yasutomi, S. Tokuriki, M. Mayumi, H. Naiki and Y. Ohshima, *Allergy*, 2012, **67**, 371–379.
- 252 E. Barreto, M. F. Serra, R. V. Dos Santos, C. E. A. Dos Santos, J. Hickmann, A. C. Cotias, C. R. Rodrigues Pão, S. G. Trindade, V. Schmidt, C. Giacomelli, V. F. Carvalho, P. M. Rodrigues E Silva, R. S. Balão Cordeiro and M. A. Martins, *J. Biomed. Nanotechnol.*, 2015, **11**, 1038–1050.
- 253 H. C. Probst, S. Muth and H. Schild, *Eur. J. Immunol.*, 2014, **44**, 927–933.



- 254 P. Serra and P. Santamaria, *Clin. Immunol.*, 2015, **160**(1), 3–13.
- 255 D. R. Getts, A. J. Martin, D. P. Mccarthy, R. L. Terry, Z. N. Hunter, W. T. Yap, M. T. Getts, M. Pleiss, X. Luo, N. J. C. King, L. D. Shea and S. D. Miller, *Nat. Biotechnol.*, 2012, **30**, 1217–1224.
- 256 J. Park J, W. Gao W, R. Whiston R, T. B. Strom TB, S. Metcalfe S and T. M. Fahmy, *Mol. Pharm.*, 2011, **8**(1), 143–152.
- 257 X. Clemente-Casares, J. Blanco, P. Ambalavanan, J. Yamanouchi, S. Singha, C. Fandos, S. Tsai, J. Wang, N. Garabatos, C. Izquierdo, S. Agrawal, M. B. Keough, V. W. Yong, E. James, A. Moore, Y. Yang, T. Stratmann, P. Serra and P. Santamaria, *Nature*, 2016, **530**, 434–440.
- 258 A. C. Anselmo and S. Mitragotri, *Bioeng. Transl. Med.*, 2016, **1**, 10–29.
- 259 Nanobiotix, https://www.nanobiotix.com/wp-content/uploads/2019/06/PR_Nanobiotix_marquage_CE_04042019_VF-1.pdf, accessed May 28, 2020.
- 260 Nanobiotix, https://www.nanobiotix.com/wp-content/uploads/2019/06/PR_Nanobiotix_AACR_Results_Announcement.pdf, accessed May 28, 2020.
- 261 Globes news wire, <https://www.globenewswire.com/news-release/2018/06/11/1519433/0/en/Vical-Reports-Phase-2-Trial-of-HSV-2-Therapeutic-Vaccine-Did-Not-Meet-Primary-Endpoint.html>, accessed May 28, 2020.
- 262 O. Duramad, A. Laysang, J. Li, Y. Ishii and R. Namikawa, *Biol. Blood Marrow Transplant.*, 2011, **17**, 1154–1168.
- 263 Y.-B. Chen, Y. A. Efebera, L. Johnston, E. D. Ball, D. Avigan, L. J. Lekakis, C. R. Bachier, P. Martin, O. Duramad, Y. Ishii, S. Han, Y.-J. Jung, D. Lee, L. Kunkel, R. S. Negrin and J. D. Bui, *Biol. Blood Marrow Transplant.*, 2017, **23**, 625–634.
- 264 M. Ahmadi, M. Hajjalilo, S. Dolati, S. Eghbal-Fard, H. Heydarlou, M. Ghaebi, A. Ghassembaglou, L. Aghebati-Maleki, H. S. Kafil, A. Kamrani, B. Rahnama, R. Rikhtegar and M. Yousefi, *J. Cell. Biochem.*, 2019, **121**, 103–110.
- 265 Z. A. Nahleh, W. E. Barlow, D. F. Hayes, A. F. Schott, J. R. Gralow, W. M. Sikov, E. A. Perez, S. Chennuru, H. R. Mirshahidi, S. W. Corso, D. L. Lew, L. Pusztai, R. B. Livingston and G. N. Hortobagyi, *Breast Cancer Res. Treat.*, 2016, **158**, 485–495.
- 266 S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. W. Chan, *Nat. Rev. Mater.*, 2016, **1**, 16014, DOI: 10.1038/natrevmats.2016.14.
- 267 U. Bozuyuk, N. O. Dogan and S. Kizilel, *ACS Appl. Mater. Interfaces*, 2018, **10**, 33945–33955.
- 268 G. Fullstone, J. Wood, M. Holcombe and G. Battaglia, *Sci. Rep.*, 2015, **5**, 10649, DOI: 10.1038/srep10649.

